feel well live long glaxosmithkline annual report business review performance overview research development pipeline summary product competition intellectual property regulation manufacturing supply business review world market discuss financial nonfinancial activity gsk sale performance resource development performance segment review outline factor include trend responsible business principal risk uncertainty likely financial review affect future development financial position resource financial review governance remuneration risk factor discuss management structure governance procedure set governance remuneration remuneration policy operate director board corporate executive team member corporate executive team governance policy financial statement dialogue shareholder financial statement provide summary internal control framework group financial performance committee report position december consolidated remuneration policy financial statement prepare accordance director term condition ifrs adopt european union ifrs director senior management remuneration issue international accounting standard board director interest director interest contract shareholder information include product development pipeline discuss shareholder return form dividend share price movement financial statement director statement responsibility independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap shareholder information quarterly trend year record product development pipeline share price dividend nature trading market annual general meeting underlie sale growth exclude pandemic product investor relation registrar avandia valtrex taxation information shareholder glossary term cer represent growth constant exchange rate index sterling represent growth actual exchange rate calculation result major restructuring describe note financial statement presentation financial statement gsk annual report business review governance remuneration financial statement shareholder information content exist improve quality human life enable people feel well live long work respect people maintain focus patient consumer whilst operate integrity transparency look deliver shareholder value growth diversify global business deliver product value simplify operating model run business responsibly follow report shareholder progress year see visit website wwwgskcomcorporatereporting notice limitation director liability english law company act safe harbour limit liability director respect statement omission report director contain page english law director liable company party report director contain error result recklessness know misstatement dishonest concealment material fact liable report director page inclusive comprise report director draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law website glaxosmithkline website wwwgskcom give additional information group notwithstanding reference annual report glaxosmithkline website information available website constitute annual report shall deem incorporate reference cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report gsk annual report gsk glance world lead number researchbase pharmaceutical healthcare company commit improve quality turnover earning share human life enable people feel well live long earning share dividend share major restructuring gsk focus business delivery strategic priority aim increase growth reduce risk group sale improve gsk longterm financial performance grow diversified global business pharmaceutical deliver product value europe pharmaceutical simplify gsk operating model consumer healthcare emerge market gsk global organisation office country pharmaceutical major research centre usa belgium china share list london new york stock asia pacificjapan exchanges corporate head office brentford pharmaceuticals viiv healthcare research development consumer healthcare peerleading spend growth horlick sensodyne pipeline major india world fast grow latestage asset restructure toothpaste brand total sale year world big investor big private sector funder new compound commit unit lucozade new consumer healthcare vaccine start phase iii improve return ribena horlick research innovation clinical trial start aim increase manufacture centre open china estimate return year india investment area vaccine emerge market dose vaccine total gsk turnover supply country emerge market world broad definition pharmaceutical consumer healthcare turnover market exclude usa western europe canada japan australia new zealand gsk annual report gsk annual report business review governance remuneration financial statement shareholder information gsk glance global company site employee biological corporate consumer healthcare gms pharmaceutical research development employee share world lead presence pharmaceutical market consumer healthcare source ims health global category otc oral care nutritional gsk business model responsible business balance synergistic business multiple growth driver malaria vaccine support core pharmaceutical operation potentially malaria vaccine phase iii trial ongoing african country million commitment supply dose synflorix reduce price develop country decade amc financing mechanism year commitment treat school age children africa risk intestinal worm leader gsk rank access medicine index core pharmaceutical target date value chain raw material product disposal carbon neutral find visit wwwgskcomcorporatereporte chairman ceo summary dear shareholder gsk business build strong value deep commitment operating integrity take half year implement step company responsive flexible strategy transform business model address significant open societys expectation challenge industry face payer search cost effective healthcare demand escalate new well increase return shareholder medicine direct aim enhance return able fund return shareholder bolton shareholders improve life patient consumer acquisition significant increase legal settlement whilst reduce net debt billion achieve substantially reengineere gsk business major restructure rigorous approach adjust net cash inflow legal matter capital allocation effect change billion cash outflow legal settlement billion mask degree specific event report sale gsk remain financially strong increase dividend example impact generic competition valtrex priority deliver growth reduce sale avandia pandemic relate product dividend dividend increase year earning impact significant charge average growth fiveyear period take help resolve longstanding legal matter belie start new longterm share buyback programme good progress execute strategy enhance return shareholder buyback billion evident diversified underlying sale growth increase expect potential pipeline believe gsk balanced synergistic business low risk profile option significant potential upside pipeline sir christopher gent andrew witty chairman chief executive officer gsk annual report chairman ceo summary continue focus return investment operate valuesbase business integrity drive change improve return investment continue run business responsible way central restructure effective capital allocation continue change gsk progress year continue progress significant commitment reinvestment cost save restructure programme work neglect tropical disease candidate malaria vaccine enable diversify strengthen gsk sale base progressing phase iii trial africa go date billion cost extract business vaccine malaria potential track deliver billion annual saving save live million child infant africa announce donate albendazole take cost low return activity medicine protect schoolage children africa reinveste key growth area emerge market intestinal worm intestinal worm cause ill health vaccine consumer healthcare report sale schoolage child infection business respectively major positive health impact help reduce gsk dependency sale product improve environmental sustainability business generate white pillswestern market sale priority launch new set ambitious target market product decrease goal reduce environmental impact value time help reduce adverse impact chain raw material product disposal carbon patent expiration group neutral deliver diversified underlie sale growth continue work resolve number long report sale fall impact continue stand legal matter doubt scale legal effect generic competition valtrex rapid loss sale provisioning require significant avandia follow regulatory decision autumn continue believe group good interest resolve difficult comparison prior year include significant inherent unpredictability reduce gsk overall litigation sale pandemic product exposure legal case underline important lead value underlie sale growth sale exclude factor growth achieve despite change board ongoing impact healthcare reform government september announce julian heslop retire cfo austerity measure testament strength rest end march replace simon dingemans portfolio join company cfodesignate january expect underlying sale momentum continue like thank julian dedicated service gsk translate sustainable report growth cfo member board year integrity increase pipeline potential diligence outstanding technical ability ensure gsk remain financially strong period significant economic reforming improve return investment key turmoil simon appointment cfo bring valuable new element strategy implement see experience capability support implement strategy evidence strategy make progress conclusion gsk peerleading portfolio opportunity phase iii registration portfolio diverse doubt operate environment remain biopharmaceutical vaccine addition nce challenge pharmaceutical industry undergo highly innovative asset currently available period intense change believe gsk indication asset benlysta potentially place succeed environment new treatment lupus year currently journey create balanced synergistic business consider approval regulator usa europe increase pipeline potential progressing importantly deliver sustained progress nce accomplish like recognise significant new vaccine enter phase iii start end contribution employee partner remain expect phase iii datum asset include confident generate increase value shareholder potential new treatment type diabete rare deliver well outcome patient consumer disease multiple cancer type fundamental change allocate expenditure direct late stage pipeline reduce cost risk externalise part earlystage discovery dismantle infrastructure terminate development area low financial scientific return target remain deliver rate return gsk pharmaceutical company explicitly set sir christopher gent andrew witty challenging target chairman chief executive officer gsk annual report business review governance remuneration financial statement shareholder information discover world gsk choose case study demonstrate progress strategic priority story view online wwwgskcomcorporatereporte gsk annual report business review governance remuneration financial statement shareholder information strategy focus business delivery strategic priority aim increase growth reduce risk improve longterm financial performance grow diversified global business plan diversify business create balanced product portfolio away drive growth pharmaceutical reliance traditional white pillswestern market sale generate business core market market product decrease time fulfil potential emerge help reduce adverse impact patent expiration group market expect generate future sale growth strengthen core pharmaceutical business expand business japan supplement increase investment growth area emerge market vaccine japan dermatology consumer healthcare sale emerge market build leadership dermatology vaccine japan dermatology proforma basis exclude grow vaccine consumer acquisition consumer healthcare healthcare business deliver product value plan aim sustain industryleade pipeline product deliver value focus good science healthcare provider focus improve rate return deliver diversify externalisation good science organisation require multifaceted approach example increase level externalisation research take difficult decision repersonalise pipeline progression focus disease area believe prospect focus return investment successful registration launch differentiate medicine great large diverse development pipeline industry approximately latestage asset vast majority programme address unmet medical need importantly nearly twothird new chemical entity new vaccine simplify operating model plan evolve commercial model business continue change shape essential transform operating model reduce complexity improve efficiency reduce cost global reshape manufacturing restructuring programme remove billion cost track deliver target billion annual saving saving streamline process extract develop country sale marketing support function reduce work capital manufacturing infrastructure reinveste high return activity emerge market vaccine consumer healthcare outlook whilst operate environment remain challenge significant progress restructure rigorous returnsbased approach capital allocation expect underlie sale momentum sale exclude valtrex avandia pandemic relate product continue translate report growth constant exchange rate despite anticipate pricing reduction usa europe patent composition contain combination active substance seretide advair expire patent diskus delivery device exist usa number year outlook timing impact entry followon competition uncertain gsk notify acceptance fda application followon product refer seretideadvair contain active ingredient expect precede introduction product able predict occur followon product enter market product experience generic competition advance state patent expiry result settlement patent proceeding note legal proceeding page gsk peerleade development pipeline asset currently market indication end expect phase iii datum additional asset improvement net debt position increase return shareholder increase gsk dividend priority deliver growth dividend commence new longterm share buyback programme remain confident generate increase value shareholder deliver well outcome patient consumer performance overview weiver ssenisub strategy measure progress focus business use number measure good progress year number delivery track progress notable success strategic priority strategic priority medium long term include following grow diversified performance core exclude pandemic product avandia valtrex pharmaceutical underlie pharmaceutical include vaccine sale global business vaccine business billion grow year broaden balance diversification sale sale white pillswestern market fall portfolio move away turnover reliance white pillswestern market contribution emerge sale emerge market pharmaceutical business market overall grow billion represent sale growth pharmaceutical turnover growth consumer sale consumer healthcare business grow healthcare business billion represent group turnover build leadership position dermatology sale grow proforma basis exclude dermatology acquisition approximately nearly billion represent nearly group turnover expansion japanese business sale gsk japan grow nearly billion receive approval new compound build biopharmaceutical portfolio arzerra record sale million year market launch europe benlysta file approval usa europe deliver contribution sale new product launch exclude flu new product pandemic vaccine grow contribute product value pharmaceutical sale transform ensure number reimbursable product receive product approval usa deliver current approval filing start pipeline able seven asset currently file regulator sustain flow product year come sustain latestage pipeline maintain asset phase iii registration new chemical entity new vaccine enter phase iii start enhance productivity objective increase estimate rate return increase externalisation drug discovery sign new collaboration increase external nature discovery give external discovery engine complement discovery performance unit simplify delivery major restructuring achieve annual cost saving billion programme remain track reach billion annualise saving operating model simplify operating model reduce work capital work capital reduce billion include ensure fit purpose million cash low pandemic receivable able support business cost efficient way calculation underlie sale growth describe performance overview gsk annual report business review governance remuneration financial statement shareholder information key performance indicator turnover cer growth report sale underlie sale growth sale exclude pandemic product avandia valtrex earning share major restructuring pence cer growth earning share adversely impact legal cost million million exclude legal cost ep major restructuring penny free cash flow reduce level free cash flow reflect high legal settlement year free cash flow legal settlement million million total shareholder return glaxosmithkline total return index glaxosmithkline pharma peer return index ftse total return index index include abbott labs amgen astrazeneca bristol myers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofiaventis reflect legal charge calculation cer growth describe calculation result major restructuring describe note financial statement presentation financial statement calculation free cash flow describe gsk annual report weiver ssenisub research development research development pharmaceutical dpu develop business plan specific deliverable investment cover multiple year plan include area gsk build strong broad pipeline opportunity collaboration external organisation potential new medicine industry believe pipeline enhance dpus deliverable return include potential deliver value patient payer collaboration large small company academia improve rate financial return investment internal expertise give strong basis identify appropriately progress pipeline product safely form collaboration drug discovery typically efficiently deliver innovative new medicine patient inlicense optionbase collaboration primary goal function discovery investment board dib review business plan development new product typically long expensive dpu dib responsible revising plan identify uncertain process possible predict area improvement monitor dpu delivery agree compound development succeed fail risk inherent target investment membership dib comprise senior process describe fully risk factor commercial management external individual section risk deliver commercially relevant expertise include life science investment experience successful new product understand payer perspective chair svp gsk allocate investment reference potential medicine discovery development return available target therapeutic market individual dpu annual expenditure technical commercial risk associate product total annual expenditure pipeline factor review phase development process central decision proceed deliver medicine patient stage cost incur stage carefully manage compound advance latestage development typically maximise likely future return consistent group phase iia undergo large scale study human overall objective increase irr activity investigate efficacy safety time current level estimate work optimise compound physical property return generate primarily determined formulation produce deliver efficiently eventual commercial impact new product achieve sufficient quantity manufacturing process regulatory approval launch convert result activity regulatory file project rate return include product launch submission regulatory agency january compound phase iib iii medicine development team mdts small unit development process calculation base actual sale people responsibility compound later forecast sale relevant product stage development filing regulatory agency adjust reflect expect failure rate asset latestage development comprise broadly line standard industry failure rate cost base individual project calculation comprise estimate attributable cost actual project milestone payment gsk actively seek opportunity add product appropriate estimate profit margin capital investment latestage portfolio relationship company work capital requirement factor calculation latestage asset typically form inlicense base historical performance copromotion arrangement likely align exist area therapy expertise investment detail product development pipeline pharmaceutical vaccine asset set page product management board pmb assess technical website performance market product commercial investment case project progress discuss detail financial review page development pmb cochaire chairman president north america pharmaceutical include head discover potential medicine pharmaceutical region global manufacturing early stage drug discovery seeks identify biological project review pmb certain key decision point target involve development disease commit medicine development commit phase iii commit create small molecule biopharmaceutical interact file launch funding generally allocate key disease target wealth scientific discovery recent decision point typically year ahead pmb year essential highly selective carry annual latestage funding review investment invest drug discovery resource focus resource project review adjust necessary prioritise area likely deliver significant medical advance return investment individual latestage project incur annual expenditure total annual expenditure conduct reevaluation advance discovery global biomedical science lead exit area research governance judge unlikely provide sufficient scientific financial decision oversee number board oversight return try create entrepreneurial environment strategic issue overall budget management drug discovery pursue good scientific opportunity own executive team radex dib pmb control internal external create discovery performance unit dpus investment decision early late stage describe group scientist group focus particular disease pathway responsible scientific advisory board sab chair svp medicine drive discovery development potential new medicine discovery development include number external early stage clinical trial completion phase scientific expert sab review challenge science lla nearly dpus underlie development programme provide advice relate issue pmb key investment point gsk annual report business review governance remuneration financial statement shareholder information research development gsk chief medical officer chair global safety board biological scientific committee bsc define overall ultimately accountable oversight major decision new product licensing strategy vaccine business patient safety global safety board responsible internally chair biological president include head approve pivotal study investigate issue relate vaccine disease area clinical epidemiology business patient safety arise development programme development department member bsc postlaunch information gsk clinical trial widely easily assess high potential vaccine inlicense opportunity decide available clinical study register gsk website exploratory project inlicense opportunity wwwclinicaltrialsgov endorse target product profile start early vaccine project addition bsc align clinical commercial disease develop world plan early project responsible prioritise exploratory continue investment research disease develop research early vaccine project world essential longterm improvement health people live region development review committee drc oversee late response challenge operate drug discovery unit development vaccine portfolio include strategy project prioritisation base tre canto spain focus malaria resource allocation drc chair head global tuberculosis adapt business model pursue vaccine development membership include head open innovation strategy disease develop clinical research global industrial operation global commercial world element new approach include open centre excellence industrialisation medical intellectual property open resource launch post marketing study set assess open datum compound additional vaccination programme monitor vaccine safety site usa focus development new medicine treat hivaids drug resistant bacteria distinct group form vaccine vaccine research conduct rixensart belgium provide specific focus prophylactic antigen specific cancer immunotherapeutic asci portfolio new global vaccine effort address prevention development organisation create pull clinical treatment world health organization late development organisation allow priority infectious disease clear focus project vaccine development leader overall responsibility development particular project vaccine active field vaccine research development animal research production portfolio vaccine approve ethical regulatory scientific reason research animal market scientist devote discover remain small vital research development new innovative vaccine contribute health wellbeing medicine vaccine use animal people generation world discovery alternative constantly strive reduce number development new vaccine complex process require long commit maintain high standard humane term investment vaccine development care treatment laboratory animal undertake internal strong vaccine pipeline industry external review assure standard traditionally vaccine ward illness vaccine division work develop immunotherapeutic vast majority experimental method use animal aim educate patient immune system identify actively engage research develop validate attack cancer cell highly specific manner test avoid use animal reduce number need animal measure take vaccine discovery involve collaboration academia prevent minimise pain distress biotech industry identify new vaccine antigen express yeast bacteria mammalian cell purify understand use animal research purpose high level follow formulation clinical command high level public interest statement lot vaccine involve mix antigen select care ethical use animal research view gsk novel proprietary adjuvant system combination use nonhuman primate details voluntary decision select adjuvant design elicit appropriate immune use great ape chimpanzee response specific antigen right combination antigen information report available website adjuvant system help body mobilise effective research development consumer healthcare immunological pathway design provide maximum protection specific disease target population continuous creation development innovative product keep brand relevant vibrant valuable portfolio formulate candidate vaccine evaluate safety span major category otc medicine oral healthcare efficacy perspective different phase preclinical nutritional healthcare major brand dedicate testing clinical trial involve healthy individual team include regulatory partner work alongside range safety analysis small group volunteer commercial brand team colleague officefree hub environment phase dose adjustment proof concept phase foster collaboration fast decisionmake hub largescale safety efficacy analysis phase iii result quickly preferred way work innovation obtain clinical trial datum development centre weybridge parsippany usa quality largescale production process facility expand model china india combine regulatory file submit authority country vaccine available diverse product development pipeline key late stage project include novel technology new combination superior formulation gsk annual report weiver ssenisub pipeline summary diverse product development key pipeline project comprise new phase iii chemical entity biological entity vaccine large comparative study compound versus new combination new indication placebo andor establish exist compound phase iii treatment patient file approval recently establish clinical benefit safety approve highlight advanced status show includes file follow successful approval usa phase iii trial file product approval regulatory authority approval approval grant begin market medicine vaccine pipeline page website asset move approval asset terminate phase iii usa phase iii development ipx parkinson tyverbtykerb avandamet disease line therapy type diabete hormone receptor positive mek avandia statin breast cancer usaeu inhibitor metastatic type diabete melanoma arzerra refractory almorexant chronic lymphocytic braf inhibitor primary insomnia leukaemia metastatic melanoma new generation flu revoladepromacta vilanterol vaccine influenza idiopathic combination drug prophylaxis thrombocytopaenic copd purpura simplirix genital herpe prophylaxis duodartjalyn fix crohns disease dose combination drug zoster vaccine benign prostatic prevention shingle hyperplasia usaeu duchenne votrient renal muscular dystrophy cell cancer migalastat hci prolia post fabry disease menopausal osteoporosis integrase inhibitor hiv fix dose combination epzicomkivexa adenosine deaminase severe combine immune deficiency inlicence alliance relationship party find visit wwwgskcom gsk annual report business review governance remuneration financial statement shareholder information pipeline summary therapeutic area compound indication phase iii file approve biopharmaceutical albiglutide type diabetes arzerra chronic lymphocytic leukaemia line therapy use relapse patient arzerra diffuse large cell lymphoma relapse patient arzerra follicular lymphoma refractory relapse patient otelixizumab type diabetes benlysta systemic lupus erythematosus denosumab bone metastatic disease arzerra chronic lymphocytic leukaemia refractory patient prolia hormone ablativechemotherapy bone loss prostate cancer patient prolia postmenopausal osteoporosis cardiovascular metabolic darapladib atherosclerosis infectious disease relenza treatment influenza neuroscience ipx parkinson disease horizant restless leg syndrome trobaltpotiga retigabineezogabine epilepsy partial seizure oncology metastatic melanoma metastatic melanoma votrient ovarian cancer maintenance therapy revoladepromacta chronic liver disease induce thrombocytopaenia revoladepromacta hepatitis induce thrombocytopaenia tyverbtykerb breast cancer adjuvant therapy tyverbtykerb gastric cancer tyverbtykerb head neck squamous cell carcinoma resectable disease votrient renal cell cancer adjuvant therapy votrient sarcoma votrient tyverbtykerb inflammatory breast cancer avodart reduction risk prostate cancer duodartjalyn benign prostatic hyperplasia fix dose combination revoladepromacta idiopathic thrombocytopaenic purpura tyverbtykerb breast cancer line therapy votrient renal cell cancer respiratory copd immunoinflammation vilanterol copd vilanterol copd ccx crohns disease relovair vilanterol asthma relovair vilanterol copd paediatric vaccine mosquirix malaria prophylaxis plasmodium falciparum nimenrix menacwytt neisseria meningitis groups disease prophylaxis menhibrix hibmencytt neisseria meningitis group haemophilus influenzae type disease prophylaxis vaccine flu vaccine seasonal influenza prophylaxis zoster herpe zoster prevention flu pre pandemic prepandemic pandemic influenza prophylaxis pumarix pandemic influenza prophylaxis antigen specific cancer magea treatment melanoma immunotherapeutic asci magea treatment nonsmall cell lung cancer rare disease duchenne muscular dystrophy adenosine deaminase severe combine immune deficiency migalastat hcl fabry disease dermatology tazarotene foam acne vulgaris duac low dose acne vulgaris calcipotriene mild moderate plaque psoriasis itraconazole tablet onychomycosis veltin acne vulgaris hiv hiv infection abacavir sulphate lamivudine hiv infection inlicence alliance relationship party gsk annual report weiver ssenisub product competition intellectual property pharmaceutical product intellectual property principal pharmaceutical product currently direct intellectual property key business asset company main therapeutic area description product page effective legal protection intellectual property analysis sale therapeutic area patent trademark register design copyright domain registration critical ensure reasonable competition return investment principal pharmaceutical competitor range small large trademark pharmaceutical company substantial resource company gsk commercial product protect register trademark major market local variation abbott laboratories example usa trademark advair cover amgen product sell seretide trademark protection astrazeneca generally extend long trademark renew necessary gsk trademark important bristolmyer squibb maintain brand identity product gsk enforce eli lilly trademark right prevent infringements johnson johnson patents merck novartis policy try obtain patent commercially important protectable invention discover develop pfizer activity patent protection new active ingredient available roche holding major market patent obtain new drug sanofiaventis formulation manufacturing process medical use device administer product obtain patent pharmaceutical subject competition product product prevent challenge period patent protection patent expire grant patent mean generic version manufacturer generic product typically issue patent necessarily hold valid enforceable incur significant research development education court court determine patent hold invalid marketing development cost consequently able non infringe unenforceable protect market offer product considerably low price brand party entry prior patent expiry significant litigation competitor research development base company concern challenge summarise note normally seek achieve sufficiently high profit margin financial statement legal proceeding sale volume period patent protection repay original investment generally substantial generate life patent country year file profit fund research future competition generic date long development time pharmaceutical product generally occur patent major market expire product result substantial patent life increasingly patent challenge prior patent expiry launch market include usa claim innovator patent valid andor europe possible lose time restore infringe generic product follow loss patent lead variation patent life actually available protection generic product rapidly capture large share product market certain country provide period market particularly usa data market exclusivity prevent party company rely clinical trial datum enter market believe remain competitive dependent copy period exclusivity discovery development new product deliver value healthcare provider improve outcome patient patent expiry date significant product effective marketing exist product follow table date provide expiry patent usa major european market active ingredient pharmaceutical industry introduction new indicate include extension patent product process competitor affect pricing term include paediatric use usa available result change pattern product use assurance patent vaccine relate vaccine composition product outmoded notwithstanding patent trademark protection addition increase government pressure physician patient use generic pharmaceutical brandname medicine increase competition product gsk annual report business review governance remuneration financial statement shareholder information product competition intellectual property pharmaceutical product product compound indication major patent expiry date competitor brands usa respiratory veramyst fluticasone furoate rhinitis nasacort flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire compound compound expire diskus device diskus device hfadevice hfadevice formulation formulation seretideadvair salmeterol xinafoat asthmacopd singulair symbicort expire fluticasone propionate spiriva asmanex pulmicort combination combination foster expire diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expire expire compound compound expire diskus device diskus device hfadevice formulation antiviral relenza zanamivir influenza tamiflu valtrex valaciclovir genital herpe coldsore famvir expire expire shingles zeffixepivirhbv lamivudine chronic hepatitis hepsera use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire requip ropinirole parkinson disease mirapex expire expire restless leg syndrome requip ropinirole parkinson disease mirapex formulation use seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro treximet sumatriptan naproxen migraine zomig maxalt relpax combination use wellbutrin bupropion depression effexor cymbalta expire expired lexapro cardiovascular urogenital arixtra fondaparinux deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post fraxiparine nadroparin deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep lovaza omega acid ethyl ester high triglyceride tricor formulation outlook detail uncertainty time followon competition generic competition possible gsk annual report weiver ssenisub product competition intellectual property pharmaceutical product product compound indication major patent expiry date competitor brands usa antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire expire potassium infection oncology arzerra ofatumumab refractory chronic mabtherarituxan pende pende lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar expire lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patient votrient pazopanib metastatic renal cell carcinoma sutent nexavar afinitor vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis hepb polio hepatitis hepb pentaxim pentavac inactivated antigen cervarix hpv virus like particle human papilloma virus gardasil silgard vlp adjuvant mpl type aluminium hydroxide fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type antigen influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type antigen influvac aggripal fluad pandemrix derive split inactivated ahnv influenza focetria celvapan emerflu influenza virus antigen prophylaxis adjuvant prepandrix derive split inactivated influenza prophylaxis aflunov influenza virus antigen adjuvant synflorix conjugate pneumococcal invasive pneumococcal prevenar prevnar polysaccharide disease hiv combivir lamivudine zidovudine hivaids truvada atripla combination combination epivir lamivudine hivaids truvada atripla expire expire epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination note financial statement legal proceeding gsk annual report business review governance remuneration financial statement shareholder information product competition intellectual property consumer healthcare product brand product application market competition oral healthcare aquafresh toothpastes toothbrushe prevention carie gum global colgatepalmolive colgate mouthwash disease bad breath procter gamble crest sensodyne toothpastes toothbrushes prevention dental global colgatepalmolive sensitivity sensitivity toothpastes biotene mouthwash gel treat dry mouth market polident denture adhesive improve comfort global fixodent poligrip denture cleanser fit denture corega clean denture otc medicine panadol tablet capulet infant drop paracetamolbase treatment global usa nurofen headache joint pain fever cold symptom nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin original lozenge withdrawal aid retailer brand nicabate quitting smoking nicorette usa nutritional healthcare lucozade energy sport drink energy hydration ireland sport drink market horlick malt milkbase drink nutrition ireland india ovaltine milo foods ribena blackcurrant juicebase vitamin cdelivere ireland robinson drink health drink market consumer healthcare competition gsk hold leading position key consumer product area worldwide second large otc medicine large oral healthcare nutritional healthcare hold lead position ireland india environment consumer healthcare business operate challenge consumer demand well quality well value improve performance retailer consolidate globalise strengthen negotiation power cycle times innovation reduce main competitor include major international company colgatepalmolive johnson johnson procter gamble unilever pfizer addition small company compete gsk certain market major competitor product otc medicines usa metamucil laxative pepcid indigestion private label smoking control product lemsip cold remedy nurofen anadin analgesic nicorette nicotinell smoking control treatment oral healthcare major competitor colgatepalmolive colgate procter gamble crest nutritional healthcare major competitor horlick ovaltine milo malt food chocolate drink competitor ribena primarily local fruit juice product lucozade compete energy drink gsk annual report weiver ssenisub regulation regulation pharmaceutical regulation consumer healthcare region countryspecific law regulation major consumer healthcare industry subject national regulation factor determine product successfully comparable prescription medicine testing develop approve define information need approval manufacturing labelling marketing product evaluate safety efficacy pharmaceutical product high standard technical appraisal frequently involve lengthy govern testing approval manufacturing labelling approval process new product launch marketing increase level cooperation gsk consumer healthcare continue gain centralised regulatory exchange information major regulatory authority approval overthecounter product history encompass development plan datum support product make otc industry european medicine registration postmarkete safety information inspection agency grant centralised approval weight loss medicine evaluation benefit risk continue alli grant approval paramount consideration approval new drug country line extension chewable product grant usa enhance focus fda safety centralise approval additionally gsk consumer healthcare medicine approval postmarketing phase embrace principle centralise application achieve product fda announce strategic priority gsk pangulf cooperation council approval alli year advance regulatory science innovation niquitin permit launch seven market strengthen safety integrity global supply chain gulf region strengthen compliance enforcement activity support value money public health address unmet public health need special population engage key area payer world concern cost interest healthcare pricing medicine requirement satisfy healthcare purchaser value money europe new regulation aim strengthen safety additional hurdle product acceptance monitoring medicine agree legislators regulatory test safety efficacy quality implement discussion continue draft legislation improve citizen access reliable information price control medicine strengthen law protect citizen threat pose fake medicine european medicine country price pharmaceutical product agency ema head national medicine agency control law government influence price hma publish fiveyear strategic plan control national healthcare organisation bear aim mainly strengthen operation exist large cost supply medicine consumer regulatory network commission publish report recent government healthcare reform country france operation ema preparation potential legislative spain germany restrict pricing reimbursement proposal change regulatory framework continue review regulation clinical trial currently usa government price control europe review expect conclude private sector purchase federal law require pharmaceutical manufacturer pay prescribe rebate certain drug regulatory environment emerge market asiapacific eligible reimbursement state federal continue evolve number country continue healthcare programme president congress develop regulatory review system actively participate pass affordable care act aca reform healthcare number specific regional national regulatory system drive cost improve quality increase access initiative provide opportunity meaningful scientific million americans health insurance reform regulatory dialogue industry agency potential create positive change healthcare stakeholder continue include broad set patient system expand access product aca population number country medicine increase prescribe rebate governmentrun development programme order increase global patient access programme change balance private new innovative medicine optimise regulatory approval public sector purchase despite passage aca pressure control healthcare cost continue issue cross border trade acceleration generic market comparative effectiveness research pharmaceutical pricing continue ongoing healthare debate usa fortunately position constructive contributor debate increase recognition chronic disease primary driver healthcare spend pharmaceutical product deliver important intervention help hold healthcare cost gsk annual report business review governance remuneration financial statement shareholder information manufacture supply gsk manufacturing cover pharmaceutical consumer vaccine manufacture healthcare vaccine vaccine manufacturing manage separately gm integral biological business particularly pharmaceutical global manufacturing supply gms complex requires use innovative technology live people work gms network microorganism comprehensive quality assurance quality site country gms support commercial ambition control procedure place ensure vaccine quality gsk deliver quality medicine consumer product safety biological nature individual health authority patient customer world subject vaccine second control guarantee high scale manufacturing gsk huge manufacture quality standard billion pack year different presentation gms support gsk commercial ambition deliver quality include tablet creamsointment inhaler injection liquid medicine consumer healthcare product patient sterile supply market consumer world billion spend gms production gms operate procurement operation behalf group spend billion annually external supplier purchase active ingredient chemical intermediate package component partfinishe finished product internal customer seek opportunity grow business focus costcompetitive supply quality product meet ambition work diligently leverage network site contractor builtin flexibility sustain future growth adapt emerge commercial business model increasingly rigorous external regulatory environment continue leverage technology support process understand control capability pharmaceutical launch global supply site work closely rd development team ensure right technical competency place support rapid successful new product introduction site serve focal point develop introduce new secondary manufacturing technology primary supply site pharmaceutical launch global supply division supply high quality competitively price bulk actives focus improvement primary technology process site antibiotic emerge market supply division focus manufacturing product late stage life cycle allow gsk compete effectively market consumer healthcare manufacture consumer healthcare manufacturing manage gm apart coleford site manage directly nutritional healthcare consumer healthcare site deliver highquality competitively price product support rapid new product introduction highly innovative competitive business new technology fundamental platform drive innovation lower cost provide flexibility operation continuously improve embed new way work simplify business achieve great efficiency focus customer service include support new product launch strong compliance culture commitment health safety environment commitment develop people deliver strong result gsk external environment demand gsk annual report weiver ssenisub world market pharmaceutical global recession cause international financial crisis continue impact world economy world market value therapeutic class total country industry sector see improvement significant growth remain elusive recovery central nervous system fragile good cardiovascular antineoplasticimmunomodulatory follow rise ftse index achieve alimentary tract metabolic modest gain usa dow jones industrial antiinfective bacterial average rise stock exchange europe record viral fungal exclude vaccine mixed performance rise germany contrast respiratory loss spain italy respectively asia chinese stock market post annual decline note datum base month september nikkei japan debt crisis greece spread economy datum market share market growth rate gsk estimate spain portugal italy ireland romania move base recent datum independent external source end year government introduce austerity include im health appropriate value sterling measure complement fiscal stimulus initiative relevant exchange rate cut case severe rapid implement education healthcare public service government take different approach healthcare specific pricing cut apply select medicine vaccine measure affect pharmaceutical industry vary degree depend company exposure area impact time see implementation healthcare reform usa associated discount price cut pharmaceutical industry global pharmaceutical sale billion compare billion world market value geographic region total usa europe rest world emerge market asia pacific japan canada total market growth cer basis usa europe rest world gsk annual report business review governance remuneration financial statement shareholder information gsk sale performance gsk deliver underlie sale growth exclude pandemic relate product avandia valtrex despite ongoing impact government austerity measure healthcare reform reduce sale approximately million commentary gsk segmental sale performance use performance measure set underlie sale growth underlie sale growth exclude sale pandemic product avandia valtrex management believe measure assist shareholder gain clear understanding group sale performance prospect size nature loss sale product reconciliation group pharmaceutical turnover follow growth cer group turnover avandia valtrex pandemic product underlie group turnover growth cer pharmaceutical turnover avandia valtrex pandemic product underlie pharmaceutical turnover sale product segment emerge asia pacific trading usa europe markets japan unallocate total pandemic product avandia valtrex emerge asia pacific trading usa europe markets japan unallocate total pandemic product avandia valtrex white pillswestern market white pillswestern market refer sale tablet simple injectable exclude biopharmaceutical vaccine north america europe cer growth order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate commentary report present term cer state gsk annual report weiver ssenisub pharmaceutical segment review make continue effort change company restate growth model improve level openness transparency example cer voluntarily stop corporate political contribution turnover company report voluntarily payment healthcare professionals usa name operate profit individual basis speak consulting service emerge period significant patent expiration business implement new system make good progress transform business model evaluating compensate professional sale representative operation meet current future challenge new programme bonus sale representative work directly customer long base sale usa billion primarily achievement individual sale target instead impact generic competition valtrex significant assess scientific business knowledge feedback reduction sale pandemic relate product low sale customer region include demonstration company avandia underlie sale exclude pandemic relate product value overall performance business unit support avandia valtrex usa year programme fully implement july despite discontinuation gsk promotion boniva sale wellbutrin impact healthcare reform consistent value integrity transparency product range underlie growth drive strong sharpen focus support continue medical performance number promote medicine include education cme example implement system flovent ventolin boostrix avodart limit grant application approximately academic medical lovaza oncology product centres nationallevel professional medical association new product launch exclude flu pandemic cme provider support directly accredit vaccine grew contribute sale recognise accredit body fund cme notforprofit provider reduce turnover partially offset low sga cost reflect saving restructure programme receipt healthcare business environment exclusive promotion right boniva operate challenge present opportunity company profit decline deliver truly innovative medicine market launch new product market usa healthcare market change radically rapidly look forward regulatory decision benlysta significant proportion healthcare cost continue pay approve new treatment lupus federal local government large pharmacy benefit manager year overall believe improvement make health plan dominate private market physician cost structure operate enable consolidate practice medical center group practice compete effectively evolve marketplace integrate delivery network hospital consolidate few year ago research triangle park campus north carolina usa payer demand high quality care low cost home number business function increasingly link reimbursement improve health outcome implementation landmark healthcare reform legislation usa begin year result january medicaid drug rebate increase extended include medicaid manage care plan new formulation exist product january eligibility certain government drug pricing program expand include additional hospital health center response evolve market condition make fundamental change operation ensure deliver value customer patient healthcare provider payer demand change enable effectively meet customer need expectation well deploy resource support evolve specialised product portfolio example majority pharmaceutical sale representative customercentre portfolio focus responsibility product specific responsibility change enable increase productivity sale force reduce size approximately importantly new customercentric model align customer desire work businessto business partner gsk annual report business review governance remuneration financial statement shareholder information europe pharmaceutical segment review enter continue pressure cost restate growth change valuebase medicine approach addition cer demonstration safety efficacy government turnover agency assess medicine value deliver healthcare system make development effective dialogue operating profit government regulator payer europe absolutely vital business continue place emphasis european pharmaceutical business deliver solid performance able demonstrate cost effectiveness gsk product despite significant government lead austerity measure deliver new medicine vaccine address unmet medical price cut need demonstrable value work report sale billion underlie target building evidence cost effectiveness performance exclude pandemic relate product avandia medicine compare current treatment example valtrex flat creditable performance include agree innovative pricing agreement approximately million sale impact government price national institute clinical excellence nice cut drive introduction new product growth advanced kidney cancer medicine votrient votrient product portfolio despite likely continue effective sunitinib current standard care government pricing pressure strong product portfolio comparative trial currently underway give confidence future performance business offer future financial rebate introduce new product particular highlight duodart treatment combination avodart tamsulosin benign prostatic hyperplasia recently introduce brand avamys requip modutab tyverb volibris wellbutrin achieve double digit growth major product seretide asthma copd impact price cut achieve sale billion whilst maintain leadership position respiratory market continue bring benefit product patient europe portfolio vaccine contribute growth synflorix pneumococcal conjugate vaccine win national tender increase sale million manage operating cost business deliver improvement efficiency close control operating expense deliver saving excess programme reduce diversity carton label leaflet range medicine deliver saving initiative reduce different format tablet blister pack reduction sga cost reflect saving restructuring programme help limit decline operating profit commitment work community europe support great access build trust stakeholder continue example project bulgaria promote awareness vaccine vulnerable ethnic minority group collaboration health mediator general practitioner representative regional health inspectorate initiative facilitate access group national healthcare system focus prevention health awareness particular benefit work improve rate immunisation group turn reduce impact outbreak measle gsk annual report weiver ssenisub emerge market pharmaceutical segment review continue introduce flexible pricing strategy work restate growth early stage result initiative far cer promise example significantly reduce price turnover gsk new innovative product include avodart avamys cervarix aim increase affordability operating profit volume sell middle income country emerge market pharmaceutical business continue develop country ldc year establish perform strongly sale billion new develop country market access business unit underlie growth market exclude pandemic relate new unit dedicated focus expand access product avandia valtrex second medicine vaccine million people consecutive year follow introduction gsk strategic live world poor country add benefit initiative emerge market business outgrow help build sustainable gsk business part pharmaceutical market growth region estimate develop world currently little presence responsible implement pricing policy deliver particularly strong performance latin america cap price patent medicine ldc grow china cis grow western price reinvesting profit respectively addition produce growth medicine sell country country sector emerge market business innovative healthcare infrastructure brand new patent protect product classic brand nonpatent protect vaccine year please announce sign advance market commitment amc pneumococcal innovative brand business show consistent performance vaccine global alliance vaccine immunisation sale growth approximately billion gavi provide million dose synflorix sale respiratory medicine seretide million year reduce price protect child poorest grow particularly strong performance key country world invasive pneumococcal disease market include china classic brand business continues strength strength sale growth billion include continue doubledigit growth augmentin year market vaccine sale million pandemic flu product pneumococcal vaccine synflorix perform particularly exclude pandemic flu vaccine sale grow turnover main business sector vaccine innovative brand classic brand emerge market pharmaceutical operating profit increase turnover increase reflect strong synflorix pandemic vaccine sale benefit acquisition partially offset increase sga investment region operational highlight year include number new strategic alliance strengthen footprint key emerge market number business acquisition include laboratorio phoenix lead argentinian classic brand business number vaccine production alliance conclude year include alliance jsc binnopharm russian pharmaceutical manufacturer enable local secondary manufacture number key gsk vaccine russia gsk annual report business review governance remuneration financial statement shareholder information asia pacificjapan pharmaceuticals segment review gsk japan deliver strong year sale restate growth million underlie sale growth exclude pandemic cer product valtrex avandia growth drive turnover primarily adoair seretideadvair contribution newly launch product cervarix avolveavodart operate profit xyzal partially offset paxil sale decline decline mature respiratory product flixotideflovent sale asia pacific grow billion exclude serevent reflect biennial sale pandemic relate product avandia valtrex price reduction underlie growth asia pacific benefit acquisition stiefel dermatology portfolio ucbs asian vaccine franchise important pillar business strong performance deliver avamys company japan arepanrix flu vaccine tykerb seretide vaccine allow import japan receive regulatory exclude flu pandemic approval january cervarix strong launch japan sale million product recognise operate profit asia pacific improve billion vaccine receive public funding reflect improved sale synflorix cervarix japanese government onwards favourable impact product mix cost good partially offset low sale relenza operating profit japan increase billion reflect high cervarix pandemic vaccine sale middle income country asia pacific region favourable impact product mix cost good partially offset centre gsk flexible pricing initiative example low sale relenza innovative pricing model monthly sale cervarix vaccine increase approximately time philippine year gsk japan receive approval compound follow price reduction similarly indonesia include revolade xyzal new indication botox vietnam introduce equivalent pricing strategy spasticity addition oral pulmonary arterial hypertension vaccine result sixfold increase treatment volibris launch year number woman vaccinate cervarix number gsk japan establish rare disease development centre human papillomavirus vaccine south east asia malaysia april accelerate delivery medicine rare disease secure region tender product treatment available initiative year synflorix grow deliver sale million gsk increase investment japan invest japan chemical year see important strategic alliance sign major research company lead technology manufacture local pharmaceutical company include donga south korea biopharmaceutical savipharm vietnam japanese pipeline potential approval pende potential approval filing include new chemical entity include new chemical entity line extension new promotion reformulation gsk annual report weiver ssenisub viiv healthcare segment review improve paediatric care hiv restate growth cer turnover operate profit viiv healthcare celebrate anniversary november business establish gsk pfizer independent company focus deliver advance clinical outcome enhance quality life people live hiv company unique structure wide portfolio available medicine provide financial stability investment capital require sustainable longterm view hiv market overall sale hiv product viiv healthcare billion sale pfizer product celsentri selzentry viracept combine sale million growth epzicomkivexa million partially offset reduction sale establish hiv product include trizivir million combivir million lexivatelzir million epivir million continue impact uptake new alternative product strong growth celsentriselzentry compare support wide acceptance genotypic testing europe increase firstline use usa country launch poland romania australia japan mexico upward trend commitment address major unmet need epzicomkivexa sale reflect role nucleoside reverse hiv viiv healthcare form key partnership elizabeth transcriptase inhibitor nrtis mainstay treatment hiv glaser pediatric aids foundation amfar improve care strategic focus international market country paediatric hiv prevent mother child transmission mtct exclude europe north america viiv healthcare establish virus fourth millennium development goal new independent local operating company important positive action child fund give million geography open regional hubs asia pacific cis community project support mother child affect latin america result revenue international hiv prevent mtct request proposal region grow end year expand fund reach scope viiv healthcare operating profit decreased primarily result healthcare reform higher sga cost partially offset onetime royalty settlement high sga cost primarily amortisation acquire intangible asset see great progress build latestage pipeline october shionogiviiv healthcare announce start phase iii development programme novel integrase inhibitor sgsk phase iii trial fix dose combination tri epzicomkivexa initiate february viiv healthcare commit support community affect hiv epidemic way company develop innovative approach improve access medicine example july viiv healthcare company entire current future antiretroviral portfolio available generic manufacturer royaltyfree voluntary licence cover develop low income country subsaharan africa country people hiv live similarly notforprofit pricing policy expand country year viiv healthcare launch positive action southern initiative usa reduce healthcare disparity community great need gsk annual report business review governance remuneration financial statement shareholder information consumer healthcare segment review year open new bottle manufacture plant restate growth coleford factory nutritional healthcare enable cer mould lucozade ribena bottle formulate drink turnover fill bottle plant bottleforme facility mould billion pet bottle year plastic chip investment operate profit eliminate roadhaulage trip miles bottle supplier consumer healthcare sale grow billion significantly ahead consumer healthcare market growth recently announce intention accelerate growth estimate approximately deliver growth focus consumer healthcare business portfolio category operate oral healthcare priority brand emerge market overthecounter otc medicine nutritional dimension represent current consumer healthcare healthcare sale base intend divest remain sale million consist european europe sale level year sale billion american noncore otc brand aim divest product growth oral healthcare nutritional healthcare offset late subject interest realise appropriate value decline otc sale business usa grow shareholder expect use proceed fund increase billion lead oral healthcare return shareholder growth particularly strong rest world grow finally objective deliver sustainable business billion indian subcontinent continue large array solar panel north america power deliver new innovation horlick brand launch regional distribution centre york pennsylvania priority brand lucozade sensodyne breathe right doorsize solar panel cover rooftop equivalent result combine sale growth china deliver football field generate kwhr year solar array sale growth expand consumer availability eliminate nearly tonne carbon dioxide emission fenbid contac bactroban strong uptake newly launch year load environment mature lucozade continue good performance product tree absorb include sensodyne breathe right denture care brand accelerate research innovation key emerge solar panel cover rooftop gsk consumer market open oral healthcare research centre healthcare regional distribution centre york pennsylvania gurgaon india innovation centre beijing china middle east africa pakistan market deliver sale growth largely strong panadol eno sale growth south america grow sale lead strong panadol eno consumption low growth japan australianew zealand respectively oral healthcare grow billion lead strong performance sensodyne continue fast grow toothpaste world position hold year remarkable record brand year follow launch india market sensodyne country aquafresh sale decline slightly biotene dry mouth treatment acquire grow strongly otc medicine record sale billion good performance smoking control product help new tax tobacco japan substantial sale brazil governmentfunde smoking cessation initiative addition supply product brazil initiative provide training smoking cessation clinic country panadol lead paracetamol analgesic outside usa deliver strong sale growth helped rollout panadol advance optizorb technology dissolve time fast regular paracetamol tablet dermatology product grow million respiratory tract product decline million nutritional healthcare grow million lead horlick modest growth ribena lucozade operating profit increase turnover increase reflect efficiency scale sga cost grow slowly sale gsk annual report weiver ssenisub pharmaceutical research development review group expenditure major restructuring focus return pharmaceutical million million represent total make fundamental change allocate turnover company expect cost pharmaceutical investment terminate development major restructure percentage turnover remain area low scientific financial return dismantle infrastructure reduce cost risk externalise part earlystage discovery direct investment late stage deliver sustained asset progression new pipeline progress include chemical entity new vaccine enter phase iii start seven asset file regulator project early announce intention cease terminate phase iii development list discovery research certain area neurology adverse trial result feedback regulator pain depression instead concentrate activity end expect phase iii datum additional neurodegenerative neuroinflammatory disease asset include treatment type type diabete rare feel prospect successful registration launch disease multiple cancer type differentiate medicine great change lead exit centre large verona italy pharmaceuticals segment comprise activity zagreb croatia operation transfer pharmaceutical business exclude vaccine consumer healthcare external group preserve majority job local central cost table analyse group expenditure category successfully outlicense spin early stage neurology asset deal convergence pharmaceutical proximagen group pharmaceutical direct project cost change action achieve excl vaccine indirect cost reduction footprint unallocated cost continue increase external nature discovery pharmaceutical activity sign new collaboration inmarket pharmaceutical access novel discovery give total external discovery development engine complement dpus vaccine streamline resource clinical trial contract corporate cost research organisation reduce supplier provide saving term economie consumer healthcare scale ensure consistency rigour clinical trial globe major restructuring combine molecular discovery research mdr major restructure preclinical development pcd create endtoend total scientific technical platform support discovery development effort remit group remain create proportion pharmaceutical investment material knowledge enable idea latestage portfolio continue grow direct generate hypothesis test preclinical clinical indirect cost setting ultimately launch new medicine sale new pharmaceutical product launch development pharmaceutical exclude pandemic flu vaccine grow million gsk rare disease create enable focus represent total pharmaceutical sale specialised area drug discovery development opportunitie new treatment rare disease grow growth cer increase scientific include genetic understanding allow researcher identify rare disease likely veramyst respond therapeutic intervention sign significant new cervarix rare disease alliance year amicus treatment coreg fabry disease fondazione telethon research develop lamictal novel stemcell derive treatment address rare genetic disorder requip gene therapy carry patient stem cell rotarix new agreement demonstrate approach seek synflorix innovative medicine add value patient payer treximet tykerb year progress commitment encourage new research neglect tropical disease research centre tre canto spain release result yearlong screen million compound gsk chemical library seek inhibit malaria parasite falciparum investment pipeline progress datum publically available online globally people work molecule structure release proprietary base major centre usa belgium china gsk information release entirely new people work pharmaceutical course research community manage project trial human gsk annual report business review governance remuneration financial statement shareholder information responsible business create successful sustainable research innovation undertaking research innovating explore business financial apply new technology constructively engage stakeholder result place great importance concern arise ensure product subject rigorous scientific evaluation testing safety achieve effectiveness quality comply exceed achieve run responsible regulation legal standard applicable research valuesbase business embed development product read strategy product customer promote product line high ethical medical scientific standard comply applicable law regulation read work hard build culture decision guide value care environment operate environmentally responsible manner commit transparency systematic management environmental impact respect people measurement performance set challenge demonstrate high integrity conduct performance target improve efficiency activity minimise material energy use waste generate patient focus aim find opportunity use renewable material know research development manufacture recycle waste read sale product raise ethical issue aim employment practice open tackle understand important treat employee respect dignity encourage communicate stakeholder seek understand diversity ensure fair treatment phase view transparent setback employment provide safe healthy working experience progress environment support employee perform potential example commitment put patient mean responsibility performance reputation focus improve access medicine vaccine business read patient irrespective live ability pay human right believe right thing contribute commit uphold universal declaration sustainable business growth human right oecd guideline multinational enterprise ultimately believe responsible business good society core labour standard set international labour good gsk help operate efficiently gain organization expect standard supplier trust stakeholder create product patient contractor business partner work gsk behalf healthcare payer need foster right condition read report expansion business leadership advocacy read approach performance responsible business establish challenging standard corporate issue include access medicine research business ethic responsibility appropriate complexity specific need environment wwwgskcomresponsibility business build external guideline experience corporate responsibility report report share good practice seek influence publish march remain competitive order sustain business read report principle engagement stakeholder principle sum approach responsible business want understand concern interest underpin value provide guidance employee corporate responsibility issue engage range standard gsk committed stakeholder communicate openly access medicine address issue way aim meet need continue research develop medicine treat different group allow pursue legitimate business disease develop world find sustainable goal read report way improve access medicine disadvantaged people community investment seek partnership support activity read positive contribution community operate invest health education programme standard ethical conduct partnership aim bring sustainable improvement expect employee meet high ethical standard aspect underserved people develop develop world business conducting activity honesty read integrity adhere corporate responsibility principle comply applicable law regulation read gsk annual report weiver ssenisub responsible business improve access medicine work community access healthcare develop world invest community partnership programme seek easy solution challenge provide improve access medicine healthcare improve live sustainable access healthcare develop country poverty people world aim real difference single big barrier country people community work partner find innovative solution food access clean water supply hospital clinic healthcare challenge believe business important receive treatment healthcare professional care role play society strive leverage resource way deliver share value community business partner support organisation goal commit play address objective reflect mission improve quality human life healthcare challenge develop world take innovative responsible sustainable approach global community investment million gsk make vital contribution develop country healthcare compare million likeforlike basis action number area include preferential pricing increase expansion patient assistance antiretroviral tiere pricing vaccine medicine programme scale donation albendazole invest target disease particularly affect lymphatic filariasis programme donation vaccine develop world flexible pursue world health organization plus increase grant hiv open innovation strategy community investment activity aid reinvestment initiative ldc partnership foster effective healthcare capacity building give comprise product donation million cash seek innovative partnership solution give million inkind donation million plus cost cover contribution improve access medicine million manage deliver community programme extensively corporate responsibility report country product donation include million gsk patient assistance programme million worth clear leader access medicine atm albendazole programme million humanitarian index publish atm foundation product donation product donation continue build product pricing partnership value cost average cost good wholesale price commitment help improve healthcare develop wac accurate reflection cost gsk world expand commitment believe pharmaceutical company adopt define list develop country ldc establish practice comparative purpose total value donation develop country market access operating unit wac product million compare focus ldc broaden patient access gsk medicine million help build presence develop country operate single charitable foundation achieve significant increase resource community investment programme number global community need support countrybase foundation grant include provide access resultant medicine vaccine sustainable investment total progress significant barrier stand way well access healthcare tackle share cash giving target primarily health education responsibility sector global society government initiative follow international agency charity academic institution pharmaceutical industry health access medicine develop world education programme usa arts culture work provide access medicine people environment limited financial resource prescription medicine insurance uninsured americans qualify medicare medicaid gsk pharmaceutical company create global health programme access programme qualified individual develop country million people continue suffer offer reduction pharmacy cost die preventable treatable disease global health medicine addition gsk offer patient assistance programme design improve health quality life programme help lowincome uninsured americans people community provision medicine access gsk oncology specialty product vaccine education advocacy investment disease prevention prescription drug gsk patient assistance programme provide healthcare infrastructure global programme product patient longterm commitment design scaleable replicable programme country sustainable introduce orange card provide discount work partnership ngo lead health certain gsk prescription medicine eligible patient number organisation believe possible achieve significant country nature discount vary longlaste improvement healthcare section highlight country way healthcare system operate major health programme gsk annual report business review governance remuneration financial statement shareholder information responsible business eliminate lymphatic filariasis local programme effort eliminate world disable disease support community different market continue close partnership government country operate programme design fit local disease endemic world health organization circumstance culture align overall goal partner organisation found partner leader support access medicine healthcare local community effort commit donate anti priority vary community community population parasitic drug albendazole require reach billion population common challenge address people risk country million albendazole term particular health need human treatment donate country donate institutional capacity require effectively tackle need billion albendazole treatment global elimination contribute million continue programme start programme charitable activity support organisation positive action hivaid health medical research science education art positive action create environment include impact award scheme pharmaceutical company programme kind support provide small charity grant consult support community affect hiv aids auspex work address health need local community viiv healthcare new hivfocuse company programme programme north america national local level target fund communityfocuse project reach focus improve public education area science affect hiv particularly marginalise vulnerable mathematic increase access healthcare child population positive action work community enable homeless gsk impact award recognise organisation tackle stigma discrimination test innovation significantly improve health local community education care treatment deliver great involvement philadelphia research triangle park north carolina total live hiv positive action child fund launch fund north american programme million million available year help prevent mothertochild transmission hiv support orphans argentina pro mujer programme work lowincome vulnerable child support project end woman access affordable financial service late proposal broaden reach healthcare provide access small loan set scope response baby child affect hiv business train affordable healthcare service glaxosmithkline african malaria partnership gsk return communitymark excellence african malaria partnership programme alleviate community investment mortality suffer malaria bring affect community information gsk grant programmes africa new malaria grant award available wwwgskcom community programme provide health education affect population train community health worker employee involvement partnership save child kenya family health employee encourage contribute local international ghana african medical research foundation community employee volunteer scheme amref tanzania plan parenthood federation nigeria support include employee time cash donation charity employee volunteer match gift programme humanitarian product donation work nonprofit partner americare direct relief gsk match gift program match international map international interchurch medical assistance employee gift value million plus project hope support humanitarian relief effort million united way campaign gsk programme community healthcare country provide grant organisation employee volunteer ukbased nonprofit respond healthcare need community organisation gsk make difference programme affect disaster include devastating earthquake strike haiti january gsk donate supply medicine groupwide volunteer initiative launch value million include shipment gsk employee pay day year volunteer significant volume antibiotic respiratory good cause continue employee support diabete treatment consumer division provide range wide range charity project include work local school product include toothpaste antacids pain reliever shelter homeless community garden nursing home vitamin cholera outbreak respond aid community affect natural disaster specific request antibiotic donate gsk pulse volunteer partnership launch enable british red cross support deployment mass sanitation gsk employee difference community patient unit serve people live temporary relief need world volunteer work fulltime camp follow earthquake chile response partner nonprofit nongovernmental organisation ngo urgent request supply dose hepatitis vaccine experience volunteer address clear ngo need antibiotic dental hygiene kit develop leadership capability pakistan provide medicine local stock pulse deploy volunteer country work thousand people affect flooding cash ngo volunteer continue receive gsk salary donation amount include contribution month assignment figure world food programme support emergency food supply operating cost manage programme represent total inkind donation million total value international humanitarian product donation million average cost gsk annual report weiver ssenisub responsible business environmental sustainability central fund finance energy saving project accelerate progress complete project commit integrate environmental sustainability avoid tonne greenhouse gas emission business especially conserve resource year address climate change opportunity responsibility increase investment onsite generation renewable energy support renewable energy fund create strategy plan gsk consumer healthcare instal north america revise environmental sustainability strategy large roof mount solar photo voltaic system regional building strategy originally introduce new distribution centre york pennsylvania save nearly strategy recognise impact entire value chain tonne carbon dioxide emission year raw material disposal product objective benefit environment engage employee tackle key issue gsk global operation certify carbon trust standard benefit gsk financially potentially save million year company achieve recognition excellence reduce energy material distribution cost carbon management global operation analysis gsk impact show need concentrate water main area water particularly important natural resource recognise carbon dioxide emission contribute gsk play positive role manage sustainably climate change endorse united nations ceo water mandate water use reduce water consumption million litre despite significant business growth vaccine manufacture environmental stewardship cover use material business net water consumption fall sale generation waste pollution cumulative reduction exceed target set ambitious goal key impact include reduction carbon footprint reduction water use exceed target improve quality value chain zero waste landfill waste water target detailed corporate responsibility report environmental stewardship climate change energy aim use material efficiently safely minimise waste longterm vision entire value chain carbon pollution avoid harm people environment neutral ambitious target mean net greenhouse gas emission manufacturing increase efficiency use material priority distribute dispose product include longterm aspiration achieve mass efficiency source raw material new pharmaceutical product transfer manufacturing time typical level need act operation pharmaceutical industry reduce input material carbon footprint stem supply chain waste average mass efficiency new product derive propellant customer use inhaler period reach confirm global carbon footprint review entire value chain carry time improvement efficiency solvent use reduce volatile organic release air gsk carbon footprint million tonne coe annum sale cumulatively packaging provide opportunity conserve resource began implement sustainable packaging materialssupply chain strategy develop begin update green packaging guide designer manager product use american institute chemical engineer present industrial production operation practice award sustainable engineer operational distribution sustainability team work embed sustainability product end life manufacturing environmental management manage environmental issue occupational health meet goal eliminate use chlorofluorocarbon safety management system align recognise cfc product end reduce international standard business accountable greenhouse emission associate inhaler product sustainability plan performance central audit group million tonne carbon dioxide equivalent include environmental issue routine audits site approximately million tonne research business process work increasingly closely programme way find way reduce impact supplier contract manufacturer reduce environmental product impact supply chain reduce energy consumption operation read environmental performance transport greenhouse gas emission relative aspect sustainability corporate responsibility sale cumulative reduction energy report wwwgskcom emission target mainly progress slow early year fiveyear period gsk annual report business review governance remuneration financial statement shareholder information responsible business ethical conduct performance reward commit create strong ethical culture gsk performance development planning process mean emphasise value develop robust policy employee businessaligne objective behavioural recruiting engage right people equip goal reward system gear promote high information need ethical decision performance help attract retain good people put patient core principle ethical performancebase pay bonus sharebase equity plan pharmaceutical company align employee interest business target code conduct set fundamental standard communication employee involvement employee support employee guide business communication channel design employee conduct help employee ethical decision inform engage involve activity area emphasise gsk key value organisation encourage twoway open honest communication employee launch ommit transparency new update global intranet portal connectgsk respect people feedback monitoring mechanism major lway demonstrate high integrity conduct communication event feedback facility patient focus core feature web communication channel introduce idea engine online tool allow stress commitment performance integrity employee submit idea recommendation mean employee understand value stand policy procedure business evolve change affect underpin approach employee remain committed consulting change number internal consultation forum internal compliance system design identify discussion european employee consultation forum address breach code reinforce gsk value similar body country national practice continual external pressure enhance system compliance oversight audits help drive change employee number region fully investigate suspect breach appropriate disciplinary action include dismissal appropriate review strengthen approach usa prevent detect address bribery corruption europe launch dedicated antibribery corruption unit rest world ensure consistent approach gsk strengthen monitoring capability introduce party code conduct apply inclusion diversity gsk supplier set standard expect committed employment policy free discrimination supplier meet cover ethical conduct labour practice exist potential employee ground race environmental health safety standard management colour religion belief gender sexual orientation gender identity help supplier understand interact appropriately expression age national origin genetic makeup disability gsk staff code include key principle employee chronic health condition gsk commit offer people guide business conduct policy receive gift disability access range recruitment career diligence process potential acquisition take account opportunity effort retain support employee ethical risk integrate ethic compliance requirement disabled work gsk detail standard practice newly acquire business seek enter diversity measure corporate responsibility report joint venture organisation share value healthy safe high performance employee meet mission strategy employee health performance initiative focus health factor enable recruitment talent management leadership develoment employee perform high level sustain energy like year recruit retain develop engagement programme develop deliver employee critical enhancing sustain health strategy range traditional immunisation performance reputation proactive talent acquisition initiative smoke control weight management cuttingedge underpin ability attract specialist leadership talent programme area team personal resilience externally assessment process align core set ergonomic energy performance programme competencie ethic integrity central available language design address root need good succession plan senior role cause excessive work pressure low energy engagement critical position organisation maintain work home complement commitment robust leadership strategy identify develop highly skilled flexible thinking way deliver work enable leadership cadre use systematic discipline approach employee good work environment help leadership development provide tool programme help integrate work personal life detail leader master skill need meet customer employee scope impact programme corporate investor expectation provide train nearly responsibility report gsk leader worldwide develop new programme future senior leader senior executivespp weiver ssenisub financial review pharmaceutical turnover respiratory growth rate include review turnover constant respiratory sale increase billion exchange rate cer state calculation seretideadvair sale grow billion strong growth underlie turnover describe sterling growth japan million emerge market rate find table pharmaceutical turnover million sale usa level billion therapeutic area geographic segment grow europe billion pharmaceutical turnover decline billion exclude respiratory product deliver growth include pandemic product avandia valtrex underlie turnover avamysveramyst million ventolin increase million flovent million segmental analysis antiviral turnover report table represent sale invoice antiviral decrease billion gsk local entity customer local market plus relenza sale million million copromotion income market previous year significant government pandemic order receive valtrex sale decline million restate growth reflect generic competition usa europe cer central nervous system cns usa cns sales decrease billion europe emerge market majority gsk cns franchise impact generic asia pacificjapan competition usa wellbutrin decline primarily viiv healthcare reflect sale wellbutrin usa biovail second quarter cardiovascular urogenital cardiovascular urogenital sale increase billion cer represent growth constant exchange rate represent growth reflect continue strong growth key product arixtra actual exchange rate turnover quarter give page million avodart million sale usa decline billion primarily lovaza million generic competition valtrex significant reduction sale pandemic relate product low sale avandia exclude metabolic product underlie turnover grow despite metabolic sale decrease billion discontinuation gsk promotion boniva sale wellbutrin avandia product sale decline million impact healthcare reform september european medicine agency suspend product range new product exclude pandemic vaccine marketing authorisation rosiglitazone contain product launch grow contribute sale include avandia food drug administration europe pharmaceutical sale decline billion primarily announce additional measure ensure benefit avandia impact significant reduction sale pandemic continue outweigh risk include risk evaluation relate product generic competition valtrex low sale mitigation strategy rem programme result gsk expect avandia exclude product underlie sale flat global sale rosiglitazone contain product include avandia reflect impact government austerity measure minimal future emerge market pharmaceutical sale grow billion oncology emesis strong growth product category oncology emesis sale increase billion help pandemic relate product sale million tyverbtykerb million grow strongly million asia pacificjapan pharmaceutical sale grow segment newly launch oncology product votrient arzerra billion exclude pandemic relate product valtrex promacta deliver sale million million avandia underlie sale grow emerge market million respectively asia pacificjapan vaccines pharmaceutical turnover therapeutic area total vaccine sale grow billion include billion pharmaceutical turnover decline impact pandemic vaccine sale million exclude flu generic competition valtrex low avandia pandemic pandemic vaccine sale growth new vaccine product sale partly offset growth key product contribute growth include synflorix double seretideadvair avamysveramyst avodart lovaza tyverbtykerb million boostrix million cervarix ventolin vaccine franchise million sale hepatitis vaccine grow million infanrixpediarix grow million seasonal flu sale grow million rotarix sale million product continue recover market share lose follow temporary suspension market early year gsk annual report business review governance remuneration financial statement shareholder information financial review pharmaceutical turnover therapeutic area total usa europe emerge market rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give financial record page gsk annual report weiver ssenisub financial review dermatological result major restructure dermatology sale billion include heritage gsk total result product acquire business acquisition october board approve implementation principally stiefel july estimate sale growth detail formal plan gsk announce significant new business proforma basis exclude acquisition operational excellence restructure programme second formal approximately addition gsk heritage consumer plan represent significant expansion operational dermatology portfolio report consumer healthcare excellence programme approve board announce contribute sale million february expansion approve board viiv healthcare hiv announce february sale hiv product viiv healthcare restructure programme comprise detailed formal billion sale pfizer product selzentry plan cover area gsk business include manufacturing viracept combine sale million growth sell infrastructure estimate total cost epzicomkivexa million offset reduction approximately billion expand programme expect sale hiv product include trizivir deliver annual pretax saving approximately billion million combivir million epivir time substantially complete approximately million cost incur december approximately expect incurred consumer healthcare turnover balance total approximately cost expect cash expenditure expect restate growth accounting writedown total cer uncertainty exist exact time cash overthecounter outflow result potential future exchange rate medicine fluctuation element restructure programme oral healthcare subject employee consultation procedure make nutritional healthcare difficult predict precision procedure complete majority remain cash payment expect give extent cost cer represent growth constant exchange rate represent growth operational excellence restructure programme management actual exchange rate turnover quarter give believe material impact gsk operating result total consumer healthcare sale billion manner gsk business conduct gsk present significantly exceed market growth estimate gsk restructuring cost incur solely direct result approximately sale rest world grow operational excellence restructuring programme billion drive strong growth india china amount million tax million grow respectively europe sale level separate column income statement title year sale billion business major restructure usa grow billion addition restructuring cost operational excellence otc medicine programme major restructuring column income statement include restructuring cost incur solely direct otc product sale grow billion drive result restructure programme follow relate sale panadol nicotine replacement therapy product material acquisition operation acquire business dermatology product partly offset low respiratory tract overlap extensively gsk exist operation product low sale alli restructuring activity follow relate oral healthcare acquisition nature undertake sale oral healthcare product rise billion sensodyne operational excellence programme carry perform strongly denture care sale grow sale aquafresh follow detailed formal plan management consider decline slightly appropriate present cost restructuring activity nutritional healthcare manner restructuring cost incur nutritional healthcare sale grow billion drive strong direct result acquisition stiefel laboratory inc performance horlick growth lucozade sale july million million restructuring cost incur direct result acquisition reliant pharmaceuticals inc acquisition october meet criterion set charge pay gsk annual report business review governance remuneration financial statement shareholder information financial review group result cost operational excellence operating profit total result programme acquisitionrelate restructuring programme total result include restructure cost relate operational meeting criterion describe present excellence programme acquisition reliant stiefel separate column income statement describe result major restructuring presentation growth gsk intend apply consistently future major restructuring cer programme material impact gsk operate turnover result manner gsk business conduct cost sale adopt clearly group result sell general cost restructuring programme administration management believe presentation assist shareholder research gain clear understanding group financial development performance make projection future financial performance result include cost virtue operating size nature limited comparative value presentation income consistent way management assess group operate profit financial performance cost sale restructuring cost incur solely direct result operational excellence programme restructuring cost sale increase turnover programme follow reliant stiefel acquisition reflect impact generic competition high margin report major restructuring column income product usa principally valtrex low avandia sale statement restructuring cost principally arise healthcare reform european austerity price cut inventory impairment property plant equipment termination asset writedown partially offset saving employment contract staff redundant operational excellence programme low restructuring cost restructuring activity set note financial million million statement major restructuring programme asset impairment sell general administration staff redundancie account million sga cost percentage turnover increase million restructuring cost incur report percentage point exclude legal cost major restructure column million million sga cost restructuring cost arise solely direct result turnover increase percentage point operational excellence programme restructuring reflect sterling cer increase sga flat programme follow relate acquisition meet sterling turnover growth sga include restructuring cost criterion describe continue report operating million million investment growth market expense result major restructuring cost year impact acquisition stiefel partly offset include restructuring cost relate minor acquisition operational excellence savings usa europe low million income million cost relate exchange loss intercompany transaction advertising restructuring activity initiate commencement promotion decline sell distribution increase operational excellence programme restructure general administration exclude legal increase activity material impact gsk operating result research development manner business conduct expenditure total turnover remain cost million arise reflect increase expenditure sterling cer miscellaneous expenditure incur solely direct result flat sterling turnover growth include restructure restructure programme include termination cost million million viiv healthcare lease accelerate depreciation site closure cost consultancy investment low intangible asset impairment million project management fee cost arise gsk million saving operational excellence ongoing operating activity report major programme addition comparison prior year restructure column unfavourably impact oneoff recognition recoverable balance anticipate duration operational excellence programme gsk currently expect incur material operating income restructuring cost related programme operating income million million acquisition meeting criterion describe primarily reflect royalty income million unanticipated material restructuring cost arise million income transfer genentech period gsk expect include major exclusive promotion right boniva usa asset disposals restructure column million million partially offset equity investment impairment million million gsk operate profit profit taxation taxation profit income include disposal wellbutrin year discuss term total result asset disposal aspen pharmacare royalty dispute settlement include major restructuring cost result gain million accounting gain million major restructuring creation viiv healthcare gsk annual report weiver ssenisub financial review operating profit total result cost sale operating profit restructuring charge million cost sale increase turnover million year end december reflect impact generic competition high margin million decrease cer decrease products usa principally valtrex low avandia sale sterling term compare exclude legal cost healthcare reform european austerity price cut million million operating profit inventory asset writedown partially offset saving million decline cer term sterle operational excellence programme company term principally reflect decline turnover high cost expect cost sale percentage turnover sale high expenditure low operating income remain profit taxation total result sell general administration sga cost percentage turnover increase percentage net finance cost point primarily reflect high legal charge million million note financial statement finance income provision detail interest finance income exclude legal cost sga cost turnover unwind discount asset decrease percentage point reflect fair value adjustment hedge sterling cer decline expenditure compare prior year flat sterling turnover growth decline expenditure reflect operational excellence savings usa europe finance cost low exchange loss intercompany transaction partially interest cost offset investment growth market year impact unwind discount liability acquisition stiefel fair value adjustment hedge advertising promotion decline sell distribution finance expense decline general administration exclude legal decline collectively item account decline total sga company expect sga cost exclude legal profit disposal interest associate charge turnover profit disposal interest associate million research development million profit arise sale expenditure total turnover million quest share subsequent yearend reflect flat expenditure flat sterling turnover growth group sell entire shareholding quest rise include saving operational excellence programme pretax profit disposal associate approximately low intangible asset impairment million million million tax million high viiv healthcare investment share tax profit associate joint venture comparison prior year unfavourably impact share tax profit associate million oneoff recognition recoverable balance million arise principally group hold company expect cost percentage turnover quest remain profit taxation total result operate income take account net finance cost profit disposal operate income million million interest associate share profit associate total primarily reflect royalty income million profit taxation million compare million income transfer genentech million cer decline exclusive promotion rights boniva usa asset sterling decline disposal million million partially offset equity investment impairment million operating profit result major million income include disposal wellbutrin restructure asset disposal aspen pharmacare royalty dispute settlement gain million accounting gain result major restructuring set million creation viiv healthcare company expect operating income million growth exclude profit arise propose consumer healthcare cer divestment noncore otc brand turnover cost sale sell general administration research development operating income operating profit gsk annual report business review governance remuneration financial statement shareholder information financial review operate profit result major restructure low tax charge reflect high legal charge operate profit major restructuring year end billion billion december million decline cer term charge taxation total profit amount million decrease sterle term exclude legal cost represent effective tax rate million million operating profit million decline cer term decrease sterling term charge taxation profit major restructuring principally reflect decline turnover high cost sale charge amount million represent effective high expenditure low operating income partly tax rate gsk currently expect offset reduce sga cost operate profit margin exclude legal tax rate profit exclude profit disposal cost operating income company quest shareholding tax expect operate profit margin exclude legal cost profit realise disposal shareholde quest operating income percentage point low expect increase overall tax rate exclude effect tax arise propose profit taxation result major consumer healthcare divestment noncore brand restructure gsk continue believe adequate provision net finance cost liability likely arise open assessment ultimate liability matter vary amount provide finance income dependent outcome litigation proceeding negotiation relevant tax authority interest income unwind discount asset profit year fair value adjustment hedge growth cer total profit taxation finance cost year interest cost total profit attributable unwind discount liability shareholder fair value adjustment hedge basic earning share penny finance expense basic earning ad result major restructure profit taxation year net interest payable year million result major restructuring million company expect similar charge profit attributable shareholder profit disposal interest associate adjust earning share penny profit disposal interest associate million adjust earning ad million profit arise sale weight average number million quest share subsequent yearend gsk share million sell entire shareholding quest rise diluted total earning share penny pretax profit disposal associate approximately million million tax diluted total earning ad dilute weight average number share tax profit associate joint venture share million share tax profit associate million million arise principally group hold total result include restructuring cost produce basic eps quest diagnostics inc compare decline cer term decline sterling term exclude major profit taxation result major restructuring restructuring cost ep compare take account net finance cost profit disposal decline cer decrease sterling interest associate share profit associate profit term percentage point currency benefit arise tax major restructuring million compare weakness sterle major international currency million cer decline compare year partly offset strengthen decline sterling term sterle euro taxation charge dividend board declare fourth interim dividend penny share result dividend year penny pence corporation tax statutory rate increase penny share equivalent double taxation relief interim dividend receivable adr holder cent ad base exchange rate exdividend date february record date february overseas taxation payment date april current taxation defer taxation taxation total profit gsk annual report weiver ssenisub financial review critical accounting policy reconciliation gross turnover net turnover pharmaceutical business follow consolidated financial statement prepare accordance ifrs adopt use european union ifrs issue iasb follow accounting policy approve restate restate board describe note financial statement accounting principle policy management require gross turnover estimate assumption affect amount asset chargeback liability revenue expense report financial statement manage care medicare actual amount result differ estimate gpo critical accounting policy adopt relate follow area rebate turnover government taxation state programme legal dispute cash discount customer return property plant equipment prior year adjustment goodwill item intangible asset total deduction pension postemployment benefit net turnover information judgement estimate area give note financial statement key accounting information relate restate follow judgement estimate change segmental reporting set note financial statement segment information respect turnover accounting policy group large business pharmaceutical market rebate give government state programme complex arrangement rebate discount allowance increase year result healthcare reform follow briefly describe nature arrangement amendment additional expense arise new existence group pharmaceutical business legislation include manage medicaid sale discount feeforservice rate increase basic medicaid rebate gsk arrangement certain indirect customer new definition average manufacturer price incremental customer able buy product wholesaler consumer price index penalty line extension reduce price chargeback represent difference invoice price wholesaler indirect customer total accrual rebate discount allowance return contractual discount price accrual estimate chargeback pharmaceutical business follow calculate base term agreement historical experience product growth rate december december customer rebate offer key manage care group restate purchasing organisation gpo direct indirect customer arrangement require customer achieve chargeback certain performance target relate value product manage care medicare purchase formulary status predetermine market share relative gpo rebate competitor accrual customer rebate estimate base government state programme specific term agreement historical experience cash discount product growth rate customer return medicaid programme stateadministere programme provide assistance certain poor vulnerable patient total medicaid drug rebate program establish reduce state federal expenditure prescription drug accrual rebate government state programme patient affordable care act law increase result healthcare reform implement gsk participate provide rebate state accrual medicaid rebate calculate base specific term monthly process operate monitor inventory level individual state agreement combination historical wholesaler abnormal movement process use gross experience product population growth anticipate price sale volume prescription volume base party datum increase impact contracting strategy source information receive key wholesaler aim cash discount offer customer encourage prompt maintain inventory consistent level year year payment accrue time invoicing base pattern consumption adjust subsequently reflect actual experience basis pharmaceutical inventory level wholesaler historical experience customer return gsk distribution channel december record accrual estimate sale return apply historical estimate approximately month turnover experience customer return amount invoice calculation use party information accuracy market relate information stock level wholesaler totally verify believe sufficiently reliable anticipate price increase competitor activity purpose gsk annual report business review governance remuneration financial statement shareholder information financial position resource financial position property plant equipment gsk business sciencebase technologyintensive highly regulate governmental authority group allocate asset significant financial resource renewal maintenance noncurrent asset property plant equipment minimise risk interruption property plant equipment production achieve compliance regulatory standard goodwill number process use chemical hazardous material intangible asset total cost group property plant equipment investment associate joint venture december million net book investment value million land building represent defer tax asset million plant equipment million asset derivative financial instrument construction million gsk invest million noncurrent asset new renewal property plant equipment mainly relate large number project renewal improvement total noncurrent asset expansion facility worldwide site property current asset mainly hold freehold new investment finance group liquid inventory resource december gsk capital contractual current tax recoverable commitment future expenditure million operate trade receivables lease commitment million gsk believe facility derivative financial instrument adequate current need liquid investment group observe stringent procedure use specialist cash cash equivalent skill manage environmental risk activity asset hold sale environmental issue date operation total current asset modify discontinue report environmental total asset sustainability note financial statement legal proceeding liability goodwill current liability shortterm borrowing goodwill increase year million december million increase primarily trade payable reflect goodwill arise acquisition laboratorio derivative financial instrument phoenix saicyf million impact current tax payable strengthen overseas currency shortterm provision intangible asset total current liability intangible asset include cost intangible acquire noncurrent liability party computer software net book value longterm borrowing intangible asset december defer tax liability million million increase pension postemployment benefit reflect addition million business combination provision currency movement partly offset amortisation derivative financial instrument impairment exist intangible noncurrent liability investment total noncurrent liability gsk hold investment include associate joint venture total liability carry value december million net asset million market value december million million large equity investment associate quest diagnostic inc share capital book value december million share premium account million aspen pharmacare holding limit retain earning book value december million reserve million investment include equity stake shareholder equity company group research collaboration provide access biotechnology development potential interest noncontrolle interest interest company arise business divestment total equity derivative financial instrument asset gsk noncurrent current derivative financial instrument hold fair value million million small decrease primarily reflect decrease net investment hedging volume gsk annual report weiver ssenisub financial position resource inventory net debt decrease million free cash flow inventory million decrease million generate company exceed amount pay year decrease reflect initiative reduce manufacturing dividend shareholder invest new business cycle time reduce stockholde day efficient movement net debt use inventory supply chain trade receivable trade receivables million decrease net debt begin year reflect recovery significant level debt decreaseincrease cash bank overdraft year specific action take reduce overdue cash inflow liquid investment receivable group initiative reduce work net increase longterm loan capital reduction partly offset strengthen net repayment shortterm loan yearend foreign exchange rate debt subsidiary undertaking acquire exchange movement derivative financial instrument liability movement gsk hold current noncurrent derivative financial instrument hold fair value million million current net debt end year relate primarily hedge exchange translation currency asset consolidation small increase reflect marginally total equity high currency volatility euro dollar yen summary movement equity set trade payables trade payable amount million increase reflect work capital initiative total equity beginning year extend supplier term group day term objective total comprehensive income year strengthen yearend foreign exchange rate dividend shareholder provision ordinary share issue group carry defer tax provision shortterm change noncontrolle interest noncurrent provision million december option noncontrolle interest million respect estimate future consideration receive share transfer liability million million related esop trust legal dispute provision legal ordinary share acquire esop trust dispute indemnify disposal liability cost sharebase incentive plan restructure programme extent balance tax sharebase incentive plan sheet date legal constructive obligation exist distribution noncontrolle interest reliably estimate total equity end year pension postemployment benefit december total equity decrease group account pension postemployment million december million arrangement accordance ias deficit net decrease arise principally increase provision surplus allow deferred taxation million legal charge year million pension arrangement million million unfunded postemployment share purchase liability pension liability decrease follow increase employee share ownership plan esop trust acquire asset value usa deficit reduction contribution million share gsk plc million share company decrease longterm inflation rate hold trust satisfy future exercise option award partly offset reduction rate discount pension group share option award scheme proportion liability rate discount share hold trust respect award pension liability rule scheme require gsk satisfy exercise market december scheme purchase insurance contract purchase issue new share share hold guarantee payment specify pensioner liability trust match option award grant contract value billion december december esop trust hold million net debt million gsk share future exercise share option share award carry value million million deduct reserve market value share million cash cash equivalent million liquid investment borrowing repayable year borrowing repayable year net debt gsk annual report business review governance remuneration financial statement shareholder information financial position resource gsk purchase share nil commitment respect loan future interest payable february gsk announce company intend loan disclose take account effect repurchase billion share depend market derivative group enter number condition factor exact time research collaboration develop new compound future purchase share hold pharmaceutical company term arrangement treasury share cancel determined company include upfront fee equity investment loan commitment dependent market condition factor fund specify level research addition group december gsk hold million share treasury share agree payment future milestone million share cost million achieve agreement relate compound million deduct retain earning early stage development milestone payment continue number year compound successfully share purchase period january development process generally close product february period february marketing approval great possibility success february million share purchase amount show intangible asset represent cost million maximum pay milestone achieve commitment contingent liability include billion relate externalised project financial commitment summarise note financial discovery portfolio number new commitment statement commitment contingent liability licensing agreement include obligation respect short longterm debt set arrangement amicus therapeutics inc amplimmune inc note financial statement contingent liability apeiron biologics fondazione telethon isis pharmaceutical note financial statement net debt inc shionogi limit amount provide pension postretirement benefit gsk reach agreement trustee set note financial statement pensions pension scheme additional contribution postemployment benefit amount provide restructure year period eliminate pension deficit identify programme legal environmental dispute set december actuarial funding valuation table note financial statement provision show commitment exclude normal ongoing annual funding requirement approximately million contractual obligation commitment information pension obligation note financial follow table set group contractual obligation statement pension postemployment benefit commitment december fall payment contingent liability total yrs yrs yrs follow table set contingent liability comprise discount bill performance guarantee letter credit loan item arise normal course business interest loan expect expire finance lease obligation finance lease charge total yrs yrs yrs operate lease commitment guarantee intangible asset contingent liabilitie property plant equipment total business combination investment normal course business gsk provide purchase commitment indemnification guarantee respect business disposal pension legal dispute subsequently arise provision commitment outflow resource consider probable total reasonable estimate likely outcome dispute include note financial statement provision group policy provide settlement cost assert claim environmental dispute outflow resource consider probable reliable estimate prior point liability record legal environmental cost discuss risk factor page note financial statement legal proceeding gsk continue believe adequate provision liability likely arise open taxation assessment ultimate liability matter vary significantly amount provide dependent outcome litigation proceeding negotiation relevant tax authority discuss note financial statement taxation gsk annual report weiver ssenisub financial position resource cash flow free cash flow gsk management planning summary consolidate cash flow set reporting purpose discussion presentation investment analyst rate agency gsk free cash flow measure define ifrs measure directly comparable similarly describe measure net cash inflow operating activity company reconciliation net cash inflow operate net cash outflow investing activity activity close equivalent ifrs measure free net cash outflow financing activity cash flow show decreaseincrease cash bank overdraft reconciliation free cash flow exchange adjustment cash bank overdraft begin year net cash inflow operating activity cash bank overdraft end year purchase property plant equipment cash bank overdraft end year purchase noncurrent intangible asset comprise disposal property plant equipment interest pay cash cash equivalent interest receive overdrafts dividend receive joint venture associate undertaking distribution noncontrolle interest net cash inflow operating activity taxation pay million decrease million free cash flow reflect high legal settlement year partly offset net work capital reduction investment appraisal gsk formal process assess potential investment net cash outflow investing activity million proposal order ensure decision align group decrease million primarily reflect low overall strategy process include analysis impact business purchase million business project earning return invest capital assessment purchase million primarily stiefel laboratories inc return base discount cash flow discount rate addition purchase property plant equipment lower perform financial analysis decide internally allow million determination extent investment cover group free cash flow cost capital specific investment discount rate free cash flow cash generate business adjust account country risk weighting meet obligation interest tax dividend pay capital expenditure financial investment noncontrolle interest capital expenditure non cash payment tangible intangible fix asset amount current tangible intangible asset million million disposal realise million million cash payment acquire equity investment million million year sale equity investment realise million million future cash flow group expect future operating cash flow sufficient fund operate debt service cost satisfy normal level capital expenditure meet obligation exist licensing agreement meet expenditure arise major restructuring programme precise time uncertain outlined note financial statement major restructuring programme meet routine outflow include tax dividend subject risk factor discuss page free cash flow adversely impact legal settlement gsk time time additional demand finance million million free cash flow exclude legal acquisition share repurchase access settlement million compare source liquidity short longterm capital market million improvement reflect reduction work bank financial institution addition cash capital low expenditure property plant equipment flow operation need gsk annual report business review governance remuneration financial statement shareholder information financial position resource payment policy liquidity group company responsible monitoring manage december cash liquid investment work capital term sale collection supplier hold follow payment reflect local commercial practice company subsidiarie policy ensure supplier pay time particular bank balance deposit company seek treasury treasury repo money market fund settle term payment supplier agree corporate debt instrument term transaction government security ensure supplier aware agree term payment abide term payment centrally manage cash reserve amount billion policy permit arrangement accelerate payment december available month exclude small supplier billion centrally manage cash hold viiv healthcare own subsidiary billion undrawn payment performance commit facility date short term overdraft december average number day payable loan repayable year million outstanding represent trade payable parent company net debt billion december table nil nil respect company summarise cash gross debt effect hedging subsidiary aggregate day day treasury policy gsk report sterling pay dividend sterling profit cash liquid investment role corporate treasury manage monitor gross debt fix external internal funding requirement financial risk float support strategic objective treasury activity govern noninterest bearing policy procedure approve board director net debt recently october treasury management group tmg chair chief manage net borrowing requirement portfolio financial officer meet monthly basis review treasury longterm borrowing include bond short activity member receive management information relate term finance billion commercial paper programme treasury activity billion commit facility facility renew october consider level commit capital management facility adequate give current liquidity requirement gsk operate global basis primarily subsidiary information facility note financial company establish market trade statement net debt benefit strong positive cash significant level patent trademark protection product flow operating unit compete largely product efficacy differentiation price selling margin sufficient cover normal operate european medium term note programme cost operation cash generative billion december billion note issue programme shelf operate cash flow fund investment research registration statement december development new product routine billion billion note issue programme outflow capital expenditure tax dividend repayment tmg monitor cash flow forecast monthly basis mature debt extent determine board share repurchase new longterm share longterm borrowing mature date buyback programme depend market condition longterm debt rating remain stable factor expect repurchase billion share february currently rate stable outlook standard poor stable outlook moodys investor policy borrow centrally variety capital market service moodys shortterm debt rating issue borrow facility meet anticipated funding standard poor moodys respectively requirement borrowing cash generate operation onlent contribute equity certain subsidiary pay dividend acquisition gsk share repurchase detail note financial statement financial instrument relate disclosure gsk annual report weiver ssenisub financial position resource maturity profile gross debt equivalent gbp bonds eur bond usd bond bank borrowing lease treasury operation interest rate risk management objective treasury activity manage posttax net policy interest rate risk management limit cost income financial operation benefit earning float rate interest payment prescribe percentage corporate treasury operate profit centre use trading profit variety financial instrument finance operation use series interest rate swap redenominate derivative financial instrument manage market risk external borrowing interest rate coupon require gsk operation derivative principally comprise forward duration swap match duration principal foreign currency contract interest rate currency swap instrument interest rate derivative instrument account swap borrowing liquid asset require fair value cash flow hedge relevant asset liability currency manage exposure funding risk change foreign exchange interest rate counterparty risk management policy counterparty risk management work select hold issue derivative speculative purpose group relationship bank global counterparty limit assign treasury policy specifically prohibit activity transaction gsk banking investment counterpartie base financial instrument undertake manage risk arise longterm credit rating moodys standard poor underlie business activity speculation corporate treasury usage limit monitor daily foreign exchange management corporate compliance officer cco operate independently foreign currency transaction exposure arise internal corporate treasury breach limit report external trade flow hedge exposure overseas cfo immediately cco monitor credit rating operating subsidiary transaction risk minimised matching counterpartie change rating occur notifie local currency income local currency cost corporate treasury change investment level authority limit appropriate counterparty analysis purpose internal trading transaction match present tmg annually approval centrally manage intercompany payment term reduce foreign currency risk exceptional foreign currency cash flow financial asset liability hedge selectively management corporate treasury analysis net debt give note financial manage cash surplus borrowing requirement statement net debt analysis financial asset liability subsidiary company centrally forward contract hedge carry value fair value give note financial future repayment originate currency statement financial instrument relate disclosure seek denominate borrowing currency continue benefit strong positive cash flow principal asset cash flow primarily denominate operating activity net debt decrease year dollar euro sterle certain borrowing december reflect benefit ongoing swap currency require restructure programme success work capital initiative borrowing denominate swap foreign currency match investment overseas asset treat financial asset liability december hedge relevant asset forward contract representative treasury policy strategy approve major currency reduce exposure investment board director recently october overseas group asset net investment hedge section gsk raise debt capital market note detail tmg review ratio share repurchase borrowing asset major currency gsk annual report business review governance remuneration financial statement shareholder information financial review accordance sec disclosure requirement follow cns discussion compare result year december cns sale decrease billion result year december majority gsk cns franchise impact generic financial information discussion follows present competition usa wellbutrin decline primarily basis gsk organise manage reflect sale wellbutrin usa biovail second quarter exchange cardiovascular urogenital currency influence group result remain cardiovascular urogenital sale increase billion dollar euro japanese yen continue strong growth key product arixtra average sterling exchange rate weak million avodart million lovaza dollar euro yen compare million partly offset generic competition yearend sterling exchange rate strong coreg currency compare december metabolic pharmaceutical turnover metabolic sale decrease billion growth rate include review turnover constant sale avandia million continue decline exchange rate cer state sterling growth region bonvivaboniva sale decline usa rate find table pharmaceutical turnover grow europe rest world therapeutic area geographic region oncology emesis pharmaceutical turnover grow billion pharmaceutical growth help sale pandemic product regional oncology emesis sale increase billion basis usa decline reflect continued erosion tyverbtykerb million grow strongly europe product generic competition strong performance rest world follow product approval gain deliver europe emerge market asia zofran decline result generic competition pacificjapan sale contribution stiefel acquire july total million vaccine vaccine sale increase billion pharmaceutical turnover therapeutic area pandemic vaccine sale million record gsk turnover grow impact generic year deliver fourth quarter gsk competition range gsk product low avandia sale partner government respond pandemic decline hiv business offset strong growth key product seretideadvair avodart lovaza relenza sale gsk new synflorix vaccine total million reflect vaccine franchise include pandemic vaccine launch market begin shipment brazilian government year billion agreement respiratory sign august strong contributor growth respiratory sale increase billion year include boostrix million cervarix million rotarix million partially seretideadvair grow billion especially strong offset performance sale infanrixpediarix fall growth emerge market million million primarily result continued impact japan million ventolin sale grow increase competition dtpa sector usa hepatitis million drive performance usa sale vaccine sale fall million double million veramyst sale rise competitor product return market million antiviral antiviral increase billion relenza sale million million reflect successful capacity expansion meet government order world strong retail performance japan million sale valtrex decline billion result generic competition product usa begin november sale hiv medicine total billion year epzicom sale grow million offset decline rest portfolio viiv healthcare specialist hiv company establish gsk pfizer officially launch november gsk annual report weiver ssenisub financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major product cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip seroxatpaxil treximet wellbutrin wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis engerix fendrix havrix twinrix infanrix pediarix rotarix synflorix stiefel product cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report business review governance remuneration financial statement shareholder information financial review regional analysis consumer healthcare turnover turnover report table represent sale invoice gsk local entity customer local market plus growth total cer copromotion income market overthecounter growth medicine cer alli usa breathe right europe cold sore franchise emerge market nicotine replacement therapy asia pacificjapan panadol franchise trading tum oral healthcare aquafresh franchise cer represent growth constant exchange rate represent growth biotene actual exchange rate include stiefel denture care sensodyne franchise usa sales usa decline billion principally reflect nutritional healthcare continue decline avandia competition lucozade infanrixpediarix return market competitor horlick hepatitis franchise generic competition ribena significant product lamictal imigran valtrex requip coreg addition wellbutrin sell biovail cer represent growth constant exchange rate represent growth decline partly offset significant sale actual exchange rate relenza pandemic vaccine double ventolin sale total consumer healthcare sale year rise good growth lovaza contribution recently billion growth region category launch product boostrix rotarix otc medicine europe otc product sale grow billion drive sale sale europe increase billion continued growth panadol million alli seretide relenza particularly strong vaccine growth double million result launch europe drive pandemic vaccine offset impact generic begin april sale nicotine replacement therapy competition number product continue price cut product decline government region oral healthcare emerge market sale oral healthcare product rise billion sensodyne sale emerge market increase billion perform strongly sale million denture care strong growth region therapeutic area help sale grow million sale aquafresh decline acquisition ucb bms business different reduction white tray market offset growth country region aquafresh toothpaste brand help launch asia pacificjapan new isoactive product sale asia pacificjapan grow billion reflect nutritional healthcare continue seretideadvair growth strong relenza sale particularly nutritional healthcare sale grow billion drive retail market japan strong vaccine growth strong performance horlick million partly offset decline lucozade sale million impact low sale impulse market market gsk annual report weiver ssenisub financial review result major restructuring operating profit total result total result total result include restructure cost relate operational october gsk announce significant new operational excellence programme acquisition reliant stiefel excellence restructure programme second formal plan represent significant expansion operational excellence growth cer programme approve board announce february turnover cost sale addition cost operational excellence programme sell general major restructuring column income statement include administration restructuring cost incur solely direct result research restructuring programme follow relate material development acquisition operation acquire business overlap operate extensively gsk exist operation income acquisition stiefel laboratories inc july operating profit acquisition meet criterion set acquisition cost incur direct result cost sale relate restructuring programme include major restructure column restructuring cost expect cost sale percentage turnover reduce marginally incur direct result acquisition estimate turnover principally reflect impact approximately million million charge generic competition high margin product usa restructuring cost incur direct result change product mix offset benefit restructure acquisition reliant pharmaceuticals inc programme low restructuring cost million acquisition october meet criterion set million charge pay sell general administration restructuring cost incur solely direct result sga cost percentage turnover increase operational excellence programme restructure percentage point include year legal charge programme follow reliant stiefel acquisition million million charge relate report major restructuring column income major restructure programme million statement set note financial statement million exclude legal restructure major restructure programme asset impairment staff cost sga cost turnover redundancy account million reflect investment growth market acquisition million restructuring cost incur remain cost stiefel increase pension cost donation product million arise miscellaneous expenditure exchange loss intercompany transaction incur solely direct result restructure programme compare exchange gain year partially offset cost arise gsk ongoing operating activity benefit current restructure programme report major restructuring column research development late position result major restructuring expenditure total turnover total result result major restructure total result include million intangible asset writeoff financial review million partially offset low charge relate major restructure programme million gsk operate profit profit taxation taxation profit million provision release reassessment year discuss term total result receivable balance increase investment vaccine include major restructuring cost result late stage pharmaceutical broadly offset saving major restructuring restructure programme operating income operating income million include gain asset disposal million million primarily reflect disposal wellbutrin asset aspen pharmacare royalty income million million royalty dispute settlement gain million onetime accounting gain million creation viiv healthcare partially offset equity investment impairment million operating profit total result total operating profit year million increase cer sterling term compare operate profit margin increase percentage point reflect high operating income broadly flat expenditure partially offset increase cost sale sga gsk annual report business review governance remuneration financial statement shareholder information financial review profit taxation total result sell general administration sga cost percentage turnover increase net finance cost percentage point include year legal charge million increase reflect investment growth market finance income acquisition stiefel increase pension cost donation interest finance income product exchange loss intercompany unwind discount asset transaction compare exchange gain year partially fair value adjustment hedge offset benefit current restructure programme research development expenditure total turnover finance cost include million intangible asset writeoff interest cost million partially offset provision release unwind discount liabilitie reassessment receivable balance increase investment fair value adjustment hedge vaccine latestage pharmaceutical broadly offset saving restructuring programme operate income profit disposal interest associate operating income million include gain profit disposal interest associate million asset disposal million million million share group hold quest diagnostic primarily reflect disposal wellbutrin inc sell quarter asset aspen pharmacare royalty income million million royalty dispute settlement gain share tax profit associate joint venture million onetime accounting gain million share tax profit associate million creation viiv healthcare partially offset equity million arise principally group hold investment impairment million operating quest income profit disposal associate amount profit taxation total result million take account net finance cost profit disposal operate profit result major restructure interest associate share profit associate operating profit major restructuring year total profit taxation million compare million cer decline sterling term million cer increase compare operate profit margin sterling increase compare margin decline margin primarily generic competition usa operating profit result major impact cost good increase investment support restructure group diversification strategy impact sga partly offset result major restructuring set high level operating income information operating profit major restructuring growth provide note segment information cer turnover cost sale sell general administration research development operating income operate profit cost sale cost sale increase turnover principally reflect impact generic competition high margin product usa change product mix partly offset benefit restructure programme gsk annual report weiver ssenisub financial review profit taxation result major profit year restructuring growth net finance cost cer total profit taxation finance income year interest income total profit attributable unwind discount asset shareholder fair value adjustment hedge basic earning share penny basic earning ad result major restructuring finance cost profit taxation year interest cost result major restructuring unwind discount liability profit attributable shareholder fair value adjustment hedge adjust earning share penny adjust earning ad weight average number share million profit disposal interest associate profit disposal interest associate million diluted total earning share penny million quest share sell quarter dilute total earning ad dilute weight average number share tax profit associate joint venture share million share tax profit associate million million arise principally group hold total result include restructuring cost produce basic eps quest diagnostics inc compare growth cer term growth sterling term exclude major profit taxation result major restructuring restructuring cost ep compare take account net finance cost profit disposal interest associate share profit associate profit dividend tax major restructuring million compare board declare fourth interim dividend penny million cer decline increase share result dividend year penny penny sterling term increase penny share taxation corporation tax overseas taxation current taxation defer taxation taxation total profit charge taxation total profit amount million represent effective tax rate charge taxation profit major restructuring charge amount million represent effective tax rate group balance sheet december include tax payable liability million tax recoverable asset million november irs concede asserted tax deficiency penalty arise reclassification intercompany financing arrangement debt equity result additional tax cost gsk late position taxation taxation financial review gsk annual report business review governance remuneration financial statement shareholder information risk factor risk uncertainty relevant group increase pressure healthcare budget business financial condition result operation average age population develop market increase affect group performance ability achieve objective absolute population develop market grow payer factor group believe increasingly demand great incremental benefit cause actual result differ materially expect drug agree reimburse supplier price supplier historical result risk uncertainty consider appropriate failure develop commercially successful affect group performance ability achieve product develop additional use exist product objective currently know group reason materially adversely affect group deem immaterial financial result group review assess significant risk regular basis intellectual property protection implement oversight programme help ensure competition generic manufacturer system internal control place system include group face intense competition manufacturer policy procedure communication training programme generic pharmaceutical product major market generic supervision monitoring process escalate issue product enter market expiration patent data appropriate level senior management system help exclusivity period group product introduction generic facilitate group ability respond appropriately risk product particularly usa group high achieve group objective help ensure compliance turnover margin typically lead dramatic loss sale applicable law regulation internal policy group reduce group revenue margin proprietary management risk discuss page product group pharmaceutical product corporate governance million annual global sale product possible group implement controls augmentin lamictal ventolin valtrex respond risk face generic competition usa certain market europe assurance step group take address certain risk addition detailed timing impact entry manage risk effectively principal risk followon product seretideadvair contain affect gsk business break follow area active ingredient uncertain risk deliver commercially successful generic drug manufacturer exhibit readiness new product market generic version group important group operate highly competitive market product prior expiration group patent effort pharmaceutical vaccine business face competition involve challenge validity enforceability patent proprietary product large international manufacturer assertion generic product infringe group producer generic pharmaceutical significant product patent group successful defend attack innovation technical advance intensification price patent maintain exclusive right market competition competitor materially adversely affect major product particularly usa europe group group financial result group predict financial result adversely affect expiration date time impact competitive product potential patent group major product description impact sale group product light competitive litigation settlement affect date generic environment group operate continue development version group product introduced set commercially viable new product development legal proceeding involve patent challenge set additional use exist product critical group ability note financial statement legal proceeding replace sale old product decline expiration potential change intellectual property law exclusive right increase overall sale regulation develop new product costly lengthy uncertain process proposal change exist patent datum exclusivity law new product candidate fail stage development regulation major market group sell product process late stage product candidate fail continue feature political process country receive regulatory approval include proposal effect make prosecution patent new product difficult time new product candidate appear promise development consuming adversely affect exclusivity period significant investment group economic human group product include biological product resource fail reach market limit proposal enact materially adversely affect commercial success example result group financial result example efficacy safety concern inability obtain necessary comprehensive healthcare reform usa new regulation regulatory approval difficulty manufacture excessive followon biologic introduce allow sufficiently manufacturing cost erosion patent term result similar biologic able rely innovator approval lengthy development period infringement patent follow year datum exclusivity period addition current intellectual property right inability differentiate administration usa propose reduce year product adequately compete seven period time pharmaceutical company furthermore health authority fda european product exclusive generic competition medicine agency japan pharmaceuticals medicine device agency increase focus safety product differentiation assess benefitrisk balance drug difficult pharmaceutical product gain regulatory approval gsk annual report weiver ssenisub risk factor weakness intellectual property protection instance party perform analysis publish certain country clinical trial result necessarily accurate country group operate patent meaningful raise question safety protection significantly weak usa pharmaceutical product publicise medium european union develop country reduce result product liability claim group currently threaten reduce effective patent protection defendant number product liability lawsuit include class pharmaceutical product generally particular therapeutic action involve substantial claim damage relate area facilitate early competition market group pharmaceutical product litigation particularly generic manufacturer loss patent protection include usa inherently unpredictable class action sweep reduce scope patent right compulsory licensing person prescribe group product inflate government force manufacturer license potential liability force number claim pain intellectual property competitor materially adversely suffer punitive damage frequently assert product affect group financial result market absence liability action allow represent potentially open adequate patent protection limit opportunity rely end exposure materially adversely affect market future sale growth group product group financial result risk substantial adverse outcome litigation antitrust litigation government investigation usa increasingly common patent note financial statement legal proceeding infringement action prompt claim antitrust law discussion proceeding governmental investigation violate initial prosecution patent currently involve group prove rise litigation involve defence patent claim civil criminal liability unfavourable resolution direct indirect purchaser payer typically file similar future proceeding investigation material class action relief seek include treble damage adverse effect group financial condition result restitution claim damage adverse antitrust verdict subject operation group material provision automatic trebling usa similarly antitrust claim prior year related legal proceeding investigation bring follow settlement patent litigation allege reduce earning settlement anticompetitive violation antitrust law successful antitrust claim group materially future group additional significant adversely affect group financial result provision relate legal proceeding investigation reduce earning case group believe sale marketing regulation practice plaintiff bar claim damage amount group operate globally complex legal regulatory bear reasonable relationship underlie harm allegedly environment vary jurisdiction failure cause group product action accordingly comply applicable law rule regulation potentially mislead group quantify base jurisdiction result civil criminal legal proceeding damage claim potential exposure claim rules regulation change governmental proceeding investigation type describe note interpretation rule regulation evolve prior conduct financial statement legal proceeding call question recent insurance loss experience include pharmaceutical usa example group respond federal product liability exposure increase cost reduce state governmental investigation pricing marketing capacity insurer provide coverage pharmaceutical reimbursement prescription drug product company generally include group investigation result related restitution civil litigation behalf federal state government relate order contain insurance cost recent year group proceeding initiate group behalf continue adjust coverage profile accept great degree consumer private payer proceeding result uninsured exposure area less degree treble damage award fine respect violation order optimise value insurance market addition law criminal proceeding initiate group claim insurance policy insurer regularly consequence materially adversely affect reserve right deny coverage ground group financial result product liability litigation preclinical clinical trial conduct development potential product determine safety efficacy product use human follow approval regulatory authority notwithstanding effort group make determine safety product regulate clinical trial unanticipate effect evident drug vaccine introduce marketplace gsk annual report business review governance remuneration financial statement shareholder information risk factor governmental payer regulatory control addition case group voluntarily cease pricing marketing product face decline sale base concern pharmaceutical product subject price control pressure efficacy safety example decline sale restriction market include japan germany avandia beginning follow publicity question spain france italy government intervene directly risk associate product set price scientifically justify absence regulatory action development postapproval adverse event profile addition market major purchaser pharmaceutical product product class materially adversely affect product governmental agency private health care group financial result provider economic power exert substantial pressure price term access formulary group risk interruption product supply accurately predict exist control pressure restriction manufacture pharmaceutical product constituent increase new control pressure restriction material require compliance good manufacturing practice introduce measure materially adversely affect regulation group manufacture site subject group ability introduce new product profitably review approval fda regulatory agency financial result compliance failure supplier key service material group manufacture facility lead product recall example usa group high margin seizure interruption production delay approval sale country government price new product pende resolution manufacturing issue control private sector purchase federal law require noncompliance result fine disgorgement pharmaceutical manufacturer pay prescribe rebate certain profit interruption supply incur fine drug eligible reimbursement state disgorgement materially adversely affect group federal healthcare programme primarily medicare medicaid financial result pricing pressure likely increase government share national health spending continue increase additionally group undertake business continuity planning passage comprehensive health care reform single source certain component bulk active material government role provide subsidise health insurance finish product create risk failure supply expect significantly expand indicate event regulatory noncompliance physical disruption grow role leverage government bring bear manufacturing site group rebate liability respect federal program unaffiliate thirdparty supplier provide number good recent year number state propose service group operation service implement scheme control price low example service provide clinical research organisation income senior citizen programme include increase support development key product important rebate liability pharmaceutical company importation operation group business material provide country bulk purchase drug give new state thirdparty supplier necessary commercial production mandate contain health care reform law product include speciality chemical commodity increase number medicaid eligible participant component necessary manufacture package economic pressure state government budget pricing pressure group pharmaceutical consumer healthcare group product likely increase trend product group believe materially adversely affect group financial result thirdparty relationship individually significant context overall group failure thirdparty supplier fulfil regulatory control contractual obligation timely manner result delay group comply broad range regulatory control service interruption materially adversely affect test approval manufacturing marketing group financial result pharmaceutical vaccine consumer healthcare product particularly usa countries european union taxation treasury affect cost product development time group effective tax rate drive rate tax require reach market uncertainty successfully jurisdiction higher lower apply detailed health authority increase addition jurisdiction belgium focus safety assess riskbenefit balance usa currently offer regime encourage innovation new drug context initial product approval scientific endeavour provide tax incentive example context approval additional indication review tax credit furthermore give scale international nature information market product strict regulatory group business intragroup transfer pricing inherent control heighten risk change product profile tax risk international business change tax withdrawal regulator basis postapproval concern law application respect matter transfer product safety reduce revenue result price foreign dividend control company tax credit product recall product liability lawsuit great restriction tax relief allow interest intragroup regulatory scrutiny especially usa advertising debt increase group effective tax rate materially promotion particular directtoconsumer advertising adversely affect financial result gsk annual report weiver ssenisub risk factor tax charge include financial statement group global political economic condition good estimate tax liability time audits describe world large economy tax authority conclude degree uncertainty include major market group operate final tax liability period group policy financial institution recent past faced extreme financial submit tax return statutory time limit engage difficulty include decline asset price liquidity problem tax authority ensure group tax affair current limited availability credit economy possible difference interpretation tax recover economic recovery pace legislation regulation resolve quickly possible prove uneven exceptional case matter settle agreement continue economic weakness material adverse effect tax authority gsk resolve dispute group sale result operation financial condition formal appeal proceeding example canadian ability raise capital group business include tax authority currently seek leave appeal court pharmaceutical consumer healthcare particularly decision respect transfer pricing discuss note sensitive decline consumer spending addition financial statement taxation renew decline asset price result low return group deal high value transaction frequent basis group financial investment cause value result increase risk financial loss group investment pension plan decrease require mismanagement cash enter high risk position group increase fund pension plan hedge transaction materially adversely group conduct substantial portion operation outside affect group financial result group management foreign exchange rate discuss business review foreign exchange management number risk affect fluctuation exchange rate sterle financial condition result group follow currency especially dollar euro antibribery corruption japanese yen materially adversely affect group financial result group extensive increase international operation rise possible claim bribery corruption failure group control change inflation interest comply applicable legislation foreign rate foreign currency exchange rate control corrupt practice act recently enact bribery act economic factor affect business possibility expose group senior officer civil criminal political unrest legal regulatory change nationalisation sanction include fine prosecution potential debarment jurisdiction group operate public procurement reputational damage materially adversely affect group financial result group operate number middle eastern north compliance mechanism monitor programme african market subsequent yearend experience group place adequately prevent detect possible political unrest event lead business disruption violation applicable antibribery corruption legislation liquidity problem adversely impact group result risk concentration sale wholesaler environmental liability usa similar pharmaceutical company group environmental law jurisdiction impose actual sell product small number wholesaler addition potential obligation group remediate contaminate hospital pharmacie physician group sale site group identify potentially large wholesaler amount approximately responsible party comprehensive environmental group pharmaceutical sale december response compensation liability act number site group trade receivable wholesaler remediation cost relate group use ownership totalling million december million site failure manage properly environmental risk group expose concentration credit risk respect result additional remedial cost materially adversely wholesaler affect financial affect group financial result note financial difficulty materially adversely affect group statement legal proceeding discussion environmental financial result relate proceeding group involve accounting standard new revise accounting standard rule interpretation issue time time international accounting standard board result change recognition income expense materially adversely affect group financial result international financial reporting standard change market valuation certain financial instrument require gain loss instrument reflect group report result gain loss actually realise significant impact income statement give period accounting defer taxation intercompany inventory rise volatility depend group entity own inventory gsk annual report business review governance remuneration financial statement shareholder information risk factor regulator regularly review financial statement list attraction retention company compliance account regulatory group rely heavily recruit retain talented requirement group believe complie employee range skill meet objective group appropriate regulatory requirement concern financial face intense competition qualified individual supply statement disclosure company people specific skill specific geographic region experience investigation potential noncompliance limit particularly give group plan expand operation accounting disclosure requirement result emerge market biological consumer healthcare restatement previously report result inability attract staff specific technical leadership significant penalty investigation require skill retain key employee ensure effective succession planning restatement materially adversely affect group critical position materially adversely affect group financial result financial result protection electronic information asset implement group strategic priority group rely critical sensitive datum personally group establish strategic priority grow identifiable information trade secret intellectual property diversify business deliver product value simplify corporate strategic plan security type datum expose operating model group able implement increase external threat group subject strategic priority fully group able implement standard protection personally identifiable information strategic priority strategic priority deliver failure implement appropriate safeguard adequately protect expect benefit unauthorised unintentional access acquisition use modification loss disclosure critical sensitive datum example strategic priority grow diversified business adversely affect group operation involve expand group business emerge market group pharmaceutical sale emerge market grow alliance acquisition nearly billion represent group group strategy diversify new product pharmaceutical turnover guarantee area market group grown expect group sale emerge market continue grow continue grow acquisition business market continue experience relatively high growth alliance intense competition alliance acquisition rate emerge market especially vulnerable candidate pharmaceutical industry group aftereffect recent global financial crisis unable deal acceptable term limited resource spend healthcare competition acquire form alliance company group market staff skill training suitable assume significant debt subject unknown employment enterprise group intense contingent liability fail realise benefit expect emerge market group require rely transaction example pharmaceutical company party agent group risk liability include group consider acquire emerge market lack sufficient protection crime involve patent dispute product liability litigation government counterfeiting failure continue expand business investigation legal proceeding outcome emerge growth market materially adversely affect subject considerable uncertainty assumption debt group financial result unknown contingent liability failure realise expect benefit materially adversely affect group addition group undertake restructure programme financial result estimate cost approximately billion expect deliver annual pretax saving approximately process integrate company group acquire billion time substantially complete result disruption ongoing business effort group able execute fully transformation integrate organisation different location business furthermore change group structure thing differ system corporate culture divert operation revenue cost efficiency result attention resource result loss key employee restructure activity strategic initiative result adverse consequence materially high expect cost difficulty failure realise adversely affect group financial result expect cost saving end restructure programme achieve maintain competitive cost base materially adversely affect group financial result gsk annual report noitarenumer dna ecnanrevog board sir christopher gent professor sir roy anderson larry culp aged simon dingemans age aged aged appoint july appoint january appoint june appoint october nonexecutive director executive director chief chairman nonexecutive director larry president chief financial officer designate sir christopher non sir roy professor infectious executive officer danaher simon join gsk executive director ferrari spa disease epidemiology corporation prior join goldman sachs chief executive faculty medicine imperial danaher hold position manage director officer vodafone group plc college london accenture previously partner years retirement july member international andersen consulting experience investment nonexecutive director advisory board hakluyt banking include recently lehman brothers holdings ltd trustee leader goldman sachs inc member kpmgs natural history museum european business chairmans advisory group london fellow head senior adviser bain royal society foreign investment banking member advisory associate member board reform institute medicine national academy sciences french academy science position sir crispin davis aged include rector imperial appoint july college chief scientific nonexecutive director adviser ministry sir crispin chairman defence director starbev netherlands member citigroup andrew witty aged julian heslop aged global advisory board appoint january appoint april serve council oxford chief executive officer chief financial officer university previously andrew name chief julian join glaxo wellcome chief executive officer reed executive officer designate financial controller april elsevi plc prior gsk october january appointment chief executive appoint chief executive appoint senior vice president aegis group plc officer ceo operation controller prior join guinness plc join group join group hold member hold senior stephanie burn senior finance role grand main board group position asia africa age metropolitan julian retire manage director usa immediately prior appoint february chief financial officer united distiller early appoint ceo andrew executive director career work procter president pharmaceuticals nonexecutive director march gamble europe position hold stephanie chairman president north january chief executive officer dow american food division board member phrma corn corporation sit president european federation presidents export pharmaceutical industry council chair association appoint american chemistry lead nonexecutive board council officer member department society chemical industry business innovation america section skill board member board society insead business school womens health research january burns hold phd member prime minister organic chemistry business advisory group iowa state university member singapore economic development board international advisory council adviser governor guangzhou china gsk annual report business review governance remuneration financial statement shareholder information board sir deryck maughan daniel podolsky tom swaan age aged aged appoint january appoint june appoint july nonexecutive director nonexecutive director nonexecutive director tom chairman sir deryck partner daniel president supervisory board kohlberg kravis roberts university texas southwestern vanlanschot bankier member nonexecutive director medical center hold board director thomson reuters blackrock phillip obryan montgomery zurich financial services inc serve distinguish presidential nonexecutive director board director lincoln chair academic administration kpmgs public interest center doris bryan committee vice chairman chief executive wildenthal distinguish chair chairman supervisory officer citigroup international medical science member board chairman audit salomon brothers inc institute medicine committee royal ahold national academy sciences member supervisory board royal dsm previously member managing board chief financial officer abn amro james murdoch aged appoint nonexecutive director james chairman chief executive europe asia moncef slaoui aged sir robert wilson news corporation appoint age nonexecutive chairman chairman research appoint november bskyb member board development news corporation moncef join gsk biological nonexecutive director nonexecutive director engineer senior independent director sothebys previously serve development sir robert nonexecutive chief executive officer robust vaccine pipeline chairman group plc bskyb subsequently lead worldwide previously executive chairman chief business development chairman rio tinto plc executive officer star pharmaceuticals retirement october appointment lead chairman economist june moncef group give overall responsibility gsk oncology business month responsibility gsk biological transition member board agency science technology research astar phd molecular biology immunology universit libre bruxelles gsk annual report noitarenumer dna ecnanrevog corporate executive team cet john clarke julian heslop president consumer healthcare chief financial officer john responsible julian chief financial consumer healthcare business officer april head produce oral healthcare finance function overthecounter nutritional responsible activity healthcare product join financial reporting control beecham tax treasury finance system andrew witty president future group marc dunoyer insurance join glaxo chief executive officer current appointment head rare disease unit wellcome financial controller andrew appoint chief january chairman gsk japan april leave executive officer marc appoint chairman cet retire gsk join glaxo gsk japan january end march career february lead company hold role gsk rare disease business manage director south commercialisation africa vice president join group general manager marketing previously president usa senior vice pharmaceutical japan president asia pacific january appoint president deirdre connelly president pharmaceuticals europe president north america pharmaceuticals asia pacific glaxosmithkline january pharmaceutical japan abbas hussain deirdre join gsk february july president emerge market work eli lilly asia pacific company year abbas join gsk june hold variety position eli lilly company include sale professional spend year general manager puerto rico oversee market executive director human europe africamiddle east resource recently australasia president operations simon bicknell senior vice president eddie gray governance ethic president assurance pharmaceuticals europe simon appoint eddie responsible role january group operation responsible risk europe january management compliance join beecham internal auditing prior current bill louv svp appointment senior vice simon dingemans senior vice president company secretary president general manager chief financial officer designate core business service corporate compliance officer pharmaceutical simon appoint chief chief information officer simon join corporate financial officer designate bill appoint chief secretariat january join information officer january appoint company secretary gsk goldman sachs addition role glaxosmithkline plc managing director appoint create combine partner year lead core business service position role experience investment april responsible corporate compliance officer banking include recently information technology april leader goldman sachs gsk bill join glaxo current appointment european business vice president head medical data sciences prior investment banking current role bill senior vice president information technology gsk annual report business review governance remuneration financial statement shareholder information corporate executive team cet moncef slaoui patrick vallance chairman research senior vicepresident medicine development discovery development moncef lead group drug patrick appoint senior discovery development vice president medicine activity oncology discovery development business july responsible month assume ensure flow new david pulman operational responsibility claire thomas medicines president global gsk biological join senior vice president pipeline early discovery manufacturing supply group human resource approval david responsible key player building gsk claire lead global human medicine patrick join gsk global manufacturing vaccine pipeline resource function prior supply organisation appoint senior vice previously oversee clinical academic lead global procurement join president worldwide business pharmaceuticals international division medicine glaxo broad development current pharmaceuticals europe university college london experience manufacture appointment june claire join company operation previously lead appoint primary supply european director human resource manufacture north american pharmaceutical manufacture global logistic claire honour manufacturing strategy outstanding european woman organisation achievement change cet duncan learmouth senior jean stphenne vice president global chairman president communication leave cet biological august new jean lead gsk global role senior vice president vaccine business develop country previously vice president market access phil thomson human vaccines research dan troy appoint senior david redfern development senior vice president vice president global chief strategy officer production join general counsel communication august david responsible company head dan joined gsk senior vice proactive exploration new bacterial viral vaccine president general counsel member invite attend business opportunity strategic production jean name september cet meeting require planning dermatology addition current role baron king albert partner dan phelan chief staff appoint chairman belgians recognition washington law firm sidley step cet board viiv healthcare leading contribution austin llp chief counsel december act ltd effect april industry belgium fda advisor ceo advance begin career chair american eventual retirement gsk corporate bar association section gsk administrative law development previously adjunct scholar appoint finance director american enterprise europe pharmaceuticals institute washington appoint area director central europe northern europe gsk annual report noitarenumer dna ecnanrevog corporate governance dear shareholder behalf board please present corporate governance report review operating environment remain challenging believe significant progress substantially reengineere gsk business restructure rigorous approach capital allocation effect change increasingly evident delivery diversify underlie sale growth increase pipeline potential improve cash generation legal settlement balanced synergistic business broad diverse pipeline generate increase potential board believe generate increase value shareholder deliver well outcome patient consumer corporate governance development see continuation review consultation aim examine improve corporate governance arrangement predominantly light recent global financial crisis gsk active participant debating issue raise consultation relevant long term interest shareholder take opportunity review board practice governance procedure standard contain financial reporting council frc update corporate governance code update code publish june combine code corporate governance combine code review indicate strong position comply fully provision report formally gsk compliance update code year board role effectiveness chairman role primarily provide leadership board necessary promote success company create value shareholder long term ensure sound effective corporate governance practice embed organisation decisionmake process number ingredient effectively function board gsk approach set great detail follow report notable example practice exercise audit risk committee oversight power delegate board decision resolve inherent unpredictability reduce overall litigation exposure core focus committee board audit risk committee hold regular dialogue executive management provide update progress resolve outstanding legal matter board acknowledge scale legal provisioning require significant continue believe good long term interest shareholder resolve matter usual conduct rigorous evaluation test board committee effectiveness pleased note frc endorse update code approach externally facilitated board evaluation undertake year approach gsk previously adopt detail late board evaluation action identify agree drive standard board governance performance find report area board practice like particularly focus business awareness succession planning shareholder engagement key area good progress business awareness succession planning year board seek develop knowledge understanding business gain great visibility executive talent management succession board visit group site meet key talent senior executive march board visit vaccine site wavre belgium receive update progress main vaccine business continue grow term contribution group include specific briefing important vaccine development programme magea synflorix malaria board please meet thank gsk staff site extraordinary effort enable group respond pandemic july board visit gms site research triangle park zebulon united states visit include briefing discovery performance unit tour pharmaceutical development pilot plant workshop senior executive board hold reception locally base executive key talent gsk annual report business review governance remuneration financial statement shareholder information corporate governance gsk continue target growth emerge market establish important new corporate hub group far east singapore summer abbas hussain president emerge market asia pacific corporate executive team cet member relocate singapore centrally locate region october board hold joint strategy review meet cet member singapore please visit gms site tour gms production facility pilot plant board workshop result gsk investment green chemistry continuous manufacture technology singapore contribute group effort reduce cost minimise impact environment board please opportunity meet local senior executive key talent addition plan visit nonexecutive director encourage attend cet meeting relate executive meeting provide good perspective management operate give great insight key business issue provide opportunity board member observe skill knowledge integrity behaviour senior management cadre key executive talent whilst enable employee direct feedback board member shareholder engagement gsk value open constructive effective interaction shareholder particular ceo cfo maintain ongoing dialogue institutional investor regular programme meeting cover range issue andrew witty attend oneonone meeting investor cover separate fund julian heslop attend nearly oneonone meeting investor cover separate fund addition meet multiple additional investor group meetings broker conference personally meet representative cross section shareholder course year available meet shareholder request board colleague remuneration committee chairman head human resource company secretary attend meeting institutional investor specifically discuss remuneration policy governance relate matter process conduct annually believe level quality engagement key ensure board senior management understand shareholder view perspective theme welcome introduction frc stewardship code institutional investor code good practice major shareholder aim strengthen quality engagement process major shareholder company invest company agm board director able attend available usual meet investor meeting discuss issue facetoface basis combine code compliance statement company comply provision apply main principle section combine code stephanie burns larry culp tom swaan unable attend company agm stephanie burns larry culp prevent attend travel disruption cause ash cloud volcano iceland tom swaan require chair shareholder meet public company day result partial noncompliance code provision annual reelection director gsk like number organisation interested party express view consultation period update combined code frc proposal mandate annual reelection director damaging fear erode principle unitary board likely increase shorttermism difficult recruit new board member change include new provision update code board agree board member stand reelection agm monitor effect provision time corporate governance report follow set gsk comply provision apply principle combine code year sir christopher gent chairman gsk annual report noitarenumer dna ecnanrevog corporate governance governance policy board process section discuss gsk management structure board responsible longterm success company governance procedure remuneration authority accountable shareholder report page include detail company ensure group appropriately manage achieve apply complie principle provision strategic objective set board discharge combine code maintain frc law responsibilitie annual programme meeting regulation include approval overall budgetary planning business strategy board review group internal control risk board corporate executive team management policy approve governance structure director list board page code conduct member cet corporate executive team board appraise approve major financing investment page license decision excess define threshold addition board responsible group system corporate board evaluate monitor performance group governance ultimately accountable group activity include strategy risk management financial performance engage board meeting challenge ceo independence executive director members cet board consider nonexecutive director appropriate financial operating performance gsk independent character judgement free external issue material group prospect business relationship materially interfere evaluate progress achievement group exercise judgement chairman satisfied financial business objective annual plan non independence criteria appointment board executive director scrutinise performance management date publication majority meeting objective plan board member exclude chairman independent monitoring report receive directly nonexecutive director committee significant risk face group chairman ceo senior independent director board overall responsibility succession planning sir christopher gent chair company january ceo executive nonexecutive director chairman biographical board give ceo broad authority operate business detail find andrew witty ceo group ceo accountable report biographical detail find page board performance business cet member chairman lead manage board ceo regular presentation board area responsibility manage group implement strategy policy board director meet cet member annual adopt board chairman chairmen board basis discuss develop proposal collectively relation committee communicate regularly ceo cet group strategy member division responsibility role board meet time member attend chairman ceo set writing agree follow board appear governance section company website number meeting hold whilst board number ceo responsible executive management group member meeting attend assist cet cet meet time year sir christopher gent necessary andrew witty term engagement chairman julian heslop nonexecutive director expect devote time moncef slaoui necessary proper performance duty professor sir roy anderson stephanie burn sir robert wilson appoint senior independent director larry culp sid follow sir ian prossers retirement sir crispin davis board date responsibility include annual sir deryck maughan evaluation performance chairman board committee director collaboration committee james murdoch chairmen year process internally facilitate daniel podolsky available additional point contact board tom swaan shareholders sir robert wilson sir deryck unable attend meeting personal reason give comment chairman matter discuss advance meeting addition schedule meeting board meet quorate basis occasion gsk annual report business review governance remuneration financial statement shareholder information corporate governance director unable attend board committee board establish procedure handle situational meeting communicate comment observation conflict interest line good practice guidance matter consider chairman board issue general counsel group accordance relevant board committee chairman raise appropriate company article authorise nomination relevant meeting attendance meeting consider committee grant review periodically event onetoone meeting conduct chairman annually potential actual conflict authorisation director director count quorum authorisation actual potential conflict company secretary minutes business environment personal development consideration conflict authorisation grant record ensure board keep uptodate important matter company secretary register conflict authorisation include legal governance regulatory development note board meeting presentation regular basis external internal adviser ongoing basis director responsible inform company secretary new actual potential conflict nonexecutive director gain great insight understanding arise change circumstance business access gsk employee visit affect authorisation previously give provide group operational facility attendance internal authorisation director absolve statutory management meeting include cet research development duty promote success company actual conflict executive product marketing board meeting arise post authorisation board choose exclude hoc basis director receipt relevant information participation customise induction process conduct company debate suspend director board secretary new nonexecutive director focus resort require director resign particular experience take account different nomination committee review register conflict background primary element process include meeting authorisation october conclude member cet informally collective individual basis conflict appropriately authorise process appropriate senior executive visit authorisation continue operate effectively particular operational facility group company secretary addition chairman meet director annually company secretary responsible board available onetoone basis discuss agree individual ongoing individual director respect board procedure simon training development requirement bicknell company secretary december independent advice secretary board committee board recognise occasion remuneration committee victoria whyte deputy director feel necessary independent legal company secretary appoint company secretary effect andor financial advice company expense january secretary remuneration agree procedure enable explain committee act secretary board governance section company website committee appointment company secretary solicitor fellow institute charter secretary indemnification director administrator qualify party indemnity provision define section board committee company act force benefit director director hold office board establish number committee provide sufficient resource enable undertake director conflict interest duty executive director member audit director statutory duty avoid situation risk remuneration nomination corporate responsibility direct indirect conflict interest possible committee invite attend meeting conflict interest company duty apply particular director member corporate administration exploitation property information opportunity transaction finance committee gsk advantage company article association include general power board authorise conflict breach duty relevant matter authorise advance gsk annual report noitarenumer dna ecnanrevog corporate governance corporate governance framework board chairman executive director independent nonexecutive director audit risk committee remuneration committee nomination committee chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive director director chairman director chairman corporate responsibility finance committee corporate administration independent nonexecutive executive nonexecutive transaction committee cet directors chairman director directors company secretary cet members key board committees management committee executive director appointment chief financial officer designate january executive director follow retirement chief financial officer march current membership committee show table corporate audit risk remuneration nomination responsibility sir christopher gent professor sir roy anderson stephanie burns larry culp sir crispin davis sir deryck maughan james murdoch daniel podolsky tom swaan sir robert wilson key chairman member gsk annual report business review governance remuneration financial statement shareholder information corporate governance committee write term reference approve board review annually ensure comply late legal regulatory requirement reflect good practice development follow summary role term reference committee current term reference committee obtain company secretary governance section company website meeting committee report committee role term reference membership comprise year audit risk review financial internal reporting process independent non cid external internal audit process system executive director internal control identification management risk committee propose shareholder appointment reappointment removal external auditor directly responsible remuneration oversight work remuneration determine term service remuneration independent non cid executive director member executive director cet assistance external chairman independent adviser evaluate make recommendation board overall executive remuneration policy assist longterm success group chairman ceo responsible evaluating make recommendation board remuneration nonexecutive director nomination review structure size composition independent non cid board include skill knowledge executive director independence experience diversity chairman appointment members board cet make recommendation board appropriate committee monitor plan succession board senior management committee consider appropriate authorise director conflict interest corporate provide boardlevel forum regular review independent non cid responsibility external issue potential executive director impact group business reputation chairman committee responsible oversight gsk worldwide donation community support finance review approve behalf board executive non necessary annual report form convene executive director agm preliminary quarterly statement trading result approve certain major licensing capital transaction change group investment instrument counterparty limit corporate review approve matter connection executive non necessary administration administration group business executive director transaction certain corporate transaction cet member company secretary gsk annual report noitarenumer dna ecnanrevog corporate governance evaluation board board committee director high level confidence performance board decide undertake externally facilitate ceo strong belief board dynamic facilitate open evaluation process year honest constructive discussion issue major change requirement corporate governance code update board practice procedure deem necessary code intervening period review facilitate term implementation action point previous sid chairman externally facilitate evaluation year board undertake end increase focus activity successful delivery reminder form board evaluation review pipeline please progress take action point agree set year separately behalf board remuneration committee initiate discussion management shareholder introduction strategically align method evaluation action area focus performance criterion company long term incentive plan long boardroom utilise board committee result successful conclusion discussion review facilitate time effectively grant lti option february review facilitate contribution additional performance criterion focus nonexecutive director new product performance detail refer enhance continuous remuneration report page education process non seek assistance audit risk committee executive director fully understand group key risk work ongoing provide great visibility board continue consider regular report executive talent audit risk committee advance management succession board annual review effectiveness company risk planning process management year sir robert wilson increase board time devote pleased operation nomination committee senior independent strategic discussion enhance succession planning process result director indicator success appointment cfo designate positive progress delivery recruitment new board members pipeline refresh board devote time focus consideration board agree follow action discussion company key risk evaluation report ensure continues improve way ongoing basis operate provide board give fundamental strategic challenge face regular update insight pharmaceutical industry board seek continue newly enhance allocate time regular basis focus strategic issue management succession significant challenge face industry direct planning process aim enhance return shareholder board evaluation process enhance information flow provide board accordance establish practice sid sir robert members wide variety external perspective wilson conduct evaluation performance company industry chairman board committee director continue major expense company collaboration committee chairman board seek assess extent new board evaluation process include onetoone interview policy implement recent year add value director topic discuss circulate continue support executive management ethical director advance include variety aspect associate leadership group board effectiveness include board committee information flow handle strategic issue collective effectiveness director lead sid meet separately exploration way improve way board chairman present discuss chairman performance operate consider leadership performance overall contribution high standard result high chairman board committee undertake level confidence share director sir christopher separate evaluation outcome report chairmanship board unanimously agree extend discuss respective committee board appointment chairman period year effect feedback overall evaluation process provide january subject reelection shareholder form write report board debate ensure continuity leadership board finding period nonexecutive director approach retirement serve year board board evaluation review conclude board committee operate effectively high level board continue feel receive high quality information readily understandable format timely basis order fulfil role gsk annual report business review governance remuneration financial statement shareholder information corporate governance dialogue shareholder share capital control financial result announce quarterly basis detail company issue share capital number fullyear result include company annual report share hold treasury december find company produce annual summary send note financial statement share capital share shareholder advise availability annual report premium account gsk share list london stock notice meet wwwgskcom exchange quote new york stock exchange nyse form american depositary share ad ad ceo cfo presentation halfyear represent ordinary share year result facetoface meeting institutional investor analyst medium accessible webcast holder ordinary share entitle receive dividend teleconference release quarterly declare company annual report attend result company hold webcast teleconference institutional speak general meeting company appoint proxy investor analyst medium quarterly result exercise voting right available investor section company website restriction transfer limitation hold agm take place london formal notification send ordinary share requirement obtain prior approval shareholder month advance meeting transfer ordinary share carry special right business presentation shareholder director able regard control company restriction attend available formally agm informally vote right major shareholder voting right question committee chairman ordinarily attend share shareholder know arrangement agm respond shareholder question entire board financial right hold person attendance company agm save holder share know agreement restriction stephanie burns larry culp prevent share transfer voting right attend travel disruption cause ash cloud share acquire gsk share plan rank equally volcano iceland tom swaan require share issue special right trustee chair shareholder meet public company company employee share ownership plan esop trust day resolution agm decide poll waive right dividend share hold esop trust require company article association result poll announce london stock exchange post change control essential contract investor section company website detail company contract arrangement agm set section annual general meeting individually essential business party notice agm publish investor significant agreement effect alter terminate section company website change control follow takeover bid ensure nonexecutive director aware company agreement director understand view major shareholder company officer provide compensation loss office board place briefing process manage employment result takeover provision chairman focus sectorspecific issue general company share plan cause option award grant shareholder preference plan vest takeover detail termination provision company framework contract executive group investor relation department office london director give philadelphia act focal point contact investor year interest voting right state far company aware ceo cfo chairman maintain dialogue institutional person significant direct indirect holding shareholder performance plan objective company information provide company pursuant programme regular meeting appointment ceo financial service authority fsa disclosure transparency andrew witty undertake extensive ongoing rule dtrs publish regulatory information service series meeting gsk institutional shareholder investor section company website chairman meet regularly institutional investor february company receive notification hear view discuss issue mutual importance accordance fsa dtrs follow notifiable interest communicate view investor board voting right company issue share capital sid available shareholder chairman remuneration committee chairman percentage issue share capital senior vice president human resources company blackrock inc secretary meet annually major shareholder discuss legal general group plc executive remuneration policy governance matter nonexecutive director include new appointee available percentage ordinary share issue exclude treasury share meet major shareholder request company website provide access current financial business information group gsk annual report noitarenumer dna ecnanrevog corporate governance bank new york mellon depositary company share buyback programme ad list nyse ordinary share represent billion programme share repurchase commence july company american depositary receipt program share cost billion repurchase manage depositary register bny programme repurchase nominee limit detail number ordinary share hold company announce publicly february depositary find intend commence new longterm share buyback programme expect buyback billion share company acquire disposed interest period february february million share period review detail share share purchase cost million programme purchase prior year cancel hold cover purchase company share cancellation treasury share disclose note financial statement hold treasury share accordance authority renew share capital share premium account shareholder agm company director officer authorise purchase maximum million share interest director officer connect detail share purchase cancel hold person issue share capital company give treasury share disclose note financial statement remuneration report page share capital share premium account rule appointment replacement director exact time future purchase contain company article association company share hold treasury share cancel article approve shareholder accordance determine company dependent market condition legislation force time time factor article provide director appoint ordinary donation political organisation political expenditure resolution member resolution director effect january ensure consistent approach provide instance director appoint political contribution group gsk introduce global way retire agm follow appointment policy stop voluntarily political contribution article provide director normally subject reelection agm interval year annually political donation hold office continuous period year political organisation board agree director seek noneu political organisation election reelection accordance update code comprising company member remove director pass usa ordinary resolution special notice give canada pass special resolution director automatically cease director notwithstanding introduction policy accordance heshe resign federal election campaign act company continue heshe offer resign board accept offer support political action committee pac facilitate director number require voluntary political donation eligible gsk employee pac resign control gsk decision recipient contribution participate employee exercise heshe suffer physical mental ill health legal right contribute pool resource heshe miss director meeting continuous period political contribution subject strict limitation month permission board resolve total donate political heshe shall cease director organisation gsk pac heshe bankrupt compound hisher agm shareholder authorise creditor generally company donation political organisation heshe cease director virtue article incur political expenditure provision political company act party election referendum act heshe prohibit director law year authority renew annually company act require company continue article association obtain shareholder approval donation power director determine legislation political organisation incur political expenditure company article association available governance company intend section gsk website article amend donation political party independent election special resolution member director exercise candidate donation political company power provide article applicable organisation incur political expenditure legislation stipulate power exercise member director authorise issue definition political donation political expenditure allot ordinary share current article power political organisation legislation wide article authority company purchase particular definition political organisation extend share subject shareholder authority body concern policy review law reform seek annual basis agm share purchase representation business community special interest company cancel hold treasury share group concern environment company subsidiary wish support gsk annual report business review governance remuneration financial statement shareholder information corporate governance result definition cover legitimate business activity internal control framework ordinary sense consider political donation board recognise responsibility present balanced political expenditure activity design support understandable assessment group position prospect political party independent election candidate authority board seek annually precautionary measure board accountability review approve ensure company subsidiary inadvertently adequacy effectiveness internal control operate breach legislation group include financial operational compliance control risk management board delegate responsibility annual general meeting review audit risk committee committee agm hold thursday receive regular reporting align gsk assurance programme queen elizabeth conference centre broad sanctuary responsibility management cet westminster london swp business transact implement board policy risk control cet responsible meeting include identify approve monitoring enforce key policy heart group conduct business receive adopt glaxosmithkline annual report internal control framework include central direction resource allocation risk management key activity research approve remuneration report development manufacturing marketing sale legal human remuneration report page set resource information system financial practice remuneration policy operate gsk disclosure framework comprehensive planning system director remuneration include require annual budget approve board result operate company act large mediumsize unit report monthly compare budget company group account report regulation forecast prepare regularly year resolution propose approve remuneration report group place establish procedure identify consolidate reporting entity group control activity include retirement reelection director policy practice cover appropriate authorisation simon dingemans appoint agm approval transaction application financial reporting standard retire accordance article eligible review significant judgement financial performance offer election agm continue director retire rotation agm offer extensive financial regulatory operational control procedure reelection risk activity review group internal auditor responsibility clearly delegate local business unit reappointment remuneration auditor support regional management structure principle resolution propose authorise audit risk design provide environment central leadership couple committee reappoint pricewaterhousecooper llp local operating autonomy framework exercise auditor determine remuneration accountability control group special business group attach importance clear principle company seek authority procedure design achieve appropriate accountability donation political organisation incur control group policy risk management legal compliance political expenditure cap mandate business unit establish process manage monitoring risk significant business group allot ordinary share company director authority disapply preemption right internal control framework rely follow allot new share connection right issue mechanism oversee report risk compliance issue maximum current issue share capital purchase ordinary share maximum current issue share capital exempt auditor state senior statutory auditor company gsk annual report reduce notice require general meeting clear day shareholder entitle appoint proxy attend agm speak vote behalf provide event single shareholder appoint multiple proxy proxy appoint exercise right attach different share share hold member detail appoint appoint corporate representative proxy find notice agm publish investor section company website gsk annual report noitarenumer dna ecnanrevog corporate governance risk oversight audit risk compliance committee council internal assurance business unit report audit report report independent external audit emerge business internal review business regulatory incident risk control audit business unit monitor agency event management infrastructure activity internal outcome audit activity gsk risk universe management internal assurance audit risk oversight compliance council rocc corporate ethic compliance cec rocc council senior executive authorise board rocc rmcbs assisted cec department assist committee oversee risk management internal responsible support development control activity group membership comprise cet implementation practice facilitate employee compliance member head department internal control law group policy department provide assistance risk management assurance audit compliance responsibility help employee meet high ethical standard comply applicable law regulation corporate responsibility rocc meet regular basis review assess significant risk mitigation plan provide oversight internal thrust group compliance effort diligence control ensure compliance applicable law regulation prevent detect misconduct noncompliance law internal gsk policy rocc respond group policy regulation promotion ethical behaviour compliance refer provide business unit framework law regulation corporate responsibility level risk management upward report significant risk effective compliance system mitigation planning identification manager overall gsk employee encourage seek help report responsibility management give risk requirement concern suspect case misconduct fear risk management compliance board rmcbs retaliation employee line management rmcbs establish major business unit gsk integrity confidential reporting line manage membership comprise member senior executive cec concern allegation fairly independently team respective business unit augment specialist investigate disciplinary action applicable commensurate appropriate rmcbs oversee management risk issue present consider important respective business unit cec department manage senior vice president include risk designate significant gsk governance ethic assurance report directly increase number risk actively ceo chair rocc provide summary report manage group roccs activity group significant risk cet business unit corporate function periodically review committee regular basis direct reporting line significant risk face business review committee provide mechanism bypass executive include identify operational risk legal compliance risk risk management need arise achievement strategic goal objective review occur annually embed aligned annual planning process ensure significant risk identify change management direction external environment gsk annual report business review governance remuneration financial statement shareholder information corporate governance assurance assurance reporting assurance programme implement assurance reporting committee follow structured enhance governance provide independent assessment programme integrate reporting business unit assurance governance risk management control process internal audit organisation gsk comprise main element business unit corporate function require present internal audit report annually rocc committee detail gsk internal audit group responsibility independently risk management compliance approach provide balanced assess adequacy effectiveness management assessment status internal control key risk significant risk area report outcome committee highlight significant compliance issue manager line agree assurance plan internal audit group oversee risk consider important respective comprise principal team focus follow area business unit include risk designate significant group information control place manage commercial financial risk provide assure committee risk information technology adequately manage internal control framework anufacture include environmental health safety addition significant compliance issue internal audit result sustainability escalate rocc committee early opportunity research development risk management group risk management programme extend legal internal audit activity conduct single organisation regulatory issue consider group overall strategy leadership head audit assurance head change external environment furthermore risk management audit assurance dual reporting line senior vice principle embed management practice president governance ethics assurance committee business strategy objective set process chairman global audit function allow holistic assurance consistency approach independence report detail risk affect group risk factor page help eliminate overlap gap potential note financial statement legal proceeding auditing effectiveness control internal audit undertake continuous process risk assessment internal control framework operation contribute evolution gsk audit strategy year review continue operate compilation delivery audit schedule approach date approval report system internal control allow audit assurance respond expeditiously change design manage eliminate risk achieve business risk environment ensure audit strategy business objective provide reasonable fitforpurpose absolute assurance material misstatement loss issue control deficiency identify committee receive report area significant risk audit engagement internal audit recommend process group relate internal control follow consideration improvement gsk manager develop corrective action plan report receive assurance framework address cause noncompliance gap internal control committee report annually board effectiveness internal audit track plan completion report result control executive management committee internal audit result area group business necessary compile report rocc committee risk achieve satisfactory return shareholder detailed assurance reporting section investment acquire new product business supplement audit programme strategic risk evaluation case group objective apply expertise sre perform significant issue face gsk prudent management elimination risk conduct assurance team partnership business director review relate company subsidiary approach design evaluate risk area enable extend material associate undertaking development implementation appropriate mitigation plan joint venture investment new sre perform cover area board committee review assessment change management evaluation risk associate risk internal control framework operates gsk exist propose sale force incentive scheme addition consider effectiveness system internal audit assurance provide implementation support control operation group year cover sre include acquisition diligence use report date approval board pseudoephedrine gsk product process follow board reviewing system internal control accord guidance internal control issue turnbull committee gsk annual report noitarenumer dna ecnanrevog corporate governance committee report attendance board committee report regularly board performance meeting activity assign member committee member audit risk committee report tom swaan chairman september january professor sir roy anderson sir deryck maughan january daniel podolsky january sir robert wilson december dear shareholder structure committee meeting change committee focus number meeting split part deal activity associate core financial internal fundamental aspect internal financial control control responsibility consider stand item receive report external auditor audit assurance entire board implementation new assurance model end invite attend meeting usually consider involved consolidation audit group development external risk environment receive legal new audit assurance function enable update new business unit corporate function report report committee streamline help report outcome strategic review evaluation ensure business unit risk internal audit activity topical issue fully align addition schedule meeting committee meet reflect group strategy expand quorate basis occasion emerge market eastern hemisphere audit hub establish focus audit activity asia attendees committee meeting include pacific region ceo response new bribery act dedicate anti cfo bribery compliance abac team establish chairman audit assurance detail general counsel gsk abac programme find report head audit assurance publication section company website company secretary end work commence assist board chairman research development review cet understand nature extent risk gsk take order achieve chief medical officer strategic objective work ongoing frcs head governance ethic assurance review turnbull guidance continue report external auditor work progress committee main responsibility include continue visit group operation review corporate accounting financial help committee accessible employee report process senior management discuss issue bring committee management meet network monitor integrity financial statement compliance officer group rely oversee evaluate system internal control identify drive compliance gsk manage risk include relation financial reporting process preparation consolidated account committee continue examine improve approach audit assurance overseeing activity group compliance audit ongoing initiative progress area function oversee compliance law regulation report year ethical code practice committee oversight role require address regularly relationship management internal external auditor understand monitor reporting relationship tom swaan tier accountability audit risk committee chairman gsk annual report business review governance remuneration financial statement shareholder information corporate governance committee receive regular report member cet senior manager cover key risk management scientific expertise compliance activity group include cover professor sir roy world renowned medical scientist manufacturing sale marketing corporate function anderson advance knowledge infectious disease detail report framework committee epidemiology set page internal control framework professor infectious disease epidemiology december committee term reference faculty medicine imperial college amend reflect role oversee identification london management risk new assurancebase audit fellow royal society framework refer time foreign associate member institute audit committee change audit medicine national academy risk committee science qualification audit risk committee member foreign associate member french committee member exception professor sir roy academy sciences anderson daniel podolsky bring considerable financial rector imperial college london accounting experience committee work member chief scientific adviser ministry past employment experience finance accounting defence role comparable experience corporate activity professor sir roy anderson daniel podolskys background world renowned medical scientist researcher enable bring daniel podolsky world renowne researcher scientific expertise committee deliberation advance knowledge underlie mechanism disease new therapy gastrointestinal disorder financial accounting experience president university texas tom swaan chief financial officer abn amro southwestern medical center professor december internal medicine determine board audit member institute medicine committee financial expert define national academy sciences sarbane oxley act sarbanesoxley mallinckrodt professor medicine nonexecutive director kpmgs public harvard medical school interest committee chief academic officer partner healthcare sir deryck maughan partner kohlberg kravis roberts kkr chairman kkr japan chairman ceo citigroup international vice chairman citigroup inc chairman cochief executive officer salomon smith barney chairman chief executive officer salomon brothers inc sir robert wilson economist nonexecutive chairman economist group chairman group plc retired rio tinto hold senior management position culminate appointment executive chairman gsk annual report noitarenumer dna ecnanrevog corporate governance committee work structure programme evaluate effectiveness audit process prior make activity stand item committee require recommendation reappointment external auditor consider meet matter focus committee review effectiveness performance coincide key event annual financial reporting cycle criterion agree conjunction management begin year audit process committee consider feedback prior year external audit external auditor report critical accounting gather survey facilitate auditor client service policy significant judgement review team independent engagement team practice group alternative undertake audit work survey seek feedback accounting treatment number source include certain member board discuss management involve audit process financial management resultant conclusion material write team corporate business unit level communication management restriction access information agree audit fee propose external auditor committee consider cost comparison ensure fair cfo report financial performance appropriate gsk contractual obligation company technical financial restrict committee capacity recommend particular firm accounting matter external auditor group pricewaterhousecooper llp general counsel report material litigation remain place auditor group inception december performance review annually company secretary report corporate governance committee time corporate activity undertake rocc compliance officer make assessment committee consider paper detail relevant legislative regulatory professional head audit majority head group requirement relate external auditor evaluate assurance report audit scope annual report external auditor compliance group compliance coverage audit resource requirement safeguard establish audit group result audits conduct internal quality control procedure consideration year give committee need include risk company secretary report matter affect withdrawal external auditor market risk chairman quality timely disclosure financial evaluation plan external auditor require disclosure material information rotate audit engagement partner year current committee oard public market audit partner commence engagement january shareholder enable audit subject rotation audit gsk financial risk committee review clarity statement conclude completeness disclosure sarbanesoxley act prohibit engagement publish annual financial statement external auditor provision certain service legal interim report quarterly preliminary actuarial internal audit outsource financial information system result announcement formal design external auditor permit provide non announcement relate financial audit service committee ensure auditor objectivity performance prior approval independence safeguard policy require preapproval board committee service service include audit auditrelated tax service preapproval detailed committee management internal auditor particular service category service subject board work ensure quality company specific budget corporate accounting financial reporting committee serve primary link board external guideline set group policy engage internal auditor facilitate necessary independence external auditor provide nonaudit service include management encourage external internal auditor ascertain skill experience external auditor communicate freely regularly committee suitable supplier nonaudit service adequate committee meet collectively separately safeguard place objectivity independence external auditor head audit assurance group audit threaten compromise fee corporate compliance officer member management level relative annual audit fee limit set present committee external auditor appointment fee external auditor management report regularly committee primary responsibility make committee extent service provide accordance recommendation shareholder appointment preapproval fee services perform appointment removal external auditor annually committee preapprove additional service case assess qualification expertise resource independence bycase basis expenditure audit nonaudit service set external auditor effectiveness audit process note financial statement operate profit gsk annual report business review governance remuneration financial statement shareholder information corporate governance code conduct succession process cfo focus need company number wellestablishe policy gsk operate creativity continue financial discipline include code conduct available website identify candidate able bring helpline facility report investigation unlawful experience capability support strategy grow conduct waiver code diversify gsk business organic mean bolton acquisitions successful candidate responsible nomination committee report deliver cost saving global restructure programme implement additional measure simplify operational model consider potential external internal candidate committee please recommend simon dingemans board companys cfo designate simon dingemans manage director partner goldman sachs european business previously head investment banking year investment banking build relationship offer strategic advice sir christopher gent multiple industry sector include pharmaceutical consumer nomination committee chairman healthcare work closely gsk year help establish viiv healthcare new worldleading specialist attendance meeting hiv company member committee member board approve announce appointment simon sir christopher gent dingemans september join gsk chairman january january december committee recommend appointment patrick larry culp march vallance cet svp drug discovery medicine sir crispin davis july development effect july join gsk sir deryck maughan july head drug discovery transform gsk discovery engine focus therapy area underpin sir robert wilson march promise mature science offer fresh insight disease new role assume responsibility addition schedule meeting committee medicine development responsible ensuring meet quorate basis occasion gsk maintain flow potential new medicine attendee committee meeting pipeline early discovery late stage development ceo recruit nonexecutive director committee consider head human resource particular skill knowledge independence diversity experience benefit board significantly company secretary appointment broad selection criterion focus relevant appropriate external adviser achieve balance representation european nomination committee committee main responsibility emerge market individual ceo level include propose appointment board committee experience skill develop sector speciality member particular focus continued place committee main focus succession recruiting replacement ronaldo schmitz retired process cfo search new nonexecutive director board agm committee place refresh board emphasis candidate current recently retire ceo cfos audit partner significant financial appoint new executive director cet members expertise preferably individual bring increase diversity committee consider skill knowledge experience board composition deliberation professional search require particular executive position committee agency engage specialise recruitment consider potential external internal candidate high calibre nonexecutive director dossier potential recommend board approve new appointment nonexecutive appointee consider committee new director offer election company shortlist interview merit objective criterion agm appointment announce publicly consider relevant qualification positive progress recruitment new nonexecutive director refresh board gsk annual report noitarenumer dna ecnanrevog corporate governance remuneration report gsk principle discuss remuneration report find page year committee review approve corporate responsibility report corporate responsibility committee report work committee principle committee area focus access medicine access pricing medicine middle income develop country standard ethical conduct embed ethical value organisation research innovation policy use animal sir christopher gent research development corporate responsibility committee chairman research integrity transparency attendance governance research meeting conduct external supplier member committee member collaborator sir christopher gent treatments rare chairman condition disease january december develop world stephanie burn december potential stem cell science james murdoch regenerative medicine employment practice diversity inclusion daniel podolsky july lead develop employee attendee committee meeting employee relation include ceo consultation arrangement general counsel realignment pay head governance ethic assurance performance strategy head global communication management health head corporate responsibility safety risk manufacture company secretary community investment community partnership independent external corporate responsibility adviser investment independent external corporate responsibility adviser humanitarian donation augment gsk engagement stakeholder opinion caring environment environmental sustainability march sophia tickell appoint independent strategy external adviser corporate responsibility committee management environment committee sophia tickell cofounder director risks manufacturing meteo direct pharma future series product customer disclosure payment aim align well societal shareholder value sit healthcare professional expert review committee access medicine foundation member european healthcare corporate responsibility integrate management innovation leadership network gsk business annual report read sophia tickell attend meeting committee provide advance ensure gsk work efficiently effectively independent advice guidance corporate social possible whilst ensure act responsibly responsibility matter chairman ceo interested detail publish comprehensive main responsibility committee corporate responsibility report available company website main responsibility committee set committee rolling agenda receive report member cet senior manager ensure progress meeting gsk corporate responsibility principle review committee annually review progress follow corporate responsibility principle access medicine standard ethical conduct research innovation employment practice community investment gsk annual report business review governance remuneration financial statement shareholder information corporate governance law regulation section corporate responsibility financial report number provision law regulation apply gsk sarbanesoxley introduce requirement ceo company share quote nyse form cfo complete formal certification confirm ad review annual report form nyse rule base knowledge contain material misstatement general nyse rules permit company follow omission corporate governance practice instead apply usa provide company explain significant variation base knowledge financial statement explanation contain company form file financial information fairly present material respect access security exchange commission financial condition result operation cash flow sec edgar database company website nyse rule date period present annual report come effect require company file annual form interim write affirmation concern audit risk responsible establish maintain disclosure committee company statement significant difference control procedure ensure material information corporate governance known evaluated effectiveness sarbanesoxley act control procedure yearend result follow number corporate accounting scandal evaluation contain annual report usa congress pass sarbanesoxley act sarbane form oxley wide range piece legislation concern largely responsible establish maintain internal financial reporting corporate governance control financial reporting provide reasonable recommend sec gsk establish disclosure assurance reliability financial reporting committee committee report ceo cfo preparation financial statement external purpose audit risk committee chair company secretary accordance generally accept accounting principle member consist senior manager finance legal disclose annual report form compliance corporate communication investor relation change internal control financial report external legal counsel external auditor internal expert period cover annual report form invite attend meeting periodically responsibility materially affect reasonably likely affect materially consider materiality information timely company internal control financial reporting basis determine disclosure information disclose base recent evaluation responsibility timely filing report sec internal control financial report external auditor formal review annual report form audit risk committee significant deficiency committee meet time material weakness design operation internal sarbanesoxley require annual report contain control financial report reasonably likely statement member company audit risk affect adversely company ability record process committee audit committee financial expert define summarise report financial information fraud sarbanesoxley summary board judgement regardless materiality involve person significant matter refer additional disclosure requirement role company internal control financial reporting arise section section sarbanesoxley group carry evaluation supervision respect disclosure control procedure internal control participation group management include financial reporting ceo cfo effectiveness design operation group disclosure control procedure december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective ceo cfo expect complete certification report conclusion effectiveness disclosure control procedure march follow certificate file sec group form gsk annual report noitarenumer dna ecnanrevog corporate governance section management annual report internal control financial reporting accordance requirement section sarbane oxley follow report provide management respect company internal control financial reporting define rule securities exchange act management responsible establish maintain adequate internal control financial reporting group internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance ifrs management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organisation treadway commission change group internal control financial reporting materially affect reasonably likely affect materially group internal control financial reporting management assess effectiveness internal control financial reporting december conclusion file group form pricewaterhousecooper llp audit consolidated financial statement group year end december assess effectiveness group internal control financial reporting auditing standard public company accounting oversight board united states audit report file group form gsk annual report business review governance remuneration financial statement shareholder information remuneration report sir crispin davis remuneration committee chairman dear shareholder behalf board please present remuneration report seek approval agm year remuneration committee committee implement number change include tailor benchmarking versus market simplify align remuneration corporate executive team consult shareholder encourage level support preview year priority align closely executive remuneration gsk strategic priority enhance governance practice report describe progress objective strategic alignment longterm incentive board carry thorough review gsk key strategic priority describe annual report board firmly believe achievement priority deliver strong longterm financial performance shareholder value creation sustainable basis accordingly move align longterm performance incentive closely group key strategic priority help ensure senior management fully focus right priority incentive deliver longterm incentive award february base equally weight performance measure directly link group key strategic priority overarch goal deliver value shareholder key strategic priority longterm incentive performance measure grow diversified global business cid business diversification performance deliver product value cid new product performance simplify operating model cid adjust free cash flow deliver value shareholder cid relative total shareholder return tsr target set committee challenging require significant stretch performance target adjust free cash flow relative tsr set give close linkage performance measure business diversification new product performance strategy target commercially sensitive publish date grant update regularly progress achieve performance period target outcome award disclose end performance period believe combination measure apply performance share plan defer annual bonus plan ensure balanced framework target focus strategic objective year year executive eligible participate defer annual bonus plan introduce encourage longterm shareholding drive shareholder return please report takeup positive governance follow progress report year remuneration report please report continue executive director contract severance term year base salary similarly andrew witty moncef slaoui chairman voluntarily agree remove contractual entitlement bonus severance term severance term contract simon dingemans new cfo base year base salary order effectively manage risk continue operate clawback mechanism introduce annual bonus longterm incentive award problem arise year award adapted pension arrangement light new pension tax legislation continue meet longstanding commitment company offset additional individual tax cost year review market competitiveness executive director base salary package take account prevail economic condition position relativity pay broad gsk workforce result review ensure appropriate market competitiveness context moncef slaouis enhance role include transition responsibility biological receive increase base salary andrew witty simon dingemans receive increase base salary believe change recent year support longterm success business good interest shareholder sir crispin davis remuneration committee chairman march gsk annual report noitarenumer dna ecnanrevog remuneration report remuneration committee addition allen powley senior vice president corporate compensation judy lynch senior vice president benefit role committee invite meeting require role committee set company remuneration policy executive director corporate executive team cet exception victoria whyte company secretary member executive gsk able recruit secretary committee employee company retain motivate executive policy regularly review involve conduct committee meeting ensure consistent company scale scope committee access external advice require deloitte operation support business strategy growth plan llp appoint committee provide help drive creation shareholder value independent advice executive remuneration year set remuneration policy level senior deloitte llp provide independent commentary matter executive committee give consideration remuneration consideration committee provide update good policy level wide employee population group practice legislative requirement market practice ensure remuneration consistent industry deloitte llp provide consult tax assurance broad market norm service gsk year provide advice term reference executive remuneration matter committee committee term reference available tower watson pay governance provide additional market company website term reference review datum committee annually revise january light good practice corporate governance development commitment shareholder committee engage regular dialogue shareholder governance hold annual meeting gsk large investor discuss board consider member committee feedback remuneration policy governance matter independent nonexecutive director accordance key development year particular committee combine code exception sir christopher gent discuss significant change policy measure chairman company independent appointment assess performance committee meet time member annual meeting hold november attend follow sir crispin davis committee chairman share progress attendance remuneration matter month proposal meeting outline sir christopher gent chairman updated committee member attendee corporate governance development member sir crispin davis chairman july sir robert wilson march january larry culp january sir christopher gent january james murdoch october tom swaan larry culp unable attend meeting personal reason review paper provide view committee chairman advance meetings tom swaan chairman audit risk committee addition schedule meeting committee meet quorate basis occasion principally approve formal grant vest longterm incentive lti award accordance gsk remuneration policy andrew witty ceo claire thomas senior vice president human resource invite attend meeting committee require executive committee attendee involve decision present discussion remuneration gsk annual report business review governance remuneration financial statement shareholder information remuneration report diary committee key activity matter address set month executive remuneration annual bonus longterm incentive plan governance matter january approve cet set ceo bonus annual committee remuneration include objective evaluation result salary ceo cfo chairman review bonus plan review remuneration report arrangement chairman review remuneration budget review vote policy guideline remuneration february review approve set psp cash flow target approve remuneration executive director report cet bonus approve psp share option plan vest grant lti awards executive director cet approve defer annual bonus award election march scope review strategic review voting policy alignment lti performance guideline remuneration measure july agree cfo retirement review progress review strategic alignment review general market appointment package bonus lti performance measure development include objective pension grant interim lti awards october agree cet salary review cet review strategic alignment annual committee review process bonus process lti performance measure assessment november annual meeting annual meeting investor investor december consider feedback consider new lti performance review tax change annual meeting target framework implication pension investor remuneration arrangement policy review remuneration benchmarke competitiveness cet level gsk annual report noitarenumer dna ecnanrevog remuneration report remuneration policy table outline key element remuneration gsk executive remuneration structure cet member include moncef slaoui simon dingemans cfo designate harmonise andrew witty result share option normally long grant cet member instead cet member receive additional performance share award eligible participate gsk defer annual bonus plan improve alignment executive remuneration arrangement gsk key strategic priority incentivise management deliver longterm financial performance shareholder value creation sustainable basis new business specific performance measure introduce longterm incentive award executive february ensure balanced framework measure focus gsk strategic objective information longterm incentive performance measure outline page fix pay salary salary level review annually influence executive role experience benchmarke relevant comparator group pension executive define contribution plan legacy final salary plan close new entrant executive participate define contribution plan benefit company contribution base salary plus match contribution base salary follow change pension tax regime change arrangement executive continue meet longstanding commitment new regime executive gsk operate cash balance plan plan executive participate plan benefit contribution salary variable pay annual bonus aximum bonus opportunity majority bonus base achievement financial target group salary profit interest tax business unit operate profit individual performance predetermine personal objective rdspecific key performance indicator employee clawback committee review ongoing financial impact prior year activity executive role appropriate adjustment individual bonus award reflect circumstance defer individual elect defer award vest end threeyear performance period base annual bonus earn equally weight performance measure bonus plan business diversification performance defer bonus match new product performance oneforone subject adjust free cash flow performance relative tsr performance performance share award relative tsr calculate month averaging period share follow comparator group comprise pharmaceutical company vest plan psp median vest upper quartile performance salary business diversification new product measure adjust ceo free cash flow vest threshold rise stretching chairman performance exceed set threshold specify margin cfo designate gsk annual report business review governance remuneration financial statement shareholder information remuneration report total remuneration benchmarking decide executive director receive base salary committee review gsk total remuneration increase year moncef slaoui particular comparable company regular basis ensure committee consider package context enhance remuneration arrangement structure appropriately deliver role include transition responsibility biological value money shareholder long term table immediately follow set current base salary competitive relevant comparator group determine propose salary increase typically effect individual executive april year benchmarking purpose total remuneration incorporate base salary bonus ltis set pay committee base effective date base effective date salary salary salary salary change consider pension arrangement andrew witty ceo april april crossindustry comparator group global pharmaceutical comparator group julian heslop cfo april angloamerican france sanofiaventis simon dingemans astrazeneca switzerland novartis cfo designate january barclay roche holding moncef slaoui chairman april april group astrazeneca bhp billiton usa abbott laboratories julian heslop retire board march amgen simon dingemans join board january british american tobacco bristolmyers squibb variable pay diageo eli lilly hsbc johnson johnson significant proportion gsk total remuneration package reckitt benckiser merck approximately variable particular royal dutch shell pfizer emphasis longterm sharebase incentive order closely rio tinto align executive interest shareholder standard charter balance fix base salary variable annual tesco bonus lti element remuneration vary depend unilever performance chart anticipate mix vodafone fix variable pay expect value basis current remuneration policy exclude pension actual mix amgen include benchmarking higher low depend performance gsk current tsr comparator group individual base salary base salary set reference relevant comparator group level consider appropriate secure retain ceo talent need deliver gsk strategic priority salary level review annually influence salary executive role experience pay environment cash bonus defer bonus include match committee decide individual executive basis performance share primary pay comparator global pharmaceutical sector ukbase large crossindustry multinational andor comparator group global primary comparator group crossindustry pharmaceutical cfo designate andrew witty ceo cid salary julian heslop cfo cid cash bonus mon aoa mde cid cid defer bonus includ ing match performance share julian heslop retire board march simon dingemans join board january committee consider prevail economic condition market competitiveness executive director chairman package position relativity pay broad gsk workforce agree andrew witty salary salary hold level cash bonus defer bonus include match performance share gsk annual report noitarenumer dna ecnanrevog remuneration report safeguard risk management committee want reward failure view group profit interest important incentive payout circumstance tax performance outcome reflect genuine achievement original target stretch financial addition give nature gsk business annual target increase focus risk group committee take number step ensure design incentive bonus business unit operate profit arrangement underpin effective risk management chairman audit risk committee member committee provide input audit risk committee review group performance oversight risk factor relevant remuneration matter consider committee individual objective annual bonus year committee review ongoing financial impact prior year activity role individual executive activity committee majority annual bonus opportunity base appropriate adjustment individual bonus award formal review performance stretch financial reflect circumstance clawback mechanism target base group profit interest tax business committee ensure continuity unit operating profit target remainder base executive responsibility initiation adverse event achievement specific individual objective emergence problem adverse event take significant weighting financial performance account assess annual bonus year problem measure committee decide profit remain identify accordingly charge legacy legal matter key financial metric company key performance exclude assessment financial performance indicator committee intend review reflect view committee current management annual bonus plan ensure strategic alignment gsk responsible legal action shortterm incentive support seek resolve matter long term annual bonus calibrate reflect stretch target interest shareholder establish drive significant change gsk longterm incentive plan approve shareholder business model bonus threshold target committee reduce grant vest level maximum payable achievement target determine participant engage conduct bonus threshold reflect stretch nature contrary legitimate expectation company bonus target employee participant position bonus target andrew witty set board january safeguard relate business year set objective andrew witty board specific performance measure longterm incentive focus strategy develop plan outline detail company set annual report reason commercial sensitivity specific objective addition committee decide longterm keep confidential follow end financial year board incentive award good leaver normally vest review performance generally set objective end original vest period set grant vest committee determine bonus payable year departure ensure continue alignment shareholder interest follow cessation employment executive andrew witty set objective line company strategy make recommendation annual bonus committee performance objective annual bonus design drive achievement gsk end year recommendation consider annual financial strategic business target delivery committee determine level bonus payable personal objective bonus measure employee include moncef slaoui ontarget bonus executive director give link pipeline robust governance structure table establish ensure bonus payable fairly reflect ontarget bonus base salary productivity performance performance profit target process require review progress target andrew witty ceo bonus compensation review committee simon dingemans cfo designate include andrew witty company nonexecutive moncef slaoui chairman director designate scientific expert professor sir roy anderson daniel podolsky committee review maximum bonus set reference individual ontarget plan operation year decide bonus level cap bonus payment continue annual bonus committee salary cap remain unchanged annual bonus continue operation review pensionable gsk annual report business review governance remuneration financial statement shareholder information remuneration report longterm incentive plan table show award level february awards executive follow executive director line policy longterm incentive plan approve shareholder agm award level award base salary defer annual bonus plan andrew witty ceo share simon dingemans performance share plan cfo designate share award share option plan long moncef slaoui grant executive instead cet member receive additional chairman ad performance share award eligible participate defer annual bonus plan performance measure follow appointment andrew witty board typically award deliver resident executive form carry thorough review gsk key strategic priority ad award deliver form ordinary share describe annual report board executive resident country award firmly believe delivery objective transform plan incorporate dilution limit consistent gsk organisation deliver longterm financial guideline provide association british insurers current performance shareholder value creation sustainable estimate dilution exist award gsk employee basis year focus committee share plan year approximately improve alignment executive remuneration company issue share capital december arrangement priority incentivise management provide close link shareholder return payment deliver goal executive notional dividend reinveste pay award executive february proportion share defer vest award value introduce new businessspecific performance reinveste dividend incorporate benchmarking measure business diversification new product award level performance addition adjust free cash flow structure performance measure relative tsr measure order ensure defer annual bonus plan balanced framework measure focus gsk defer annual bonus plan encourage longterm strategic objective outline diagram shareholding discourage excessive risk taking help award vest subject performance end focus gsk key strategic priority threeyear performance period begin january start bonus year cet member end december base equally eligible participate plan weight measure business diversification new product adjust free cash flow relative tsr annual bonus earn defer year company match share oneforone depend strategy remuneration company performance measure outline threeyear performance period key strategic lti performance measure performance share priority year performance period award performance share plan ensure focus delivery grow diversify gsk strategic priority longterm shareholder return business diversification global business relative pharmaceutical company deliver performance share plan award vest new product product value end threeyear performance period subject achievement company performance measure simplify outline operating model adjust free cash flow individual award limit maximum initial value deliver value performance share grant individual shareholder relative tsr year exceptional circumstance maximum face value performance share grant individual year time base salary detail performance measure target threshold longterm incentive award give follow table gsk annual report noitarenumer dna ecnanrevog remuneration report longterm incentive measure awards award vest schedule award business diversification performance commercial sensitivity target business incentivise growth global diversify business diversification new product measure disclose outcome remuneration design focus major growth area vaccine report consumer healthcare emerge market japan exclude vaccine dermatology business proportion threshold proportion award achieve available aggregate revenue target business division threshold threeyear performance period reflect strong growth threshold previous period market growth maximum new product performance target maximum performance express recognise importance future business growth percentage threshold measure show revenue target base new product sale incentivise maximum express well performance measure threshold new product define product launch performance business period precede year diversification performance period product launch year include measurement new product aggregate threeyear revenue target award new product sale reflect growth historic performance adjust free cash flow year adjust free cash flow target vest recognise importance effective work capital threshold cash management threshold billion billion billion maximum billion relative tsr proportion vest focus delivery value shareholder relative tsr comparator group comprise global pharmaceutical company complementary measure relative tsr measure year line performance period performance measure measure performance stable basis well reflect longterm nature pharmaceutical industry twelvemonth averaging period relative tsr tsr rank position median performance upper quartile performance gsk annual report business review governance remuneration financial statement shareholder information remuneration report board believe current strategic priority pension fundamental longterm objective recognise pension provide important tool create longterm possibility goal evolve time culture loyalty committee intend review longterm incentive performance executive participate gsk senior executive pension plan measure periodically ensure remain appropriate pension arrangement structure accordance inevitably measure link directly strategy sensitive plan operate executive country particular committee consider appropriate likely retire detail individual arrangement executive disclose target business diversification new director set product performance grant result competitive harm new executive gsk eligible define commit fully disclose target contribution scheme cash balance pension plan end performance period detail extent exist obligation define benefit scheme performance target meet addition continue honour committee commit provide update achievement date target performance period pension arrangement company currently operate define contribution plan addition set robust target committee legacy final salary plan close new entrant implement number safeguard ensure target newly hire executive participate define meet sustainable way performance outcome contribution plan reflect genuine achievement original target value shareholder government announce series change pension initially impact pension approximately business diversification new product measure people gsk pension legislation significant light significant event include acquisition negative consequence effectiveness pension divestment committee review target payment reduce pension continue scale adjustment consider appropriate important tool create longterm culture promote maintain integrity original target addition employee retention committee decide committee reserve right reduce vest level target exist pension promise honour pension achieve manner undermine overall health new limit deliver gsk exist unfunded scheme business executive participate define contribution plan receive committee normally include revenue company contribution base salary depend opportunistic event pandemic assess grade opportunity receive performance business diversification new match contribution line policy product measure recognise successful response member pension plan event pandemic generate significant value shareholder response usually require supply capacity andor legacy final salary plan provide twothird final resource divert product salary age employee subject cap benefit include revenue committee satisfied excess cap currently provide unfunded decision pursue opportunistic revenue clearly arrangement legacy final salary plan actuarial good interest shareholder value creation reduction factor apply participant leave employment performance relevant measure sufficiently positive hisher accord age ultimately committee expect management act employment terminate company cause way enhanced shareholder value way member legacy final business diversification measure market salary plan reduction factor apply growth achieve end performance period pension arrangement committee normally reduce vest level usa gsk operate cash balance plan provide group strategy increase return annual contribution interest sum accumulate investment new product revenue target achieve cash balance plan contractual promise provide committee determine insufficient progress specific level retirement income plan incorporate measurement period increase return executive pension credit senior executive contribution investment committee reduce level vest rate plan range base salary new product measure depend grade current senior executive eligible adjust free cash flow measure target executive pension credit adjust material factor distort free cash flow cap employee usa benefit cap performance measure typically include exchange provide unfunded nonqualified plan rate movement include legal major taxation settlement special pension contribution materially distort calculation impact acquisition divestment quantify adjust event major adjustment calculation disclose shareholder gsk annual report noitarenumer dna ecnanrevog remuneration report share ownership requirement variable pay performance period end align interest executive december shareholder executive require build section provide detail performance maintain significant holding share gsk time achieve company annual bonus longterm current share ownership requirement sor set incentive plan performance period end table december annual bonus share ownership requirement majority annual bonus base ceo base salary achievement financial target base group profit executive director base salary interest tax business unit operating profit cet member base salary individual performance achievement additional operational efficiency goal take account determine executive require continue satisfy shareholde annual bonus level requirement minimum month follow retirement company support longterm nature business objective set company focus particular shareholding purpose sor february continue development launch late stage pipeline asset delivery commercial target execution restructuring programme simplify operating model hold hold ordinary share ordinary share despite challenging year gsk sor purpose sor purpose increase pharmaceutical industry effect generic competition shareholde usa rapid loss sale avandia follow regulatory andrew witty decision autumn healthcare reform significant julian heslop legacy litigation cost management achieve key financial simon dingeman strategic objective include moncef slaoui deliver underlie sale growth exclude pandemic share sell tax follow vest psp award product avandia valtrex exclude disclosure simon dingemans date join board strong sale performance investment area business january particularly emerge market consumer healthcare remuneration element increase pipeline potential achieve key milestone transformation productivity particularly relation executive participate allemployee share plan late stage pipeline product usa simplification gsk business model improve cash sharesave plan sharereward plan revenue generation legal settlement achievement customs approve plan open employee operational efficiency base executive director term overall committee take account gsk success sharesave participant save month achieve objective individual net salary fix term year end performance determine bonus award saving period option buy gsk share management fully achieve group discount market price set launch profit interest target set bonus plan andrew witty julian heslop sharesave member determine accordingly actual bonus payment executive contribute month plan provide director show range option buy share end base salary december year saving period sharereward participant contribute month gross salary purchase gsk share company annual bonus annual bonus match number gsk share buy month change arrangement share hold trust leave andrew witty year remove free tax national julian heslop insurance contribution andrew witty julian heslop simon moncef slaoui dingemans contribute month buy share sharereward plan follow executive director elect participate executive receive benefit include healthcare defer annual bonus plan respect matching award medical dental personal financial advice life assurance vest february subject continued employment cash value benefit receive executive director achievement longterm incentive performance measure show moncef slaoui normally reside outlined report usa second year period november enable close executive total bonus defer award matching award gsk biological assume operational responsibility andrew witty shares share business moncef slaoui ad ad gsk annual report business review governance remuneration financial statement shareholder information remuneration report longterm incentive plan executive director term condition performance share plan vest award executive director contract committee review performance criterion policy set provide framework contract performance share plan award grant executive director executive director threeyear performance period start january end december notice period calendar month company rank median position comparator group termination company award vested employ company executive award senior executive dependent relative tsr performance ep termination payment annual salary performance ep portion award vest payable termination vest schedule award vest ltis rule relevant incentive plan show approve shareholder share option vest award pension base exist arrangement share option award grant executive base term relevant pension plan eps performance performance condition award meet result award lapse noncompete clause month termination notice date detail subsist option performance condition attach grant provide audit section ability impose month noncompete period nonsolicitation report restriction executive consider important company order ability protect group intellectual property staff light historical vest gsk ltis committee believe appropriate provide gsk lti performance condition continue challenge mitigation contract demonstrate table relative tsr important lti measure year measure andrew witty moncef slaoui agree retain current remuneration policy amendment contractual term remove entitlement bonus termination package contract follow table show vest level gsk new executive normally include bonus element performance share share option award executive termination payment tsr vest percentage indicate gsk relative tsr performance median comparator group term new contract seek balance commercial performance period imperative good practice company consider important individual work performance share share option notice period compensatory payment respect plan plan bonus period restraint vest vest tsr ep performance period measure measure julian heslop retire early company march term contract enter entitle receive year notice termination payment include year annual salary month ontarget bonus simon dingemans join board january cfo designate cfo april follow average annual vest julian heslops retirement line company policy go forward simon dingemans contract provide termination award change payment base year base salary award cycle gsk annual report noitarenumer dna ecnanrevog remuneration report follow table set detail executive director term engagement nonexecutive director service contract sir christopher gent set letter appointment nonexecutive director initial appointment current director date contract effective date expiry date subsequent reappointment subject election andrew witty june august periodic reelection shareholder julian heslop march april january letters appointment nonexecutive director simon dingemans september january april contain provision notice period compensation moncef slaoui december december august appointment terminate andrew wittys contract renew june follow appointment follow table show date initial letter ceo amend february reflect change appointment nonexecutive director severance term outline moncef slaouis previous contract date replace december reflect change severance term outline nonexecutive director date letter appointment sir christopher gent termination payment respect professor sir roy anderson september notice period extend contract expiry date stephanie burn february larry culp june entitlements sir crispin davis june addition contractual provision outline sir deryck maughan event executive director service agreement terminate james murdoch february employ company follow apply daniel podolsky july case outstanding awards glaxosmithkline tom swaan december annual investment plan close new deferral sir robert wilson june effect quarter provide agreement terminate cause executive chairman nonexecutive director fee exercise bonus investment right month company aim provide chairman nonexecutive termination receive defer amount income director fee competitive pay gain company equivalent size complexity subject limit contain gsk article association line policy applicable senior executive moncef slaoui eligible future date chairman fee currently annum plus receive continue medical dental insurance retirement allocation share value annum follow merger participant legacy share option nonexecutive director fee apply december scheme elect exchange legacy option option follow gsk share receive additional cash benefit equal grant price original option additional benefit annum trigger option exercise lapsed qualify standard annual cash retainer fee additional cash benefit participant retain option second anniversary effective date supplemental fee merger follow payment chairman audit risk committee payment arrangement senior independent director outside appointment executive director scientificmedical expert outside appointment consider nomination committee ensure cause conflict interest chairman remuneration corporate approve chairman behalf board responsibility committee companys policy remuneration earn nonexecutive director undertaking appointment keep individual executive director intercontinental travel meeting meet chairman nonexecutive director sir christopher gent current chairman corporate responsibility committee receive additional fee list term condition sir christopher gents letter appointment date agree serve company deputy chairman december january chairman conclusion agm follow anniversary appointment extend term year mutual agreement effect reelection director agm hold extended period year subject reelection effect january detail provide corporate governance report gsk annual report business review governance remuneration financial statement shareholder information remuneration report reflect increase focus company compliance tsr performance graph risk gsk significantly enlarge remit responsibility follow graph set performance company audit risk committee commitment require relative ftse index company tom swaan chairman company agree constituent pharmaceutical performance comparator time requirement role committee chairman moving group january december graph approximately day approximately day annum prepared accordance regulation define reflect increase fee payable indication likely vest award follow independent review supplemental fee grant company incentive plan chairman audit risk committee increase tsr performance annum annum effect october detail current committee term reference gsk audit assurance model give page recent year increase time commitment demand responsibility place role nonexecutive director generally lead increase fee result development market nonexecutive director fee gsk independently review review highlight scope increase nonexecutive director fee light current environment board decide increase fee time continue keep review exchange rate glaxosmithkline total return index fee pay dollar convert follow glaxosmithkline pharma peer return index exchange rate ftse total return index exchange rate date approval period rate apply july march december give fluctuation sterle dollar exchange rate agree effect october exchange rate set annually base average daily rate quarter year prior payment rate review exchange rate move significantly year nonexecutive director share allocation plan enhance link director shareholder gsk require nonexecutive director receive significant fee form share nonexecutive director total fee exclude chairman pay form share ad allocate share account non executive director opportunity invest balance fee share account share ad notionally award non executive director allocate interest account include director interest table wthe accumulate balance share ad notional dividend subsequently reinveste pay nonexecutive director retirement board retirement nonexecutive director receive share ad cash equal value share ad date retirement date payment later gsk annual report noitarenumer dna ecnanrevog remuneration report annual remuneration total total fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director andrew witty abce julian heslop moncef slaoui cde nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson stephanie burns larry culp sir deryck maughan daniel podolsky director michle barzach sir ian prosser ronaldo schmitz jeanpierre garnier total remuneration analyse executive director nonexecutive director director total remuneration remuneration director payroll report dollar dollar amount include total base conversion sterling average exchange rate year andrew witty julian heslop participate salary sacrifice scheme follow merger order encourage employee convert nonsaving relate option hold legacy share ad option glaxosmithkline share ad employee grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive payable new option exercise lapse underwater qualify additional cash benefit participant retain option second anniversary effective date merger year andrew witty receive julian heslop receive jeanpierre garnier receive result option grant lapsing payment andrew witty moncef slaoui elect participate gsk defer annual bonus plan respect bonus andrew witty participate moncef slaoui eligible participate year moncef slaoui nonexecutive director agency science technology research astar respect receive include benefit andrew witty moncef slaoui restate reflect certain element remuneration long deem benefit james murdoch appoint board effect michle barzach receive fee cidnil cid gsk france healthcare consultancy provide include fee salary sir ian prosser ronaldo schmitz retire nonexecutive director company leave board sir ian prosser ronaldo schmitz receive accumulate balance share previously award nonexecutive director share arrangement base share price payment date final payment respect balance sir ian prosser detail set table include fee salary director receive reimbursement expense year require separate disclosure require regulation gsk annual report business review governance remuneration financial statement shareholder information remuneration report nonexecutive director fee total cash sharesad total cash sharesad fee current nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson stephanie burns larry culp sir deryck maughan daniel podolsky nonexecutive director sir ian prosser ronaldo schmitz total remuneration table set remuneration receive nonexecutive director company nonexecutive director require total fee form share allocate share account pay retirement board detail total value share ad date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share ad table set accumulate number share ad hold nonexecutive director relation fee receive board member december movement account year number share ad allocate dividend nonexecutive director share arrangement december elect reinveste pay december current nonexecutive director share professor sir roy anderson sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson ads stephanie burns larry culp sir deryck maughan daniel podolsky nonexecutive director share sir ian prosser gsk annual report noitarenumer dna ecnanrevog remuneration report table set settlement nonexecutive director share arrangement leave board value value date awards award payment payment footnote leave allocation leave sir ian prosser changes value award allocation leave subsequent payment attributable dividend reinveste change share price award awards sir ian prosser nonexecutive director share arrangement partially settle share balance share settle director interest follow interest director company connected person show accordance fsa listing rule share ad february december january february december january footnote executive director andrew witty simon dingemans julian heslop moncef slaoui nonexecutive director professor sir roy anderson stephanie burn larry culp sir crispin davis sir christopher gent sir deryck maughan james murdoch daniel podolsky tom swaan sir robert wilson glaxosmithkline ad represent glaxosmithkline share interest abovementione director february reflect change yearend date include share purchase glaxosmithkline sharereward plan andrew witty totalling december december share february julian heslop totalling december december share february simon dingemans join board january include ad purchase glaxosmithkline stock fund retirement saving plan executive supplemental saving plan performance share plan vest condition approve february detail share vest february include total include share ad receive fee describe nonexecutive director share allocation plan dividend receive share ad convert share ad december gsk annual report business review governance remuneration financial statement shareholder information remuneration report longterm incentive plan share option plan award option share grant december december footnote date grant exercise period grant price number lapse andrew witty julian heslop moncef slaoui option ad grant december december date grant exercise period grant price number lapse moncef slaoui detail include change slaouis connect person employee gsk option outstanding december early late vesting lapse date option market price glaxosmithkline share yearend give table weight average vest date lapse date andrew witty grant price number early latest early late option market price yearend vest option market price yearend vest unvested total share option december weight average vest date lapse date julian heslop grant price number early latest early late option market price yearend vest option market price yearend vest unvested total share option december weight average vest date lapse date moncef slaoui grant price number early latest early late option market price yearend vest option market price yearend vest total share option december option market price yearend vest unvested option market price yearend unvested total ad option december include share option hold moncef slaouis connect person employee gsk gsk annual report noitarenumer dna ecnanrevog remuneration report gsk grant share option executive director annual basis director hold option share option plan refer note financial statement employee share scheme nonexecutive director interest option company share table set share option grant performance period performance target option vest december performance target vest status annualise growth percentage grant footnote performance period december ep award vest february unvested rpi rpi rpi rpi rpi performance target share option meet result lapse anniversary date grant table set share option grant respect performance period target performance target vest status annualise growth percentage grant performance period december ep award vest february award unvested rpi february award unvested rpi rpi rpi rpi highest low closing price year end december glaxosmithkline share respectively high low price glaxosmithkline ad year end december respectively market price glaxosmithkline share december december glaxosmithkline ad december price february glaxosmithkline share glaxosmithkline ad performance share plan psp award performance share award executive director annual basis director hold option psp plan refer note financial statement andrew witty share vest unvested market price additional unvested number price share number december grant date market vest dividend december grant performance period grant number price gain lapse reinveste julian heslop share vest unvested market additional unvested number price share december grant date market vest dividend december performance period grant number price gain lapse reinveste gsk annual report business review governance remuneration financial statement shareholder information remuneration report moncef slaoui ad vest unvested market additional unvested number price share number december grant date market vest dividend december grant performance period grant number price gain lapse reinveste include performance share hold moncef slaouis connect person employee gsk lapse performance period relate change connected person simon dingemans share vest unvested market additional unvested number price share number december grant date market vest dividend december grant performance period grant number price gain lapse reinveste term psp number share actually vest determined follow end relevant measurement period dependent gsk performance period describe page committee adjust comparator group remove scheringplough wyeth follow delist revised vest schedule accordingly outstanding future awards tsr performance measure revise comparator group include gsk set dividend reinveste performance share award executive performance period date final award dividend reinvestment calculate dividend payment date term psp participant defer receipt vested award total gain vest psp award executive director connect person follow vest schedule apply psp award tsr vest schedule award award performance period tsr rank company percentage award vest median median follow vest schedule apply psp award tsr vest schedule award award performance period tsr rank company percentage award vest median median adjust free cash flow vest schedule cash flow target award award performance period percentage award vest gsk annual report noitarenumer dna ecnanrevog remuneration report defer annual bonus plan award defer annual bonus plan award executive director annually base individual voluntary bonus deferral election term defer annual bonus plan outline andrew witty share vest unvested market additional unvested number price share number december grant date market vest dividend december grant performance period grant number price gain lapse reinveste moncef slaoui ad vest unvested market additional unvested number price share number december grant date market vest dividend december grant performance period grant number price gain lapse reinveste share value plan awards moncef slaoui share ad vest defer unvested market unvested plan year price number december date market december grant grant number price gain executive director moncef slaoui eligible receive award share value plan award show reflect holding moncef slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk pension benefit accrue annual pension benefit transfer value executive director office december retirement set company act require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year fsa list rule require additional disclosure change accrue benefit net inflation transfer value change pension executive director disclose currency pension payable accrue change benefit accrue change personal transfer transfer accrue transfer value benefit accrue contribution value value change benefit change december december benefit december december transfer year net accrue year year value inflation benefit executive director andrew witty julian heslop moncef slaoui moncef slaoui cid cid cid cid cid cid cid show net contribution individual andrew witty julian heslop participate glaxo wellcome define benefit plan accrual rate final pensionable salary annum benefit accrue glaxo wellcome pension arrangement augment trustee plan reflect distribution surplus augmentation apply element andrew witty julian heslop pension earning march gsk annual report business review governance remuneration financial statement shareholder information remuneration report transfer value andrew witty julian heslop director senior management calculate accordance pension regulation represent information provide compensation interest present value potential payment pension plan director senior management group group actuarial assumption calculation change purpose group define executive december change increase nonexecutive director member cet financial transfer value increase andrew witty year total compensation pay member group increase julian heslop balance period serve capacity increase transfer value result increase valuation aggregate increase accrue pension benefit pension benefit accrue year reduce period net inflation aggregate payment service assume retirement age define contribution scheme moncef slaoui member executive cash balance member group grant pension plan plan provide executive pension credit share option ad option share option plan gsk make annual contribution calculate award share defer annual bonus percentage executive base salary gsk make contribution plan share ad performance base pay fund increase interest rate set share plan nil share ad share value annually advance base year treasury bond rate plan notional share ad grant defer provide cash sum retirement plan entitlement investment award plan member group spouse pension pension increase award reinvestment dividend transfer value cash sum increase share ad performance share plan share moncef slaoui year result accumulation defer annual bonus plan notional share interest contribution pay company defer investment award plan moncef slaoui active participant belgium fortis february group comprise person own plan plan define benefit plan share ad constitute lump sum payable normal retirement age issue share capital company group hold plan transfer value cash sum moncef slaouis date option purchase share plan increase cid year result ad share ad award accumulation interest performance share plan include share ad vest defer vested defer ad moncef slaoui member retirement saving plan legacy smithkline beecham midterm incentive plan share saving scheme open employee executive ad award share value plan share supplemental saving plan saving scheme open executive ad defer annual bonus plan accrue benefit government limit impose notional share award deferred investment award retirement saving plan contribution plan invest plan holding issue executive share range fund value accumulate fund pay option plan describe note financial statement retirement employee share scheme contribution pay basis preparation scheme gsk respect moncef slaoui remuneration report prepare accordance director interest contract company act large mediumsize company group account report regulation describe note financial statement relate regulation meet relevant requirement fsa party transaction end financial year list rule accordance regulation follow director connect person material interest section remuneration report contract significance relation group business subject audit annual remuneration nonexecutive director group company remuneration incentive plan share option performance share plan award vest criterion share value plan award pension benefit opinion thereon express remaining section subject audit page refer audit section remuneration report approve board director sign behalf sir crispin davis remuneration committee chairman march gsk annual report stnemetat laicnanif director statement responsibility director statement responsibility relation business review section contain annual report group financial statement include fair review development performance business position group director responsible prepare annual report description principal risk uncertainty face remuneration report group financial statement accordance applicable law regulation disclosure information auditor company law require director prepare financial statement director office date report financial year law director require confirm prepare group financial statement accordance far aware relevant audit information international financial reporting standard ifrs adopt company auditor unaware european union prepare group financial statement director elect comply ifrs issue take step ought international accounting standard board iasb company take director aware law director approve group financial statement relevant audit information establish company satisfied true fair view auditor aware information state affair group profit loss group confirmation give interpret accordance period provision section company act prepare financial statement director require go concern basis select suitable accounting policy apply consistently business review page contain information performance group financial position cash flow judgement accounting estimate reasonable net debt position borrowing facility information prudent include treasury risk management policy exposure market state group financial statement comply ifrs credit risk hedging activity give note adopt european union ifrs issue iasb financial statement financial instrument relate disclosure subject material departure disclose explain group financial statement make enquiry director reasonable expectation group adequate resource continue director responsible keep adequate accounting operational existence foreseeable future reason record sufficient explain company continue adopt go concern basis prepare transaction disclose reasonable accuracy time financial statement financial position group enable ensure group financial statement remuneration report internal control comply company act article ias board audit risk committee review regulation responsible safeguarding asset assessment risk internal control framework operate group take reasonable step prevention gsk consider effectiveness system internal detection fraud irregularity control operation group year cover report group financial statement year end december date approval board director comprise principal statement support note set financial statement page combine code report board consider glaxosmithkline plc apply main responsibility auditor relation group financial principle section combine code maintain statement set independent auditor report frc describe corporate governance section page comply provision disclose group financial statement year end december include annual report publish hard require fsa list rule auditor consider copy print form available company website director statement compliance relation point director responsible maintenance integrity combine code specify review annual report website accordance legislation govern preparation dissemination financial annual report statement access website available outside annual report year end december comparable legislation different comprising report director remuneration report current director name function list financial statement additional information investor corporate governance section annual report approve board director signed confirm good knowledge behalf group financial statement prepare accordance ifrs adopt ifrs issue sir christopher gent iasb true fair view asset liability financial chairman position profit group march gsk annual report business review governance remuneration financial statement shareholder information independent auditor report members glaxosmithkline plc audit group financial statement opinion matter prescribed glaxosmithkline plc year end december company act comprise consolidated income statement consolidate opinion information give director report statement comprehensive income consolidate balance financial year group financial statement sheet consolidate statement change equity prepare consistent group financial statement consolidate cash flow statement relate note financial reporting framework apply matter require report preparation applicable law international financial reporting exception standard ifrs adopt european union report respect follow respective responsibility director company act require report auditor opinion explain fully director statement certain disclosure director remuneration specify law responsibility set director responsible preparation group financial statement satisfy true fair view responsibility receive information explanation audit express opinion group financial statement require audit accordance applicable law international standard list rule require review audit ireland standard require comply auditing practice board ethical standard auditor director statement set relation go concern report include opinion prepare company member body accordance chapter corporate governance statement relate company act purpose company compliance provision june give opinion accept assume responsibility combine code specify review purpose person report certain element report shareholder board show hand come save expressly director remuneration agree prior consent writing matter scope audit financial statement report separately parent company financial audit involve obtain evidence amount statement glaxosmithkline plc year end disclosure financial statement sufficient reasonable december information director assurance financial statement free material remuneration report describe audit misstatement cause fraud error include assessment accounting policy appropriate company pass resolution accordance section group circumstance consistently apply company act senior statutory auditor adequately disclose reasonableness significant accounting state estimate director overall presentation financial statement opinion financial statement opinion group financial statement pricewaterhousecooper llp charter accountant statutory auditor true fair view state group affair london december profit cash flow year march end properly prepared accordance ifrs adopt european union prepare accordance requirement company act article las regulation separate opinion relation ifrs issue iasb explain note group financial statement group addition comply legal obligation apply ifrs adopt european union apply ifrs issue international accounting standard board iasb opinion group financial statement comply ifrs issue iasb gsk annual report stnemetat laicnanif consolidated income statement year end december result major major restructuring restructure total note turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny calculation result major restructuring describe note presentation financial statement consolidate statement comprehensive income year end december profit year exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement fair value movement subsidiary acquisition cash flow hedge reclassify goodwill actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report business review governance remuneration financial statement shareholder information result result major major major major restructuring restructure total restructure restructuring total gsk annual report stnemetat laicnanif consolidated balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity approved board march sir christopher gent chairman gsk annual report business review governance remuneration financial statement shareholder information consolidate statement change equity year end december shareholder equity non share share retain control total capital premium earning reserve total interest equity january profit year comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year distribution noncontrolle interest change noncontrolle interest option noncontrolle interest dividend shareholder ordinary share issue ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive income year distribution noncontrolle interest dividend shareholder ordinary share issue ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report stnemetat laicnanif consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire investment associate joint venture decrease liquid investment interest receive dividend associate joint venture proceed disposal associate net cash outflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation increase longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report business review governance remuneration financial statement shareholder information note financial statement presentation financial statement estimate total cost approximately billion expand programme expect deliver annual pretax saving description business approximately billion time substantially complete glaxosmithkline major global healthcare group give extent cost operational excellence engage creation discovery development manufacture programme management believe material impact marketing pharmaceutical product include vaccine gsk operating result manner gsk overthecounter otc medicine healthrelate consumer business conduct gsk present restructuring cost product gsk principal pharmaceutical product include incur solely direct result operational excellence medicine follow therapeutic area respiratory programme separate column income statement title antiviral include hiv central nervous system cardiovascular major restructure urogenital metabolic antibacterial oncology emesis vaccine dermatological addition restructuring cost operational excellence programme major restructuring column income compliance applicable law ifrs statement include restructuring cost incur solely direct financial statement prepare accordance result restructure programme follow relate company act article ias regulation material acquisition operation acquire business international accounting standard ias international financial overlap extensively gsk exist operation report standard ifrs relate interpretation adopt restructure activity follow relate european union acquisition nature undertake operational excellence programme carry financial statement compliance ifrs issue follow detailed formal plan management consider international accounting standard board appropriate present cost restructuring activity composition financial statement manner billion million acquisition consolidated financial statement draw sterling reliant pharmaceutical december billion functional currency glaxosmithkline plc accordance billion acquisition stiefel laboratory july ifrs accounting presentation financial statement comprise acquisition october meet criterion set acquisition cost incur consolidated income statement direct result related restructure programme consolidate statement comprehensive income include major restructuring column consolidate balance sheet group result cost operational excellence consolidate statement change equity programme acquisitionrelate restructuring programme consolidate cash flow statement meeting criterion describe present separate column income statement describe note financial statement result major restructuring presentation accounting convention gsk intend apply consistently future major restructure financial statement prepare historical programme material impact gsk operating result cost convention modify revaluation certain item manner gsk business conduct state accounting policy adopt clearly group result cost restructure programme management financial period believe presentation assist investor gain clear financial statement cover financial year january understand group financial performance december comparative figure financial make projection future financial performance result year january december include cost virtue size nature limit appropriate january december comparative value presentation consistent way composition group management assess group financial performance list subsidiary associate undertaking restructuring cost arise solely direct result opinion director principally affect profit operational excellence programme restructure net asset group give note principal programme follow relate acquisition meeting group company criterion describe continue report operating expense result major restructuring presentation restructuring cost october board approve implementation detail formal plan gsk announce significant new operational excellence restructure programme second formal plan represent significant expansion operational excellence programme approve board announce february expansion approve board announce february restructure programme comprise detailed formal plan cover area gsk business include manufacturing sell infrastructure gsk annual report stnemetats laicnanif note financial statement presentation financial statement accounting principle policy continue consolidation accounting principle policy consolidate financial statement include preparation financial statement conformity asset liability result cash flow generally accept accounting principle require management company subsidiary include esop trust estimate assumption affect report amount group share result net asset associate asset liability disclosure contingent asset joint venture liabilitie date financial statement report amount revenue expense report period financial statement entity consolidate actual result differ estimate december year financial statement prepare accordance entity group power govern group accounting policy approve board financial operating policy account subsidiary describe note accounting principle policy group ability exercise joint control information application accounting policy entity account joint venture group include area estimation judgement give note ability exercise significant influence account key accounting judgement estimate appropriate associate result asset liability associate comparative figure reclassify ensure consistent joint venture incorporate consolidated financial presentation current year information statement equity method accounting implementation new accounting standard interest acquire entity consolidated date effect january gsk implement group acquire control interest sell deconsolidate ifrs revise business combination ias revise date control cease consolidated separate financial statement minor transaction balance subsidiary eliminate amendment number accounting standard profit tax take sale subsidiary ifrs revise ias revise implement product sell customer outside group prospectively restatement comparative information relevant proportion profit transaction joint revise accounting policy business combination set ventures associate defer product sell note accounting principle policy acquisition party defer tax relief unrealise intragroup profit year discuss note acquisition account extent consider recoverable disposal revision ias impact goodwill capitalise separate item case subsidiarie current period cost investment case joint venture parent company financial statement associate goodwill denominate currency financial statement parent company glaxosmithkline operation acquire plc prepare accordance gaap cost acquisition fair value net accounting presentation company balance sheet present asset acquire difference recognise directly account policy give income statement business combination business combination account acquisition accounting method identifiable asset liability contingent liability acquire measure fair value acquisition date consideration transfer measure fair value include fair value contingent consideration cost acquisition charge income statement period incur equity subsidiary acquire non control interest recognise fair value non control interest share net asset subsidiary casebycase basis change group ownership percentage subsidiary account equity gsk annual report business review governance remuneration financial statement shareholder information note financial statement accounting principle policy continue expenditure expenditure recognise respect good service receive foreign currency translation supply accordance contractual term provision foreign currency transaction book functional currency obligation exist future liability respect group company exchange rate ruling date past event obligation reliably transaction foreign currency monetary asset liability estimate manufacturing startup cost validation retranslate functional currency rate exchange rule achievement normal production expense incur balance sheet date exchange difference include advertising promotion expenditure charge income income statement statement incur shipment cost intercompany transfer consolidation asset liability include related goodwill charge cost sale distribution cost sale customer overseas subsidiary associate joint venture translate include sell general administrative expenditure sterling rate exchange rule balance sheet date restructuring cost recognise provide result cash flow overseas subsidiary associate appropriate respect direct expenditure business joint venture translate sterling average rate reorganisation plan sufficiently detail exchange advance appropriate communication affect exchange adjustment arise open net asset undertake profit year retain overseas subsidiary associate research development joint venture translate sterling exchange difference research development expenditure charge income arise relate foreign currency borrowing hedge statement period incur development group net investment operation take separate expenditure capitalise criterion recognise asset component equity meet usually regulatory filing major translating sterling asset liability result market approval consider highly probable property plant cash flow overseas subsidiary associate joint venture equipment research development capitalise report currency hyperinflationary economy depreciate accordance group policy adjustment material reflect current price level environmental expenditure loss net monetary asset charge consolidated environmental expenditure relate exist condition result income statement past current operation current revenue future benefit discernible charge income statement revenue recognise income statement good group recognise liability sitebysite basis service supply available external customer reliably estimate liability include group portion order receive title risk loss pass total cost portion potentially responsible customer reliable estimate relevant deduction party cost probable able satisfy relevant obligation fulfil respective share cleanup obligation recovery earning process regard complete reimbursement record asset virtually certain turnover represent net invoice value deduction legal dispute discount allowance give accrual estimate provision anticipated settlement cost legal future rebate return methodology assumption dispute group outflow resource estimate rebate return monitor adjust consider probable reliable estimate regularly light contractual legal obligation likely outcome addition provision legal historical trend past experience project market condition expense arise claim receive dispute market condition evaluate wholesaler respect product liability claim relate certain product thirdparty analysis market research datum internally generate sufficient history claim settlement information value add tax sale taxis exclude enable management reliable estimate provision revenue require cover unasserted claim certain case incur report ibnr actuarial technique determine group copromote product party estimate record sale group record share revenue copromotion income turnover nature copromotion group involved legal proceeding respect activity group record cost sale possible reliable estimate expect pharmaceutical turnover include copromotion revenue financial effect result ultimate resolution million million million proceeding case appropriate disclosure case include provision cost royalty income recognise operating income associate claim group party accrual basis accordance term relevant charge income statement incur licensing agreement gsk annual report stnemetat laicnanif note financial statement accounting principle policy continue lease lease agreement transfer group substantially pension postemployment benefit benefit risk ownership asset treat cost provide pension define benefit scheme finance lease asset purchase outright calculate project unit credit method spread asset include ppe computer software period benefit expect derive capital element leasing commitment show employee service consistent advice qualified obligation finance lease asset hold finance lease actuary pension obligation measure present value depreciate basis consistent similar own asset estimate future cash flow discount rate reflect yield lease term short interest element lease rental high quality corporate bond include income statement lease operate pension scheme asset measure fair value balance lease rental cost charge income statement sheet date actuarial gain loss difference straightline basis lease term expect actual return asset effect change goodwill actuarial assumption recognise statement goodwill state cost impairment goodwill deem comprehensive income year arise indefinite useful life test impairment annually group contribution define contribution plan fair value interest acquire entitys asset charge income statement incur cost liabilitie contingent liability exceed consideration pay postemployment liability calculate similar way excess recognise immediately gain income define benefit pension scheme spread period statement benefit expect derived employee service accordance advice qualified actuary intangible asset intangible asset state cost provision amortisation employee share plan impairment incentive form share provide employee share option share award scheme licence patent knowhow marketing right separately acquire acquire business combination fair value option award calculate amortise estimate useful life generally exceed grant date blackschole option pricing model charge year straightline basis time income statement relevant vesting period available use estimate useful life determine group provide finance esop trust purchase company amortisation charge account patent life share open market meet obligation provide share applicable value obtain period non employee exercise option award cost run exclusivity asset life review appropriate esop trust charge income statement share hold adjust annually contingent milestone payment recognise esop trust deduct reserve transfer point contingent event certain reserve retain earning development cost incur group associate vest period relate share option award reflect acquire licence patent knowhow marketing right ultimate proceed receivable employee exercise write income statement incur criterion recognition internally generate intangible asset property plant equipment meet usually regulatory filing major property plant equipment ppe state cost market approval consider highly probable purchase construction provision depreciation impairment financing cost capitalise cost acquire brand value independently fair value qualify asset construction business acquire party brand value substantial longterm brand depreciation calculate write cost residual value contractual legal nature sell separately ppe exclude freehold land straightline basis rest business acquire brand amortise expect useful life residual value life review estimate useful life year appropriate adjust annually normal expect useful consider useful economic life indefinite live major category ppe costs acquire develop computer software freehold building year internal use internet site external use capitalise leasehold land intangible fix asset software site support building lease term year significant business system expenditure lead plant machinery year creation durable asset erp system software amortise fixture equipment year seven year computer software year disposal ppe cost relate accumulate depreciation impairment remove financial statement net proceed take income statement gsk annual report business review governance remuneration financial statement shareholder information note financial statement accounting principle policy continue trade receivable trade receivables carry original invoice impairment noncurrent asset provision doubtful debt provision carry value noncurrent asset review evidence risk nonpayment take account age impairment indication asset previous experience general economic condition trade impair additionally goodwill intangible asset indefinite receivable determine uncollectable write firstly useful life intangible asset available use provision available income statement test impairment annually provision impairment charge income statement year concern subsequent recovery amount previously provide credit income statement longterm receivables impairment goodwill reverse impairment loss discount effect material noncurrent asset reverse change estimate determine recoverable amount trade payable extent revise recoverable amount trade payable hold amortise cost equate exceed carry value exist net nominal value longterm payable discount depreciation amortisation impairment recognise effect material investment associate joint venture cash cash equivalent investment associate joint venture carry cash cash equivalent comprise cash hand current balance consolidate balance sheet group share net asset bank similar institution highly liquid investment date acquisition postacquisition retain profit generally maturitie month readily loss goodwill arise acquisition convertible know amount cash insignificant risk change value availableforsale investment liquid investment investment classify available borrowing forsale investment initially record fair value plus borrowing initially record proceed transaction cost remeasure subsequent reporting receive net transaction cost borrowing subsequently date fair value unrealised gain loss availableforsale carry amortise cost difference investment recognise directly comprehensive income proceed net transaction cost impairment arise significant prolong decline fair redemption recognise charge income statement value equity investment reduce carry period relevant borrowing asset directly charge income statement taxation disposal impairment investment gain current tax provide amount expect pay loss defer comprehensive income apply tax rate enact substantively enact reclassified income statement dividend equity balance sheet date investment recognise income statement defer tax provide liability method group right receive payment establish equity investment temporary difference arise tax basis asset record noncurrent asset expect liability carry amount financial statement sell year defer tax asset recognise extent probable purchase sale equity investment account future taxable profit available trade date purchase sale availableforsale temporary difference utilise defer tax provide investment account settlement date temporary difference arise investment subsidiary associate joint venture time inventory reversal temporary difference control inventory include financial statement low probable temporary difference reverse cost include raw material direct labour direct cost foreseeable future defer tax provide rate tax relate production overhead net realisable value enact substantively enact balance sheet cost generally determine basis prelaunch date defer tax liability asset discount inventory hold asset high probability regulatory approval product point provision carry value recoverable provision reverse point high probability regulatory approval determined gsk annual report stnemetat laicnanif note financial statement accounting principle policy continue key accounting judgement estimate derivative financial instrument hedge prepare financial statement management require derivative financial instrument manage exposure estimate assumption affect amount market risk principal derivative instrument gsk asset liability revenue expense report financial foreign currency swap interest rate swap forward foreign statement actual amount result differ exchange contract group hold issue derivative estimate follow consider key accounting financial instrument trade speculative purpose judgement estimate derivative financial instrument classify heldfortrading turnover carry balance sheet fair value derivative designate revenue recognise title risk loss pass hedge instrument classify inception cash flow customer reliable estimate relevant deduction hedge net investment hedge fair value hedge relevant obligation fulfil earning process regard complete change fair value derivative designate cash flow hedge recognise comprehensive income gross turnover reduce rebate discount allowance extent hedge effective ineffective portion product return give expect give vary recognise profit loss immediately amount deferred product arrangement buy group arrangement comprehensive income reclassify income statement purchasing organisation dependent submission hedge item affect profit loss claim time initial recognition sale accrual time sale estimate rebate net investment hedge account similar way cash discount allowance payable return base flow hedge available market information historical experience change fair value derivative designate fair value amount estimate fully reflect hedge record income statement final outcome amount subject change dependent change fair value hedge asset liability thing type buy group change fair value derivative instrument product sale mix qualify hedge accounting recognise immediately level accrual review adjust regularly light income statement contractual legal obligation historical trend past experience discount project market condition market condition evaluate time effect money material balance discount wholesaler thirdparty analysis market research current value appropriate rate interest unwind datum internally generate information future event discount record finance income finance cost cause assumption accrual base change affect future result group taxation current tax provide amount expect pay defer tax provide temporary difference tax basis asset liability carry amount rate enact substantively enact balance sheet date group open tax issue number revenue authority gsk continue believe adequate provision liability likely arise open assessment open issue exist ultimate liability matter vary amount provide dependent outcome negotiation relevant tax authority necessary litigation proceeding gsk annual report business review governance remuneration financial statement shareholder information note financial statement key accounting judgement estimate intangible asset continue intangible asset acquire gsk party cost acquisition capitalise licence compound legal dispute development amortise point gsk provide anticipate settlement cost outflow available use estimate useful life resource consider probable reliable estimate include period nonexclusivity estimate useful life likely outcome dispute legal review annually impairment test undertake event expense arise claim group occur question carry value asset brand acquire business capitalise independently company director take legal advice separable expect life establish provision take account relevant year brand amortise straightline basis fact circumstance matter accordance estimate useful life exceed year accounting requirement respect product liability claim end useful economic life foresee brand relate certain product sufficient history claim amortise subject annual impairment test settlement enable management reliable estimate provision require cover unasserted claim certain initial valuation valuation subsequent impairment case incur report ibnr actuarial technique test base established market multiple riskadjuste determine estimate group involved future cash flow discount appropriate interest rate legal proceeding respect possible future cash flow base business forecast reliable estimate expect financial effect inherently judgemental future event cause result ultimate resolution proceeding case assumption impairment review change appropriate disclosure case include consequent adverse effect future result group provision december provision legal dispute amount billion pension postemployment benefit billion cost provide pension postemployment benefit charge income statement accordance ultimate liability legal claim vary amount ias period benefit derive provide dependent outcome litigation employee service cost assess basis proceeding investigation possible settlement negotiation assumption select management assumption position change time include future earning pension increase discount rate assurance loss result outcome expect long term rate return asset mortality legal proceeding exceed provision rate disclose note pension report group financial statement material postemployment benefit property plant equipment expect long term rate return bond determine set note property plant equipment carry base portfolio mix indexlinke government value property plant equipment test impairment corporate bond equity risk premium add indication value asset equitie impair impairment determine reference high discount rate derive rate corporate bond yield fair value cost sell value use measure assess country deep market corporate riskadjuste future cash flow discount appropriate bond government bond yield sensitivity analysis interest rate future cash flow base business provide note pension postemployment forecast inherently judgemental future event benefit reduction discount rate lead cause assumption impairment test increase net pension deficit approximately change consequent adverse effect future result million increase annual pension cost group approximately million selection different assumption goodwill affect future result group goodwill arise business combination capitalise allocate appropriate cash generating unit deem indefinite life amortise annual impairment test relevant cash generating unit perform impairment test base established market multiple riskadjuste future cash flow discount appropriate interest rate future cash flow base business forecast inherently judgemental future event cause assumption impairment test set note goodwill change consequent adverse effect future result group gsk annual report stnemetat laicnanif note financial statement new accounting requirement exchange rate follow new amend accounting standard ifric group use average exchange rate prevail interpretation issue iasb likely affect period translate result cash flow overseas future annual report current form subsidiarie joint venture associate undertaking expect material impact result financial sterling period end rate translate net asset position group undertaking currency influence translation relevant exchange rate amendment ias financial instrument presentation classification right issue issue october implement gsk january amendment require issue right acquire additional average rate share exist shareholder recognise equity regardless currency share euro yen iasbs annual improvement project publish change effective january period end rate project make minor amendment number standard area include consolidation business combination euro financial instrument yen ia revise relate party disclosure issue november implement gsk january revise standard clarifie definition relate party provide exemption government relate entity ifric extinguish financial liability equity instrument issue november implement gsk january interpretation address accounting entity issue equity instrument order settle financial liability amendment ifric prepayment minimum funding requirement issue november implement gsk january amendment permit voluntary prepayment minimum funding requirement recognise asset follow new standard interpretation endorse ifrs financial instrument issue november amend october implement gsk january standard eventually replace ias cover classification measurement derecognition financial asset financial liability iasb intends expand ifrs add new requirement impairment hedge accounting complete replacement ias end amendment ifrs disclosure transfer financial asset issue october implement gsk january amendment require additional disclosure risk exposure relate transfer financial asset amendment ia defer tax recovery underlie asset issue december implement gsk january amendment require defer tax nondepreciable asset measure revaluation model calculate sale basis gsk annual report business review governance remuneration financial statement shareholder information note financial statement segment information gsk revise segmental information disclosure reflect change internal reporting structure effect january viiv healthcare show separate segment stiefel integrate gsk heritage dermatology business report relevant geographical pharmaceutical segment trade unallocated pharmaceutical information combine addition responsibility certain product small market move pharmaceutical business consumer healthcare comparative information restate consistent basis gsk operating segment report base financial information provide chief executive officer regard chief operating decision maker codm responsibility corporate executive team cet individual member cet responsible geographic region pharmaceutical business viiv healthcare consumer healthcare business respectively major restructure geographic information regularly provide codm investment essential sustainability pharmaceutical business segment report usa europe emerge markets asia pacificjapan regional pharmaceutical operating profit exclude allocation globally fund central cost principally corporate function unallocate manufacturing cost gsk management reporting process allocate intragroup profit product sale market sale record profit analysis present basis trading unallocated pharmaceutical segment include canada puerto rico central vaccine tender sale contract manufacturing sale cost vaccine central dermatology cost central manufacturing cost attribute segment pharmaceutical segment exclude vaccine responsibility chairman research development report separate segment corporate unallocated cost disposal profit include corporate function cost legal matter fair value movement financial instrument investment unallocate profit asset disposal restate restate turnover segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare trading unallocated pharmaceutical pharmaceutical turnover consumer healthcare turnover restate restate pharmaceutical turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatological viiv healthcare hiv consumer healthcare turnover category otc medicine oral healthcare nutritional healthcare gsk annual report stnemetat laicnanif note financial statement segment information continue pharmaceutical viiv healthcare sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare pharmaceutical trading unallocated pharmaceutical cost pharmaceutical operating profit consumer healthcare operate profit segment profit corporate unallocated cost disposal profit operate profit major restructure major restructuring total operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare pharmaceutical trading unallocated pharmaceutical pharmaceutical depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructure major restructure total depreciation amortisation gsk annual report business review governance remuneration financial statement shareholder information note financial statement segment information continue ppe intangible asset goodwill impairment segment restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare pharmaceutical trading unallocated pharmaceutical pharmaceutical impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructure major restructure total impairment ppe intangible asset goodwill impairment reversal segment restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare pharmaceutical trading unallocated pharmaceutical pharmaceutical impairment reversal consumer healthcare impairment reversal segment impairment reversal corporate unallocated impairment reversal impairment reversal major restructure major restructure total impairment reversal gsk annual report stnemetat laicnanif note financial statement segment information continue restate net asset segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals viiv healthcare pharmaceutical trading unallocated pharmaceutical pharmaceutical net operating asset consumer healthcare net operating asset segment net operating asset corporate unallocated operate net asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset trade unallocated pharmaceutical segment include asset centrally manage pharmaceutical vaccine manufacture operation depreciation total million million million recover standard cost product charge business geographical information regard group country domicile restate restate turnover location customer usa rest world external turnover turnover location subsidiary usa rest world turnover include intersegment turnover usa rest world intersegment turnover usa rest world external turnover gsk annual report business review governance remuneration financial statement shareholder information note financial statement segment information continue operate profit location usa rest world total operating profit restate net operating asset location usa rest world net operating asset restate noncurrent asset location usa rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables major restructure programme october gsk announce significant new operational excellence programme improve effectiveness productivity operation significant expansion operational excellence programme approve board announce february expansion approve board announce february total approve cost implementation expand programme increase billion approximately billion period approximately cost incur december approximately expect incur balance total approximately cost expect cash expenditure expect asset writedown uncertainty exist exact time cash outflow result potential future exchange rate fluctuation element restructure programme subject employee consultation procedure make difficult predict precision procedure complete majority remain cash payment expect programme remain track deliver total annual pretax saving billion saving realise business total restructuring cost million incur million incur operational excellence programme follow area ost save project focus primarily simplification streamline support infrastructure include site rationalisation principally verona italy harlow tonbridge adoption customise sale approach lead staff reduction number sale force principally usa france italy closure number manufacture site include dartford crawley give rise asset writedown staff reduction project simplify eliminate process lead staff reduction administrative support function remain cost million incur year restructure programme relate integration stiefel laboratories inc business usa follow acquisition july gsk annual report stnemetat laicnanif note financial statement major restructuring programme continue analysis cost incur programme follow asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset impairment million million million net cost total million million million noncash item principally accelerate depreciation charge settle cash include termination lease site closure cost consultancy project management fee gsk annual report business review governance remuneration financial statement shareholder information note financial statement major restructuring programme continue restructure cost report major restructuring column income statement income result minor restructuring activity initiate prior october amount million million cost million cost incomecost report result major restructuring cost major restructuring programme arise follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise foreign exchange gainloss recognise liquidation subsidiary noncash charge cash cost net finance expense effect profit taxation noncash charge principally accelerate depreciation arise asset life shorten result major restructuring programme cash cost include termination lease site closure cost consultancy project management fee operate income royalty income milestone income impairment equity investment disposal equity investment disposal asset asset right legal settlement gain recognise creation viiv healthcare fair value movement derivative financial instrument income royalty milestone income principally core recur income outlicense intellectual property gsk annual report stnemetat laicnanif note financial statement operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset goodwill net reversal net foreign exchange lossesgain inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration fee payable company auditor associate audit parent company consolidated financial statement audit account group overseas subsidiary pursuant legislation assurance service pursuant legislation include attestation sarbanesoxley act audit assurance service tax service service include regulatory compliance treasury relate service december pricewaterhousecooper llp associate fee invoice million comprise statutory audit million taxation service million service million addition fee pay respect gsk pension scheme audit service gsk annual report business review governance remuneration financial statement shareholder information note financial statement employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity wage salary decrease cer term group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables realise gain liquid investment fair value movement derivative fair value profit loss net investment hedge ineffectiveness unwind discount asset derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest income arise derivative fair value profit loss relate swap interest income gsk annual report stnemetat laicnanif note financial statement finance cost interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision net investment hedge ineffectiveness finance expense derivative fair value profit loss designate effective hedging instrument classify heldfortrade financial instrument ia associates joint ventures associate share tax profit quest diagnostic inc share tax profit aspen pharmacare holding limit share tax loss associate share tax lossesprofit joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover quest diagnostic inc aspen pharmacare holding limit total profit quest diagnostic inc aspen pharmacare holding limited result aspen pharmacare holding limit include summarise income statement information represent estimate earning aspen group period subsequent yearend gsk sell entire shareholding quest diagnostic inc gsk annual report business review governance remuneration financial statement shareholder information note financial statement taxation taxation charge base profit year corporation tax statutory rate double taxation relief overseas taxation current taxation defer taxation reconciliation taxation rate group profit statutory rate taxation difference overseas taxation rate benefit special tax status credit intercompany stock profit impact share base payment tax profit associate loss benefit recognise permanent difference prior year item restructure tax rate high tax rate year end december reflect impact relatively low tax relief arise billion legal provision charge year nondeductibility cost associate certain site closure partly offset settlement certain historical tax matter percentage reconciliation exacerbate relatively low report profit group operate country tax rate differ tax rate impact overseas taxis overall rate tax show profit arise certain operation singapore accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice gaap result difference accounting treatment group tax rate current period intercompany profit ifrs increase increase increase arise change location workin progress finish good tax item charge equity statement comprehensive income current taxation share base payment foreign exchange movement defer taxation share base payment define benefit plan fair value movement cash flow hedge fair value movement availableforsale investment total chargecredit equity statement comprehensive income item charge statement comprehensive income tax share base payment gsk annual report stnemetat laicnanif note financial statement taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue continue fact life gsk year gsk agree settle open year major tax authority include canada federal court appeal overturn judgement tax court canada respect gsk transfer pricing early remand case tax court reconsideration party seek leave appeal supreme court canada gsk continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate provision taxation arise distribution profit retain overseas subsidiary ground group able control time reversal temporary difference probable reverse foreseeable future aggregate unremitte profit balance sheet date approximately billion billion defer tax unremitte earning december estimate million million relate taxis payable repatriation dividend withholding taxis levy overseas tax jurisdiction legislation relate company distribution provide exemption tax repatriate profit subject certain exception movement defer tax asset liability pension manu share accelerate intra post legal facture stock option net offset capital group employment tax restruct valuation award temporary allowance intangible profit benefit loss dispute ure adjustment scheme difference country total defer tax asset january defer tax liability january january exchange adjustment creditcharge income statement credit equity creditcharge statement comprehensive income acquisition december defer tax asset december defer tax liability december defer tax credit income relate change tax rate million million million defer tax movement arise origination reversal temporary difference net temporary difference mainly include accrue expense tax deduction available pay basis gsk annual report business review governance remuneration financial statement shareholder information note financial statement taxation continue tax loss recognise unrecognised trading loss expire year year available indefinitely december defer tax asset addition group capital loss december approximately billion billion respect defer tax asset recognise defer tax asset recognise probable future taxable profit available utilise loss factor affect tax charge future year global organisation factor affect future effective tax rate group mix profit different territory transfer pricing dispute tax authority location research development activity significant impact group effective tax rate change tax legislation territory gsk business operation impact group effective tax rate government propose significant change taxation system june government announce phase reduction main rate corporation tax year april defer tax movement reflect reduction tax rate substantively enact november government reconfirm intention introduce patent box regime apply reduce rate corporation tax income patent effect april follow period consultation government continue consult business propose change legislation relate control foreign company majority change expect enact earning share pence pence pence basic earning share adjustment major restructure basic earning share major restructuring dilute earning share adjustment major restructuring dilute earning share major restructure basic adjust earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust adjust earning share calculate result major restructure earning calculation result major restructuring describe note presentation financial statement dilute earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option dilute gsk annual report stnemetat laicnanif note financial statement dividend interim second interim interim fourth interim total total dividend dividend share penny paidpayable july october january april total dividend dividend share penny pay july october january april total dividend dividend share penny pay july october january april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december gsk annual report business review governance remuneration financial statement shareholder information note financial statement property plant equipment continue plant land equipment asset building vehicle construction total depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment nil nil net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost sell value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale gsk annual report stnemetat laicnanif note financial statement goodwill cost january exchange adjustment addition business combination impairment loss cost december net book value january net book value december impairment loss year arise decision exit pliva research institute site zagreb croatia loss report consolidated income statement major restructuring programme sell general administration addition year translate acquisition exchange rate arise primarily acquisition laboratorio phoenix saicyf note acquisition disposal detail carry value goodwill translate yearend exchange rate balance arise acquisition wfollowe business cash generating unit stiefel laboratories inc europe emerge markets asia pacific pharmaceuticals biomedical corporation europe emerge markets asia pacific japan pharmaceuticals reliant pharmaceuticals inc pharmaceuticals sirtris pharmaceuticals inc europe emerge markets asia pacific japan pharmaceuticals pfizer hiv business viiv healthcare glaxosmithkline japan pharmaceuticals domantis limit europe emerge markets asia pacific japan pharmaceuticals cns inc consumer healthcare polfa poznan europe pharmaceutical certain business ucb emerge market asia pacific pharmaceuticals laboratorios phoenix saicyf emerge market pharmaceutical novamin technology inc consumer healthcare gsk annual report business review governance remuneration financial statement shareholder information note financial statement goodwill continue goodwill allocate cash generating unit test impairment annually effect january gsk revise segmental disclosure reflect change internal reporting structure viiv healthcare show separate segment stiefel business integrate gsk legacy dermatology business follow change goodwill arise acquisition stiefel allocate europe emerge markets asia pacific pharmaceuticals cgus impairment testing purpose benefit acquire business expect arise business goodwill arise acquisition biomedical sirtris pharmaceuticals domantis split europe emerge markets asia pacific japan pharmaceutical cgus impairment testing purpose benefit acquire business split cgus acquire business generate independent cash flow allocation polfa poznan goodwill change poland pharmaceuticals europe pharmaceutical cash generating unit change allocation reflect level gsk internal management monitor polfa poznan goodwill valuation pharmaceutical cash generating unit goodwill impairment testing purpose prepare fair value cost sell basis turnover earning multiple derive observed market datum recoverable amount cash generating unit assess value use fair value cost sell model value use calculate net present value project riskadjuste posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate apply calculate net present value posttax cash flow posttax discount rate base group wacc cash generating unit integrate operation large part group group wacc equivalent pretax discount rate approximately discount rate increase specific country risk sufficiently significant material impact outcome impairment test impairment test indicate recoverable value unit close carrying value test reperforme pretax discount rate pretax cash flow order determine impairment exist establish magnitude fair value calculate similar discount cash flow approach base group acquisition valuation model posttax discount rate apply project riskadjuste posttax cash flow terminal value detail relate discount cash flow model impairment test significant goodwill balance follow europe emerge market asia pacific pharmaceuticals cgus viiv healthcare cgu valuation basis value use fair value cost sell key assumption sale growth rate sale growth rate profit margin profit margin discount rate discount rate determination assumption growth rate internal forecast growth rate internal forecast base internal base internal external market information external market information margin reflect past experience margin reflect past experience adjust expect change adjust expect change discount rate base discount rate base group wacc group wacc period specific project cash flow year year discount rate terminal growth rate europe decline emerge market asia pacific gsk annual report stnemetat laicnanif note financial statement goodwill continue japan pharmaceuticals cgu consumer healthcare cgu valuation basis fair value cost sell fair value cost sell key assumption sale growth rate sale growth rate profit margin advertising promotion discount rate investment terminal growth rate discount rate determination assumption growth rate internal growth rate internal forecast forecast base internal base internal external external market information market information margin reflect past experience advertising promotion adjust expect change investment base historical level discount rate base adjust management view group wacc support need innovation expansion terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc period specific project cash flow year year discount rate terminal growth rate terminal growth rate exceed longterm project growth rate relevant market terminal growth rate value use calculation pharmaceutical cash generating unit reflect impact future generic competition account new product launch consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion pharmaceutical cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million detail indefinite life brand give note intangible asset case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill gsk annual report business review governance remuneration financial statement shareholder information note financial statement intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise internal development cost addition business combination addition disposal asset writeoff reclassification cost december exchange adjustment capitalise internal development cost addition business combination capitalise borrowing cost addition disposal asset writeoff reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff amortisation december exchange adjustment charge year disposal asset writeoff amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december gsk annual report stnemetat laicnanif note financial statement intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development include impairment million arise major restructuring programme net book value computer software include million million internally generate cost licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development net book value include million million internally generate cost impairment loss million million principally arise asset development long actively pursue note acquisition disposal give detail addition business combination year book value large individual item follow fluviral lovaza selzentry arzerra duac fraxiparine amortise brand include otc right relate alli book value december million million indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow panadol sensodyne stiefel trade breathe right physiogel polident corega biotene poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment apply fair value cost sell methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate countryspecific risk main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment brand gsk annual report business review governance remuneration financial statement shareholder information note financial statement investment associate joint venture joint associate joint associated venture undertaking total venture undertaking total january exchange adjustment addition disposal transfer investment distribution receive movement lossprofit tax recognise consolidated income statement december group hold significant associate undertakings december quest diagnostics inc clinical laboratory business list new york stock exchange investment book value december million million market value million million december group own quest group hold ownership interest voting control quest group ability exercise significant influence significant shareholding nominate director active participation quest board director board subcommittee subsequent yearend gsk sell entire shareholding quest diagnostic inc sale comprise secondary public offering accompany repurchase share quest diagnostic expect generate gross proceed billion billion tax december group own million share aspen pharmacare holding limit aspen list johannesburg stock exchange africa large pharmaceutical manufacturer major supplier brand generic pharmaceutical healthcare nutritional product southern african select international market investment book value december million million market value million million group hold ownership interest voting control aspen group ability exercise significant influence shareholding nominate director active participation aspen board director transfer investment relate group hold jcr pharmaceuticals ltd previously classify investment summarise balance sheet information respect group associate set total asset quest diagnostic inc aspen pharmacare holding limit total liability quest diagnostic inc aspen pharmacare holding limit net asset summarise balance sheet information respect aspen pharmacare holding limit base preliminary result information analyst forecast available december investments joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiviiv healthcare holding develop specify chemical compound viiv healthcare shire canada primarily comarket combivir trizivir epivir certain territory viiv healthcare business investment joint venture include interest pharmaceutical insurance limit mutual insurance company cover pharmaceutical business risk interest glaxosmithkline neptunusbio flu vaccine research development manufacturing venture gsk additional capital contribution million shenzhen glaxosmithkline neptunusbio ltd million shionogiviiv healthcare holding gsk annual report stnemetat laicnanif note financial statement investment january exchange adjustment addition net fair value movement impairment loss transfer investment associate joint venture disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million increase primarily arise number additional investment year disposal investment fair value movement reclassify equity income statement base average cost share acquire different time transfer associate relate group hold jcr pharmaceutical increase year impairment loss record table recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement investment include asset impaired follow original cost impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report business review governance remuneration financial statement shareholder information note financial statement trade receivable trade receivables prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million associate joint venture state deducting provision bad doubtful debt bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale land building plant equipment vehicle gsk annual report stnemetat laicnanif note financial statement trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa increase year result healthcare reform amendment accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group trade payable include million million associate joint venture pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme postemployment cost cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report business review governance remuneration financial statement shareholder information note financial statement pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment expect rate return bond reflect portfolio mix indexlinke government corporate bond equity risk premium add long term government bond yield expect rate return equity project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust pca standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line medium cohort improvement recently observe high level assume continue minimum improvement year male females usa mortality rate calculate fully generational table project scale white collar adjustment average life expectancy assume individual age project apply individual age follow usa male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment follow asset liability study group decide adopt strategy reduce gradually allocation investment equity agree pace reallocation increase primarily investment deficit reduction contribution bond target allocation equity property scheme reduce total define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group apply follow financial assumption assess define benefit liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report stnemetat laicnanif note financial statement pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gainslosse record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income total actuarial loss record statement comprehensive income january million amount include settlement curtailment include million million million augmentation cost arise major restructuring programme note provision gsk annual report business review governance remuneration financial statement shareholder information note financial statement pension postemployment benefit continue fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset december scheme purchase insurance contract guarantee payment specify pensioner liability include asset present value scheme obligation table value million december usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report stnemetat laicnanif note financial statement pension postemployment benefit continue usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost restriction surplus recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report business review governance remuneration financial statement shareholder information note financial statement pension postemployment benefit continue postretirement pension benefit movement define benefit obligation usa rest world group group obligation january exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer provision obligation december exchange adjustment service cost interest cost settlement curtailment actuarial lossesgain scheme participant contribution benefit pay acquisition obligation december exchange adjustments service cost interest cost settlement curtailment actuarial loss scheme participant contribution benefit pay obligation december unrecognise past service cost recognise balance sheet december define benefit scheme include define contribution section obligation total million december million million liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade postretirement healthcare scheme amend main change increase cap group cost pension postretirement healthcare plan amend change result oneoff gain million income statement december plan obligation million million million accordance ias unvested benefit improvement recognise immediately balance sheet recognise gradually income statement december unrecognised million million million primarily relate effect change postretirement scheme amount million million miilion gsk annual report stnemetat laicnanif note financial statement pension postemployment benefit continue define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded postretirement pension benefit movement fair value asset usa rest world group group assets january exchange adjustment expect return asset settlement curtailment actuarial loss employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay acquisition asset december exchange adjustment expect return asset actuarial gainslosse employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million million million million nil scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation additional contribution expect million year contribution base discount rate inflation assumption review contribution level expect december actuarial valuation employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report business review governance remuneration financial statement shareholder information note financial statement pension postemployment benefit continue postretirement pension benefit history experience gain loss usa rest world group group experience gainslosse scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset december experience gainslosse scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience loss scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gainslosse scheme asset percentage scheme asset december experience gainslosse scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficitssurpluse scheme gsk annual report stnemetat laicnanif note financial statement pension postemployment benefit continue sensitivity analysis effect change assumption annual define benefit pension postretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation provision integration legal major employee restructuring relate manufacturing dispute programme provision reorganisation provision total january exchange adjustment charge year reverse unused unwind discount utilise transfer pension obligation reclassification movement december settle year settle year december gsk annual report business review governance remuneration financial statement shareholder information note financial statement provision continue pension augmentation arise staff redundancie million million charge legal dispute year transfer pension obligation provision gsk involve number legal dispute show note pension postemployment benefit include notification possible claim set note asset writedown recognise impairment legal proceeding provision legal dispute property plant equipment note property plant include amount relate product liability intellectual property equipment majority amount provide antitrust government investigation contract termination expected utilise year selfinsurance environmental cleanup property rental employee relate provision charge year primarily relate provision relation employee relate provision include certain medical benefit investigation government group disable employee spouse usa manufacturing site cidra puerto rico product liability december provision benefit amount antitrust litigation relate paxil investigation million million employee benefit attorney office district colorado reflect variety provision severance cost jubilee awards group sale promotional practice product liability longservice benefit case avandia product discount provision decrease million million integration manufacturing reorganisation increase calculate riskadjuste project cash provision integration manufacturing reorganisation flow riskfree rate return movement include reflect cost relate ongoing restructure programme decrease million million increase arise include cost disclose note major change discount rate year restructuring programme respect product liability claim relate certain product provision sufficient history claim settlement include provision contingent consideration respect enable management reliable estimate provision business acquisition principally stiefel laboratories inc require cover unasserted claim certain case ibnr contingent consideration payable certain criterion incur report actuarial technique meet certain specified date future aggregate provision determine estimate ultimate liability matter item amount million december vary amount provide dependent million outcome litigation proceeding investigation possible settlement negotiation nature group business number matter include provide ibnr actuarial technique subject negotiation litigation year december expect million million provision legal dispute reimburse party insurer include receivables note noncurrent asset note trade receivables discussion legal issue note legal proceeding major restructuring programme october gsk announce significant new operational excellence programme improve effectiveness productivity operation note major restructure programme significant expansion operational excellence programme approve board announce february expansion approve board announce february provision staff severance payment management formal decision eliminate certain position communicate group employee affect provision staff severance payment immediately gsk annual report stnemetat laicnanif note financial statement noncurrent liability accrual defer income payable contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million million financial asset pledge collateral contingent liability discussion tax legal issue refer note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing float rate note new york stock exchange commercial paper bank loan overdraft loan stock obligation finance lease longterm borrowing cid european medium term note london stock exchange cid european medium term note london stock exchange medium term note new york stock exchange medium term note london stock exchange cid european medium term note london stock exchange cid european medium term note london stock exchange medium term note new york stock exchange cid european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange bank loan obligation finance lease net debt gsk annual report business review governance remuneration financial statement shareholder information note financial statement net debt continue current asset liquid investment classify availableforsale investment december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float fix rate million million respectively million million effective interest rate cash cash equivalent december approximately approximately cash cash equivalent balance december earn interest float fix rate million million respectively million million gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme issue december billion million commit facility day duration billion billion billion billion renewable annually liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective interest rate note december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range secure liability gsk loan secure charge noncurrent current asset year nil group pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation finance lease obligation december bear interest float fix rate million million respectively million million gsk annual report stnemetat laicnanif note financial statement share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue share option scheme share capital purchase cancel december issue share option scheme december issue share option scheme december december december number share issuable outstanding option note number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme company purchase share february gsk announce commence new longterm share buyback programme expect repurchase billion share depend market condition factor exact time purchase share hold treasury share cancel determined company dependent market condition factor share purchase period january february period february february million share purchase cost million gsk annual report business review governance remuneration financial statement shareholder information note financial statement movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity show follow table net translation exchange include non total fair value retain control translation reserve earning interest exchange january exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary december exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary december exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust option noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report stnemetat laicnanif note financial statement relate party transaction gsk hold interest quest diagnostics inc december group quest diagnostic party longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group clinical trial testing requirement worldwide quest diagnostic provide service million million group december balance payable gsk quest diagnostic million million subsequent yearend gsk sell entire shareholding quest diagnostic inc sale comprise secondary public offering accompany repurchase share quest diagnostic expect generate gross proceed billion billion tax gsk hold interest aspen pharmacare holding limited december gsk distribute million million product aspen extensive distribution network december balance gsk aspen million million balance payable gsk aspen million million group shionogi ltd enter transaction joint venture company support research development activity conduct joint venture company gsk provide service joint venture million million december balance gsk joint venture million million december gsk hold interest viiv healthcare shire canada primarily comarket combivir trizivir epivir certain territory december balance payable gsk viiv healthcare canada million nil aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance income net finance cost depreciation amortisation intangible asset impairment asset write profit sale intangible asset profit sale investment associate profit sale equity investment change work capital decreaseincrease inventory decreaseincrease trade receivables decreaseincrease receivables increasedecrease trade payable decreaseincrease payable increasedecrease pension provision sharebase incentive plan cash generate operation increase pension provision primarily reflect charge legal cost year billion partly offset legal settlement billion contribution define benefit pension scheme gsk annual report business review governance remuneration financial statement shareholder information note financial statement reconciliation net cash flow movement net debt net debt begin year decreaseincrease cash bank overdraft cash inflow liquid investment net increase longterm loan net repayment shortterm loan net repayment obligation finance lease debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year analysis change net debt exchange reclassification acquisition cash flow liquid investment cash cash equivalent overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt note net debt acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition laboratorios phoenix sacyf june gsk acquire issue share capital laboratorios phoenix sacyf leading pharmaceutical business focus development marketing sale brand generic overthecounter product latin america cash purchase price million include million net cash million intangible asset million goodwill million net liability goodwill arise acquisition business reflect potential business synergy sale growth increase gsk market presence follow acquisition establish market participant goodwill recognise expect deductible income tax purpose result phoenix report emerge market operating segment transaction account purchase method accounting proforma result laboratorios phoenix cyf year turnover million loss tax major restructuring million gsk annual report stnemetat laicnanif note financial statement acquisition disposal continue acquisition continue laboratorios phoenix sacyf acquisition gsk record turnover million tax loss major restructuring million business transaction cost expense arise acquisition laboratorio phoenix sacyf amount million fair value book value adjustment fair value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration acquisition year gsk complete small subsidiary acquisition cash total purchase price million include million net cash fair value book value adjustment fair value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill fair value gain recognise conversion associate subsidiary total consideration acquisition beginning year estimate group turnover increase million year subsidiary fully integrate gsk business practicable separately identify impact acquisition group profit year goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition establish market participant addition goodwill million recognise respect consideration prior year acquisition goodwill recognise expect deductible income tax purpose result acquisition report primarily emerge market reportable operating segment group recognise gain million result measure fair value associate hold prior acquisition date gain report profit disposal interest associate income statement acquisition cost expense arise acquisition total million gsk annual report business review governance remuneration financial statement shareholder information note financial statement acquisition disposal continue acquisition continue investment associate joint venture gsk cash noncash contribution million joint venture group share million joint venture group share investment associate million increase group share investment associate total million associate joint cash flow phoenix acquisition venture total total cash consideration cash cash equivalent acquire cash consideration net cash acquire net cash consideration pay deferred consideration cash consideration net cash acquire acquisition certain business ucb march group acquire ucb market product portfolio certain territory africa middle east asia pacific latin america include lead pharmaceutical brand number disease area subsequent date group complete country acquisition form original transaction purchase price million include million net cash million intangible asset million goodwill million net liability goodwill arise acquisition business reflect potential product growth region expect synergies group transaction account purchase method accounting transaction include acquisition number legal entity product right previously market outside entity product portfolio acquire integrate gsk business acquisition practicable identify result tax arise result transaction period acquisition prior acquisition estimate product portfolio record turnover million acquisition gsk record turnover million product acquire book fair value fair value adjustment value net asset acquire intangible asset property plant equipment cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report stnemetat laicnanif note financial statement acquisition disposal continue acquisition continue stiefel laboratory inc july group acquire share capital stiefel laboratory inc world large private dermatological company cash consideration million net cash acquire include million debt repay acquisition purchase price million include contingent cash consideration million payable certain criterion meet specify date future include million cash cash equivalent million intangible asset million goodwill represent potential additional growth combination stiefel business gsk exist dermatology portfolio million net liability purchase price include potential obligation additional payment million million depend future performance certain product stiefel laboratory inc turnover million loss tax include restructuring cost million year end december million turnover million loss tax include restructuring cost relate period acquisition include group account acquisition stiefel operating profit million restructuring cost intangible asset amortisation business provide significant opportunity sale cost synergy stiefel product benefit gsk global distribution commercial organisation particularly market brazil russia india china japan gsk product benefit stiefel speciality sale force relationship experience management dermatology cost synergies business expect primarily combine manufacture administrative function previously report gsk expect deliver annual pretax cost saving million restructuring cost approximately million exclude restructuring cost stiefel acquisition result dilution gsk earning share book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration viiv healthcare limit october gsk acquire pfizer inc hiv business combine hiv business form viiv healthcare limited subgroup own gsk pfizer consideration give gsk represent net value gsk hiv business contingent consideration transaction cost value million represent million intangible asset million defer tax liability million net asset million increase noncontrolle interest million goodwill represent economy scale gain combination business potential growth partner hiv product viiv healthcare noncontrolle interest represent pfizer interest viiv healthcare include right preferential dividend base sale performance certain product gsk recognise accounting gain million transaction arise disposal interest gsk hiv business pfizer record book value return pfizer hiv business record fair value gsk annual report business review governance remuneration financial statement shareholder information note financial statement acquisition disposal continue acquisition continue acquire pfizer hiv business turnover million loss tax million take account transition status territory million turnover million loss tax include restructuring cost recognise group account book fair value fair value adjustment value net asset acquire intangible asset asset include cash cash equivalent defer tax provision noncontrolle interest goodwill total consideration consideration fair value asset contribute gsk fair value contingent equity contribute gsk direct cost total consideration acquisition investment year include million subsidiary million joint venture group share million associate group initial share certain stiefel business laboratorie cash flow ucb inc total cash consideration cash cash equivalent acquire net cash consideration contingent consideration net purchase consideration acquisition subsidiary beginning year estimate group turnover increase million year acquisition fully integrate gsk business practicable separately identify impact acquisition group profit year gsk annual report stnemetat laicnanif note financial statement acquisition disposal continue acquisition continue sirtris pharmaceuticals inc june group acquire issue share capital sirtris pharmaceuticals inc biopharmaceutical company base massachusetts usa cash consideration million company focus discover develop proprietary orally available small molecule drug potential treat disease associate ageing include metabolic disease type diabete sirtris drug candidate design mimic certain beneficial health effect calorie restriction activation sirtuin recently discover class enzyme sirtris believe control ageing process transaction account purchase method accounting goodwill arise acquisition reflect potential enable gsk enhance metabolic neurology immunoinflammation research effort establish worldleading presence sirtuin field aid existence company highly experienced development team encompass aspect sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration acquisition investment year include million subsidiary million defer million joint venture group share million associate group hold sirtris total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition subsidiary acquire begin combine group turnover year million combine group profit year million gsk annual report business review governance remuneration financial statement shareholder information note financial statement commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment business combination pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement include arrangement amicus therapeutics amplimmune inc apeiron biologics fondazione telethon isis pharmaceuticals inc shionogi limited new arrangement offset reduced commitment prior year transaction include actelion pharmaceutical limited targacept inc neurosearch terminate curtail year commitment relate business combination reflect agreement sign complete balance sheet date gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation table show commitment exclude normal ongoing annual funding requirement approximately million group commitments principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease post balance sheet event subsequent year end gsk complete acquisition business combination refer note commitment year end gsk sell entire shareholding quest diagnostic inc sale comprise secondary public offering accompany repurchase share quest diagnostic expect generate gross proceed billion billion tax february gsk announce company initiate new longterm share buyback programme intention repurchase billion share depend market condition period february february million share purchase cost million gsk annual report stnemetat laicnanif note financial statement financial instrument relate disclosure borrowing cash generate operation onlent contribute equity certain subsidiary glaxosmithkline plc report sterling pay dividend pay dividend acquisition gsk share sterling profit role corporate treasury manage repurchase monitor external internal funding requirement financial risk support strategic objective treasury total capital equity net debt group decrease activity govern policy procedure approve million million decrease board director recently october million arise principally result excess dividend distribution year million earning treasury management group tmg chair chief financial attributable shareholder million group positive officer meet monthly basis review treasury activity cash generation sufficient finance group acquisition member receive management information relate treasury payment legal cost year net debt continue activity internal auditor review treasury internal control reduce reflect benefit ongoing restructure environment regularly programme success work capital initiative gsk use variety financial instrument finance operation liquidity risk derivative financial instrument manage risk manage net borrowing requirement portfolio operation derivative principally comprise forward longterm borrowing include bond short foreign currency contract interest rate currency swap term finance billion commercial paper programme swap borrowing liquid asset currency require billion commit facility facility group purpose manage exposure funding risk renew october consider level commit change foreign exchange rate interest rate facility adequate give current liquidity requirement gsk hold issue derivative speculative purpose information facility refer note treasury policy specifically prohibit activity financial statement net debt benefit strong transaction financial instrument undertake manage positive cash flow operating unit risk arise underlie business activity speculation european medium term note programme billion capital management december billion note issue manage capital ensure entity group programme shelf registration statement able operate go concern optimise return december billion billion shareholder appropriate balance debt equity note issue programme board review group dividend policy funding longterm borrowing mature date requirement annually longterm debt rating remain stable capital structure group consist net debt february currently rate stable outlook note net debt shareholder equity consolidated standard poor stable outlook moodys investor statement change equity service moodys shortterm debt rating standard poor moodys respectively commitment use free cash flow support increase dividend undertake share repurchase return commit facility substantial cash attractive invest bolton acquisition investment opportunitie cash equivalent liquid investment amount continue assess strict financial criterion billion december benefit strong positive cash flow operating unit tmg monitor gsk operate global basis primarily subsidiary cash flow forecast monthly basis company establish market trade significant level patent trademark protection market risk pharmaceutical product compete largely product efficacy interest rate risk management differentiation sell margin sufficient cover normal policy interest rate risk management limit operating cost operation cash generative float interest payment prescribe percentage operate cash flow fund investment research trading profit development new product routine use series interest rate swap redenominate outflow capital expenditure tax dividend repayment external borrowing interest rate coupon require gsk mature debt extent determine board share duration swap match duration principal repurchase new longterm share buyback instrument interest rate derivative instrument account programme depend market condition fair value cash flow hedge relevant asset liability factor expect purchase billion share policy borrow centrally variety capital market issue borrow facility meet anticipated funding requirement gsk annual report business review governance remuneration financial statement shareholder information note financial statement financial instrument relate disclosure continue foreign exchange risk management foreign currency transaction exposure arise internal external trade flow hedge exposure overseas operating subsidiary transaction risk minimised match local currency income local currency cost purpose internal trading transaction match centrally manage intercompany payment term reduce foreign currency risk exceptional foreign currency cash flow hedge selectively management corporate treasury manage cash surplus borrowing requirement subsidiary company centrally forward contract hedge future repayment originate currency seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterle certain borrowing swap currency require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major currency reduce exposure investment overseas group asset net investment hedge section note detail tmg review ratio borrowing asset major currency monthly credit risk group consider maximum credit risk million million total group financial asset exception investment bear credit risk detail group total financial asset gsk great concentration credit risk billion morgan chase aaaa rate moodys standard poor respectively comprise billion invest deposit billion derivative great concentration credit risk billion investment treasury treasury repo money market fund bear credit exposure government aaaaaa rate moodys standard poor respectively treasuryrelate credit risk gsk continue maintain conservative approach counterparty risk period report relationship bank credit rating present annually tmg approval aggregate credit risk respect financial instrument group counterparty limited reference longterm credit rating assign counterparty moodys standard poor table set credit rating counterpartie liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda contract risk net position counterparty million invest baabbb rate investment include bank deposit ally irish bank state bank india indian government bond counterpartie local cash management purpose local investment purpose gsk sole shareholder million invest babb rate investment include greek government bond issue lieu settlement long outstanding amount bank deposit hdfc bank domestic bank india invest fund locally credit rating counterparty aaaaaa aaaa aaaa baabbb baabbb baabbb babb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating counterparty aaaaaa aaaa aaaa baabbb baabbb baabbb babb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating table assign moodys standard poor respectively opinion rating agency differ gsk assign low rating counterparty local rating agency datum source available rating convert global rating equivalent moodys investor service standard poor publish conversion table gsk annual report stnemetat laicnanif note financial statement financial instrument relate disclosure follow method assumption estimate fair value continue cash cash equivalent approximate carry centrally manage cash reserve amount billion liquid investment base quote market price calculate december available month exclude base observable input case marketable security billion centrally manage cash hold viiv healthcare base principal amount case nonmarketable own subsidiary group invest centrally manage security short repricing periods liquid asset bank deposit aaaaaa rate treasurie treasury repo money market fund short term investment investment trade active market corporate debt instrument minimum shortterm credit determine reference relevant stock exchange quote rating bid price investment determine reference current market value similar instrument reference global counterparty limit assign gsk banking discount cash flow underlie net asset investment counterpartie base longterm credit rating shortterm loan overdraft approximate carry moodys standard poor corporate treasury usage short maturity instrument limit monitor daily corporate compliance officer cco operate independently corporate treasury longterm loan base quote market price case breach limit report cfo immediately eurobond fix rate borrowing approximate cco monitor credit rating counterpartie carry case float rate bank loan change rating occur notifie corporate treasury loan change investment level authority forward exchange contract base market datum limit appropriate exchange rate balance sheet date wholesale retail credit risk currency swap base market datum balance sheet date usa line pharmaceutical company interest rate swap base net present value group sell product small number wholesaler discount cash flow addition hospital pharmacie physician group receivables payable approximate carry sale large wholesaler approximately companyowne life insurance policy base cash group pharmaceutical sale december surrender value group trade receivable wholesaler total million million lease obligation approximate carry group expose concentration credit risk respect fair value investment gsk share wholesaler encounter december employee share ownership plan financial difficulty materially adversely affect esop trust hold gsk share carry value million group financial result million fair value million group credit risk monitoring activity relate million base quote market price share wholesaler includes review quarterly financial information represent purchase esop trust satisfy future exercise standard poor credit rating development gsk internal option award employee incentive scheme risk rating establishment periodic review credit limit carry value low cost expect proceed group believe credit risk provision share recognise deduction require excess normal provision bad doubtful reserve december gsk hold treasury share debt note trade receivables outside cost million million usa customer account trade deduct retain earning receivables balance commit facility fair value financial asset liability group commit facility billion billion table present carry amount billion billion day duration renewable fair value group financial asset liability annually december undrawn december december fair value financial asset liability include instrument exchange current transaction willing party force liquidation sale gsk annual report business review governance remuneration financial statement shareholder information note financial statement financial instrument relate disclosure continue carry fair carry fair value value value value cash cash equivalent availableforsale investment liquid investment government bond total liquid investment investment loan receivables trade receivables certain noncurrent asset scope ia financial asset fair value profit loss noncurrent asset heldfortrade financial asset derivative designate accounting hedge derivative total financial asset financial liability measure amortise cost borrowing bond designate hedge relationship bond commercial paper bank loan overdraft loan private financing obligation finance lease total borrowing trade payable provision noncurrent liability scope ias heldfortrade financial liability derivative designate accounting hedge derivative total financial liability net financial asset financial liability gsk annual report stnemetat laicnanif note financial statement financial instrument relate disclosure continue follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classify level december level level level total financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset heldfortrade financial asset derivative designate accounting hedge derivative financial liability fair value heldfortrade financial liability derivative designate accounting hedge derivative december level level level total financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset heldfortrade financial asset derivative designate accounting hedge derivative financial liability fair value heldfortrade financial liability derivative designate accounting hedge derivative movement year financial instrument measure level valuation method present january loss recognise income statement lossesgain recognise comprehensive income addition disposal transfer level exchange december net loss million million attributable level financial instrument hold end year report operate income transfer level million nil relate equity investment list stock exchange year reasonably possible change assumption unlikely result material change fair value level instrument gsk annual report business review governance remuneration financial statement shareholder information note financial statement financial instrument relate disclosure continue trade receivables noncurrent asset scope ias follow table reconcile financial asset trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset include companyowne life insurance policy asset include tax receivables pension surplus balance prepayment outside scope ias trade receivable note noncurrent asset note analyse financial asset scope ia asset follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day amount past great day total million million balance million million relate receivable state hospital authority certain european country give profile customer include large wholesaler government back agency credit risk identify trade receivable past balance allowance trade payable provision noncurrent liability scope ias follow table reconcile financial liability trade payable provision noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability liability include payment account tax social security payable provision constitute contractual obligation deliver cash financial asset outside scope ias trade payables note provision note noncurrent liability note analyse financial liability scope ias liabilities gsk annual report stnemetat laicnanif note financial statement financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing sensitivity analysis sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation place december financial instrument affect market risk include borrowing deposit derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change relevant foreign exchange interest rate foreign exchange sensitivity table group sensitivity foreign exchange rate dollar euro yen financial instrument exclude obligation finance lease certain nonderivative financial instrument net debt present material exposure currency major foreign currency gsk financial instrument denominate gsk consider movement currency year conclude movement rate reasonable benchmark table financial instrument consider sensitive foreign exchange rate functional currency entity hold intercompany loan fully hedge maturity currency swap exclude analysis increase reduction increase reduction nonfunctional currency foreign exchange exposure income equity income equity appreciation dollar appreciation euro appreciation yen depreciation state currency equal opposite effect movement income statement relate primarily hedge instrument legal provision trade payable trade receivables whilst hedge instrument provide economic hedge relate provision financial instrument include table combine sensitivity hedge instrument provision insignificant provision include movement equity relate foreign exchange position hedge group asset denominate euro dollar yen position close depreciation currency swap rise correspond appreciation group asset foreign exchange sensitivity group asset financial instrument include gsk annual report business review governance remuneration financial statement shareholder information note financial statement financial instrument relate disclosure continue table present group sensitivity foreign exchange rate base composition net debt adjust effect foreign exchange derivative net debt affect future foreign currency cash flow derivative relate primarily foreign exchange contract hedge group currency net asset legal provision increasedecrease increasedecrease impact foreign exchange movement net debt net debt net debt appreciation dollar appreciation euro appreciation yen depreciation state currency equal opposite effect interest rate sensitivity table show group sensitivity interest rate float rate sterling dollar euro financial instrument currency gsk historically issue debt hold investment gsk consider movement interest rate year conclude basis point increase reasonable benchmark debt maturity year float rate calculation basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate interest rate decrease currently maximum increasedecrease income limit million million million sterling dollar euro interest rate respectively million million million interest rate movement foreign currency derivative financial instrument net debt present material exposure group balance sheet base increase decrease interest rate contractual cash flow nonderivative financial liability derivative instrument follow analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis impact interest rate swap exclude purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance charge trade payable obligation obligation interest finance finance liability december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow finance charge trade payable obligation obligation interest finance finance liability december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow gsk annual report stnemetat laicnanif note financial statement financial instrument relate disclosure continue follow table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument receivables payable receivables payable year year year year year great year gross contractual cash flow derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie fair value hedge interest rate swap principal million million net investment hedge foreign exchange contract principal million million derivative designate accounting hedge foreign exchange contract principal million million embed derivative derivative designate accounting hedge total derivative instrument analyse current noncurrent total derivative financial instrument principal foreign exchange contract net total outstanding position balance sheet date majority contract period month december group hold outstanding foreign exchange contract consist primarily currency swap total credit fair value million million credit represent hedge intercompany loan deposit designate accounting hedge change fair value take income statement period offset exchange gain loss relate intercompany lending borrowing cash flow hedge group enter number foreign exchange forward contract designate cash flow hedge exchange arise dollar purchase consideration highly probable business acquisition acquisition occur october cash flow hedge mature date recognise comprehensive income remove maturity hedge include initial carrying value goodwill intangible record acquisition entity group enter number foreign exchange forward contract designate cash flow hedge exchange exposure arise gbp equivalent interest cost euro loan issue settle july december net fair value movement cash flow hedge disclose consolidated statement comprehensive income ineffectiveness record cash flow hedge gsk annual report business review governance remuneration financial statement shareholder information note financial statement fair value hedge group designate series interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance cost net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk principally arise consolidation group net investment dollar euro yen foreign operation december group hold net investment hedge respect euro foreign operation addition euro loan capital cid billion issue previous year designate net investment hedge respect foreign currency translation risk principally arise consolidation group net investment euro operation net investment hedge ineffectiveness disclose note finance income employee share scheme group operate share option scheme option grant employee acquire share ad glaxosmithkline plc grant price savingsrelate share option scheme share award scheme addition gsk operate performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period grant restrict share award replace grant option certain employee cost scheme readily equate potential gain employee onwards grant savingsrelated share option scheme grant share option scheme normally exercisable year date grant grant restrict share share award normally exercisable end year vestingperformance period grant savingsrelate share option scheme normally exercisable year save grant share option scheme award performance share plan normally grant employee acquire share ad gsk plc circumstance settle cash option share option scheme grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant share option award director effect grant cet subject performance criterion option pricing purpose value option award arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option share award scheme year year year weight average share price grant year ordinary share ad volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option gsk annual report stnemetat laicnanif note financial statement employee share scheme continue option outstanding share option share option savingsrelate scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option lapse december option grant option exercise option lapse december option grant option exercise option lapse december range exercise price weight average market price exercise weight average remain contractual life year year year share option share option savingsrelate option outstanding scheme share scheme ad share option scheme december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year share option share option savingsrelate option exercisable scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december december december gsk annual report business review governance remuneration financial statement shareholder information note financial statement employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period award grant director member cet prior subject single performance condition compare gsk tsr period tsr company comparator group period award grant director member cet award base achievement adjust free cash flow target year measurement period remain award base relative tsr performance comparator group describe page half tsr element award measure year half year award eligible employee prior performance condition consist part apply award performance condition compare gsk ep growth increase retail price index year measurement period second performance condition compare gsk tsr period tsr company comparator group period award grant onwards performance condition continue base eps second performance condition base strategic operational business measure year measurement period specific employee business area share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach share weight ad weight number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december gsk annual report stnemetat laicnanif note financial statement employee share scheme continue defer investment award plan group operate defer investment award plan award grant form notional share certain senior executive cost award typically vest threeyear period commence fourth anniversary date grant award initially vest subsequent year performance criterion attach share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report business review governance remuneration financial statement shareholder information note financial statement principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group december detail give principal country operation location headquarters business sector business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch brentford glaxosmithkline holding limited phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline mercury limit brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc phch brentford smithkline beecham limited phch brentford wellcome limited phch brentford glaxo group limit brentford glaxo operation limit brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline limit brentford glaxochem pte ltd brentford setfirst limited phch brentford wellcome foundation limit cambridge domantis limit brentford viiv healthcare limit brentford viiv healthcare limit brentford viiv healthcare trading service limit austria vienna glaxosmithkline pharma gmbh belgium genval glaxosmithkline rixensart glaxosmithkline biological czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare brndby glaxosmithkline pharma finland espoo glaxosmithkline france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxo wellcome production sas marly roi glaxosmithkline sante grand public sas marly roi viiv healthcare sas amand les eaux glaxosmithkline biological sas germany buehl glaxosmithkline consumer healthcare gmbh munich glaxosmithkline gmbh greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare product limited phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa verona glaxosmithkline manufacturing spa gsk annual report stnemetat laicnanif note financial statement principal group company continue europe location subsidiary sector activity luxembourg mamer glaxosmithkline international luxembourg sarl phch netherlands zeist glaxosmithkline zeist glaxosmithkline consumer healthcare norway oslo glaxosmithkline poland poznan glaxosmithkline pharmaceuticals poznan gsk service spz warsaw glaxosmithkline consumer healthcare spz portugal alge glaxosmithklineprodutos farmaceuticos limitada republic carrigaline smithkline beecham cork limited ireland cork glaxosmithkline trading services limited dublin glaxosmithkline consumer healthcare ireland limited dublin glaxosmithkline ireland limit dungarvan stafford miller ireland limited dungarvan glaxosmithkline dungarvan limited romania brasov europharm hold phch buchar glaxosmithkline gsk srl russian moscow glaxosmithkline trading zao federation moscow glaxosmithkline healthcare zao spain madrid glaxosmithkline madrid glaxosmithkline consumer healthcare aranda duero glaxo wellcome sweden solna glaxosmithkline switzerland muenchenbuchsee glaxosmithkline usa usa research triangle park stiefel laboratory inc marietta corixa corporation philadelphia glaxosmithkline llc phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline holdings americas inc phch wilmington glaxosmithkline capital inc cambridge sirtris pharmaceuticals inc research triangle park viiv healthcare company americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc mississauga glaxosmithkline consumer healthcare inc laval biomedical corporation quebec city biomedical corporation quebec mexico delegacion tlalpan glaxosmithkline mexico phch puerto rico guaynabo glaxosmithkline puerto rico inc asia pacific australia boronia glaxosmithkline australia pty ltd phch china beijing glaxosmithkline china investment ltd phch hong kong glaxosmithkline limited phch shanghai glaxosmithkline biological shanghai ltd tianjin sinoamerican tianjin smith kline french laboratories ltd gsk annual report business review governance remuneration financial statement shareholder information note financial statement principal group company continue asia pacific location subsidiary sector activity india mumbai glaxosmithkline pharmaceutical limit nabha glaxosmithkline consumer healthcare limited iii malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd selangor glaxosmithkline consumer healthcare sdn bhd new zealand auckland glaxosmithkline limited phch pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch buenos aire laboratorios phoenix sociedad anonima industrial comercial financiera brazil rio janeiro glaxosmithkline brasil limitada phch colombia bogota glaxosmithkline colombia phch venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae south africa johannesburg glaxosmithkline south africa pty limited phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch usa location associate sector activity usa madison quest diagnostic incorporate clinical testing middle east africa south africa johannesburg aspen pharmacare holding limit phch incorporate singapore exempt provision section company amendment act ireland iii consolidated subsidiary undertaking accordance section company act ground dominant influence equity account ground significant influence subsequent yearend gsk sell entire shareholding quest diagnostic inc note detail directly hold wholly own subsidiary glaxosmithkline plc key business sector pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report stnemetat laicnanif note financial statement legal proceeding revocation action basic patent cover seretide combination ireland file high court dublin group involve significant legal administrative behalf ivax july high court hand decision proceeding principally product liability intellectual property june find patent invalid obviousness tax antitrust governmental investigation relate group file appeal decision october private litigation group make provision proceeding trial date set appeal regular basis summarise note accounting principle policy note provision group action revocation french seretide combination patent involved legal proceeding respect file sandoz tribunal grande instance paris possible reliable estimate expect financial effect trial schedule june basic patent covering result ultimate resolution proceeding combination product seretide expire september case appropriate disclosure case subject spc extend protection september include provision intellectual property january sandoz initiate revocation action claim include challenge validity enforceability group belgian seretide patent group patent product process assertion noninfringement patent loss date generic seretide product approve case result loss patent protection product major european market despite revocation certain group issue consequence loss significant patent cover seretide country decrease sale product materially affect future argatroban result operation group december encysive pharmaceuticals inc mitsubishi kasei legal expense incur provision relate legal claim corporation group file action united states charge sell general administration cost provision district court southern district new york barr take appropriate legal specialist advice laboratories inc infringement mitsubishis pharmaceutical outflow resource consider probable reliable composition patent cover argatroban pursuant license estimate likely outcome dispute mitsubishi encysive develop argatroban treatment respect product liability claim relate certain product heparininduce thrombocytopenia hold new drug sufficient history claim settlement enable application approve fda encysive license management reliable estimate provision require marketing right argatroban group mitsubishi patent cover unasserted claim certain case incur expire june barr teva pharmaceuticals inc file report ibnr estimate actuarial technique appropriate abbreviate new drug application anda fda determine estimate group exposure certification invalidity unenforceability noninfringement describe note provision december mitsubishi patent june group group aggregate provision legal dispute partner prevail teva trial judge ruling include tax matter describe note taxation mitsubishis patent cover formulation injectable billion ultimate liability legal claim vary argatroban infringe invalid result court amount provide dependent outcome litigation decision teva preclude launch generic product proceeding investigation possible settlement negotiation june expiration date patent teva appeal group position change time decision court appeal federal circuit assurance loss result outcome arzerra legal proceeding exceed provision october group file action united states report group financial account material district court southern district florida declaration happen material adverse impact patent socalle cabilly patent result operation group reporting period own jointly genentech inc city hope judgment incur settlement enter invalid unenforceable infringe group product significant matter describe arzerra ofatumumab arzerra approve fda intellectual property chronic lymphocytic leukaemia orphan indication october february group voluntarily dismiss case advairseretide file new case united states district court number company challenge group patent northern district california suit currently pende cover advairseretide certain european jurisdiction include belgium france germany ireland march genentech biogen idec file suit netherlands report previously group seretide group united states district court combination patent cover product revoke southern district california allege group sale february action bring mylan arzerra induce contribute infringement patent hexal neolab ivax federal court munich revoke patent claim treatment chronic group german seretide combination patent lack inventive lymphatic leukemia anticd monoclonal antibody step group appeal decision netherlands case early stage action bring sandoz hexal district court hague january revoke supplementary protection certificate spc extend protection product september group determine appeal decision gsk annual report business review governance remuneration financial statement shareholder information note financial statement legal proceeding continue combivir patent list orange book combivir include composition avodart matter tclamivudine combination lamivudine azt january group receive notice barr laboratories lamivudine crystal form patent expire file anda fda allegation invalidity respectively september group receive notice patent list orange book cover teva pharmaceuticals inc file anda fda allege active ingredient avodart use treat benign prostatic combination patent invalid hyperplasia patent expire expire february group file action united november group file action united states district court district delaware barr states district court district delaware teva infringement patent march group pharmaceuticals usa inc infringement combination barr teva pharmaceuticals inc reach settlement patent april group teva agree settle litigation district court dismiss case suit file group term settlement teva pursuant settlement teva obtain license enter obtain license enter market fourth quarter market generic dutasteride product fourth quarter early certain circumstance light early certain circumstance settlement district court dismiss case november banner pharmacaps inc send group notice july group receive notice lupin ltd file file anda market generic version avodart certification fda allege combination patent banner notification contain paragraph certification invalid infringe product lupin file certification allege group patent expire patent group patent cover crystal form lamivudine expire invalid infringe banner propose invalid infringe august group file suit generic dutasteride product patent patent lupin united states district court district subject group settlement teva march delaware infringement combination patent march teva file complete anda action lupin stay mutual consent paragraph certification hold day exclusivity pende resolution case teva later filer banner enter market expiration group case teva anda filer settle forfeiture tevas days exclusivity group sue banner dismiss lupin choose reactivate case united states district court district delaware group term stay lupin january able obtain final approval product expiration forfeiture tevas day exclusivity period december anchen pharmaceuticals inc send group notice file andas paragraph certification levitra avodart jalyn allege group patent expiring group participate marketing levitra pursuant cover dutasteride invalid infringe copromotion agreement bayer healthcare july bayer propose product jalyn combination dutasteride bring suit teva pharmaceuticals united states tamsulosin cover patent cover district court district delaware infringement avodart anchen launch generic jalyn product patent relate levitra teva file anda fda expiration nonchallenge patent september certification patent cover active ingredient anchen launch generic avodart product later levitra expire invalid unenforceable september expiration forfeiture tevas day infringe stay fda approval effect exclusivity group sue anchen united states district filing lawsuit early decision case adverse court district delaware january bayer november january trial date matter extend october february benlysta teva consent extension stay fda february court appeal uphold early high approval equal extension trial date court decision revoke human genome science hgs group party suit patent claim revocation bring eli lilly patent claim cytokine bly lovaza antibody bind bly benlysta belimumab march group receive notice teva group licence patent hgs pharmaceuticals usa inc par pharmaceutical inc apotex party litigation proceeding equivalent european inc file andas certification patent cover patent uphold october final appeal lovaza invalid unenforceable infringe patent european patent office follow opposition proceeding file expire group licensee eli lilly decision affect european patent pronova biopharma norge owner patent patent arise european patent hgs appeal sue teva par apotex united states district court decision july supreme court decide district delaware fda approval andas stay hear appeal hearing date appeal set early decision favourable july decision affect group hgs generic trial set court march ability market sell benlysta group party suit additional patent cover lovaza grant pronova march june pronova sue teva par apotex patent separate trial schedule january additional month stay attached suit patent gsk annual report stnemetat laicnanif note financial statement legal proceeding continue product liability malarone preclinical clinical trial conduct development potential product determine safety efficacy august group file suit united states district product use human follow approval regulatory court district delaware glenmark generic body notwithstanding effort drug vaccines inc usa infringement patent relate malarone introduce marketplace unanticipated safety issue group receive notification glenmark file anda evident group currently defendant number malarone certification allege group patent product liability lawsuit relate group pharmaceutical invalid unenforceable infringe patent consumer healthcare product significant expire cover combination atovaquone proguanil matter describe hydrochloride use prevent malaria group settle case april term settlement agreement avandia glenmark receive royaltybeare licence enter market group name product liability lawsuit behalf product quarter early certain individual assert personal injury claim arise use circumstance case dismiss avandia federal case multidistrict litigation paxilseroxat proceeding pende united states district court following courtordere mediation second quarter eastern district pennsylvania case file group resolve claim apotex paxil number state court case file state court philadelphia seroxat patent infringement antitrust litigation venue coordinated mass tort program case state court district court eastern district pennsylvania california coordinate los angeles additionally litigation bring apotex group canada purport class action seek economic damage behalf litigation dismiss respect party party payer consumer assert claim arise state federal law include racketeer influence treximet corrupt organization act rico state unfair trade practice october group receive letter par andor consumer protection law pharmaceutical fda accept anda treximet september fda take action rosiglitazone include certification patent own pozen inc keep rosiglitazone product market require relate treximet invalid unenforceable infringe additional labeling restriction use ensure benefit pozen patent license group november avandia continue outweigh risk include risk evaluation pozen file suit par patent district mitigation strategy rem program ensure safe use court eastern district texas november medicine ema announce september group receive letter alphapharm designate agent determine suspend marketing authorisation mylan pharmaceutical fda accept anda rosigilitazone include avandia product regulatory agency treximet include certification pozen patent country review take regulatory action relate treximet invalid unenforceable infringe group working implement decision fda ema pozen file suit alphapharm mylan january regulatory agency february fda infringement patent district court eastern announce change label avandia restrict use district texas pozen sue teva pharmaceutical patient take rosiglitazonecontaine medicine usa inc reddys patent new patient unable achieve adequate glycemic court trial hold october party control diabete medication patient await decision treximet datum exclusivity preclude decide pioglitazone pioglitazone approval generic product april group contain medicine party lawsuit bring pozen group continue receive significant number new vesicare product liability case avandia usa group market vesicare usa license result regulatory action take fda base astellas pharma inc september astella file suit negative publicity concern product adjust teva pharmaceuticals usa inc federal district court provision potential settlement accordingly provision southern district new york infringement patent includes estimate future claim respect product cover active ingredient vesicare astella receive liability case usa group reach agreement notice teva file anda certification settle majority claim pende february basic patent expire invalid unenforceable party settle case dismiss june purport class action avandia file israel term settlement teva able enter briefing certify class action underway market october class action pende canada early stage february astellas group announce group cease promote vesicare usa january gsk annual report business review governance remuneration financial statement shareholder information note financial statement legal proceeding continue thimerosal group number pharmaceutical paxil paxil company name defendant numerous individual group receive numerous lawsuit claim allege personal injury lawsuit state federal district court use paxil paroxetine cause variety injury usa allege thimerosal preservative lawsuit claim allege use paxil manufacture vaccine cause neurodevelopmental disorder pregnancy result birth child birth defect injury include autism health issue lawsuit claim allege patient take paxil commit attempt commit suicide act case purport class action violence finally group lawsuit claim allege determination case use paxil cause patient suffer symptom permit proceed class action number purport class discontinuing treatment paxil action jurisdiction withdraw dismiss plaintiff seek remedy include compensatory punitive group reach agreement settle vast majority statutory damage cost fund medical claim pende february matter monitor research dismiss payment lawsuit remain scheduled trial include case schedule trial philadelphia date report limited number case mass tort program june concern use paxil approach trial date vaccine manufacturer pregnancy remains purport class action litigation manufacturer thimerosal contain medicinal product canada concern use paxil pregnancy successful exclude testimony plaintiff expert witness causation specifically ground plaintiff california court grant plaintiff motion certify class fail establish hypothesise link thimerosal consumer fraud lawsuit seek economic damage focus neurodevelopmental disorder generally accept reliable discontinuation symptom relevant scientific community canada court appeal affirm quebec court february office special masters united denial plaintiff motion certify class patient state court federal claim reject allegedly experience discontinuation symptom litigation approximately autism claim file national conclude vaccine injury compensation program nvicp ground public funding withdraw claimant fail produce reliable scientific evidence link hundred claimant receive funding pursue vaccination medical condition include autism common issue litigation allege paroxetine cause group party proceeding finding suffer withdrawal reaction dependency evidence pende lawsuit legal service commission decision withdraw funding group decision uphold appeal united appeal special case review panel states court federal claim nvicp claimants claimants claimants discontinue claim appeal ruling united states court appeal trial list commence early high court federal circuit affirm decision united london vacate states court federal claim claimant elect poligrip appeal reject decision nvicp begin number product liability lawsuit claim claimant option filing action file group state federal court group andor physician administer vaccine usa include purport class action allege zinc question date action commence poligrip cause copper depletion permanent neurologic remain approximately nvicp claimant injury federal case denture cream adhesive ultimately option pursue personal injury lawsuit multidistrict litigation mdl united states district court vaccine manufacturer include group southern district florida establish june february united states supreme court issue group procter gamble defendant decision bruesewitz wyeth inc involved issue litigation include mdl purport class action assert national vaccine injury compensation act nvica economic loss claim state consumer protection law preclude lawsuit vaccine manufacturer claim claim medical monitor current exception vaccine cover nvicp defectively design state court case pennsylvania new york supreme court affirm decision united states court state court case consolidate philadelphia appeal circuit hold nvica preempt mass tort program purport class action assert consumer design defect claim vaccine manufacturer bring fraud claim file canada group reach plaintiff seek compensation injury death cause agreement principle settle vast majority current vaccine effect case group voluntarily withdraw zinccontaining formulation poligrip market date group see increase number civil lawsuit file follow announcement nvcip decision scope bruesewitz ruling impact ability plaintiff pursue claim design certain childhood vaccine defective include use thimerosal preservative impact willingness plaintiff pursue civil lawsuit base legal theory remain unknown date report case schedule trial group defendant gsk annual report stnemetat laicnanif note financial statement legal proceeding continue hiv division inquiry july group receive subpoena sale marketing regulation eastern district new york attorney office sale marketing practice hiv product colorado investigation educational program grant payment physicians february group receive subpoena united drug treat hivinfecte adult group state attorney office colorado group sale cooperate investigation promotional practice relate large selling product period january investigation average wholesale price later take united states attorney office united states department justice number states district massachusetts expand present putative class private payer year respect advair particular government inquire investigate andor bring civil litigation allegation allege promotion drug offlabel use numerous pharmaceutical company include group groupsponsore continue medical education programme violate federal state fraud abuse law result speaker event special issue board advisory board speaker way average wholesale price awp wholesale acquisition training programme clinical study relate grant fee cost wac determine report drug travel entertainment original subpoena reimburse medicare medicaid insurance issue attorney office colorado scope programme group reach million civil inquiry nationwide group continue cooperate settlement federal government resolve allegation government investigation relate pricing marketing zofran kytril government inquire group response group amend exist corporate integrity agreement october letter fdas division drug marketing requirement settlement group receive advertising communication request information final approval million nationwide private payer class group allege promotion wellbutrin offlabel use action settlement relate group price reporting group cooperate investigation provide mdl proceeding united states district court district request information massachusetts number state respective attorney general avandiarelate matter county new york state file civil group process respond united states lawsuit state federal court group department justice subpoena receive june seek drug company claim damage restitution document relate development marketing awp andor wac price report pharmaceutical product avandia group receive civil investigative demand cover state medicaid programme state seek number state attorney general office relate recovery behalf state payer case development marketing avandia cooperate behalf instate patient consumer office group separately resolve awp claim state medicaid utah attorney general office louisiana attorney programme twothird state general office file suit group assert doj settlement separate negotiation litigation concern statutory common law claim relate group awp issue continue state development marketing avandia suit early day november kentucky state court jury return compensatory damage verdict group oil food programme case file state kentucky jury find follow united nations report allege bribe group liable violate state consumer protection law pay iraqi government official connection oil liable state medicaid fraud false advertising food programme group receive subpoena statute january judge case award state sec february respect group participation kentucky additional statutory penalty programme united states department justice doj group settle case kentucky judgment initiate investigation december vacate group deny liability settlement fraud office sfo issue formal notice group require production document relate group participation programme september sfo notify group complete investigation intend action group receive contact sec doj matter gsk annual report business review governance remuneration financial statement shareholder information note financial statement legal proceeding continue paxilseroxat follow group settlement lawsuit file nominal pricing new york state attorney general office allege failure disclose group respond letter request united states datum use paxil child adolescent similar case senate committee finance date april february purport class action file private document information relate nominal plaintiff seek recover amount pay paxil purchase price exception good price reporting requirement use patient age follow class settlement medicaid drug rebate programme january committee consumer united states district court release finding pharmaceutical manufacturer district minnesota approve million class inappropriately nominal price exception contrary settlement ensue lawsuit seek recovery behalf committee interpretation congressional intent insurance company thirdparty payer payment group advise united states department prescription paxil child adolescents group justice investigate certain group nominal deny liability settlement similar purported pricing bundle sale arrangement determine class action file united states district court district arrangement qualify exception good price minnesota behalf federal state local government reporting requirement violate civil statute law entity pay prescription paxil minor remain similar purport class action canada seek march group receive broad letter request economic damage behalf individual party payer department justice seek range document governmental entity purchase paxil use patient relate group nominal pricing arrangement age possible bundle sale group continue cooperate investigation produce document cidra puerto rico manufacturing site group receive subpoenas request april group receive subpoena united documents information delaware michigan state attorney office boston request production record relate group nominal price arrangement group manufacturing facility locate cidra puerto rico cooperate investigation produce responsive cease operation addition july document addition governmental investigation group learn united states district court district allegation concern nominal pricing massachusetts unseal complaint bring programme litigation group enter employee federal false claim act claim monetary nominal price arrangement december damage result allege failure cidra facility comply fda good manufacturing process gmps programme manufacture product group defend action file federal court united states district court northern district california october group finalise agreement county santa clara county seek attorney office district massachusetts represent putative class hospital clinic entity department justice respect investigation california eligible receive discount ceiling price group manufacturing facility cidra puerto rico pharmaceuticals federal programme know agreement comprehensive settlement programme plaintiff allege group numerous pende claim group arise investigation pharmaceutical manufacturer set ceiling price group pay total million million civil higher allow law contract govern criminal penalty pharmco puerto rico inc subsidiary programme overcharge entity group plead guilty certain charge group california eligible participate programme process negotiate corporate integrity agreement office inspector general cover manufacture lawsuit dismiss reinstate august compliance matter follow appeal united states supreme court agree review issue entity standing group receive civil investigative demand sue manufacturer manufacturers contract subpoena state attorney general office relate government trial court stay proceeding case matter issue federal investigation enquiry supreme court decision oral argument early stage group cooperate office supreme court occur january supreme secdoj fcpa inquiry court issue decision securities exchange commission sec department justice doj conduct industrywide investigation pharmaceutical company engaged violation foreign corrupt practice act relate sale pharmaceutical include argentina brazil canada china germany italy poland russia saudi arabia group company ask respond inquiry cooperate sec doj gsk annual report stnemetat laicnanif note financial statement legal proceeding continue wellbutrin action file biovail group antitrustcompetition purport class direct indirect purchaser allege unlawful monopolisation antitrust violation relate paxilseroxat enforcement biovail wellbutrin patent note previously group settle patent filing biovail citizen petition group motion infringement antitrust litigation apotex paxil dismiss amend complaint indirect purchaser seroxat litigation dismiss party grant respect claim class representative claim assert indirect sector inquiry purchaser case proceed discovery respect january european commission announce inquiry remain claim one bring purport certain aspect competition pharmaceutical sector class direct purchaser class certification hearing schedule initiate inspection premise number innovator april generic pharmaceutical company include group commission publish preliminary report november flonase report suggest defensive patenting strategy purport direct indirect purchaser class action lead obstacle innovation innovator company file united states district court eastern district employ measure hinder generic come market pennsylvania allege group illegally maintain monopoly final report issue july contradict power market flonase charge plaintiff supra preliminary report final report concede delay competitive price additionally suit file roxane generic entry fault regulatory environment laboratory inc generic competitor seek lose profit innovator company defensive strategy report group allege action unlawfully delay roxane entry commission state attack legitimate patent market predicate allegation filing practice identify area follow scrutiny group allegedly sham citizen petition subsequent commission recommend regulatory reform litigation motion direct purchaser certify class improvement grant court group successfully narrow january commission request information claim purport class indirect purchaser group number pharmaceutical company motion dismiss complaint amend complaint relate patent settlement agreement affect european union group motion dismiss roxane complaint deny european economic area market request information commercial corporate second monitoring exercise commission patent settlement agreement pharmaceutical sector group securitieserisa class action process respond commission request july class action suit bring behalf current employee stiefel laboratory inc file wellbutrin united states district court southern district florida december january february lawsuit complaint allege stiefel officer director purport class action file violate employee retirement income security act erisa united states district court eastern district pennsylvania federal state security law induce stiefel employee group behalf direct indirect purchaser sell share employee stock plan stiefel wellbutrin complaint allege violation antitrust greatly undervalue price disclose employee law sham litigation fraud patent office stiefel sell group january group obtain enforce patent cover wellbutrin defendant motion dismiss grant deny complaint follow introduction generic competition specifically court determine erisa claim wellbutrin april district appellate court ruling individual stiefel defendant federal generic manufacturer infringe group patent security claim individual defendant stiefel class direct purchaser certify court recently forward court dismiss florida securities act enter order grant motion indirect purchas common law breach fiduciary duty claim hold erisa plaintiff file renew motion class certification court preempt state common law malpractice claim schedule trial june regard claim stiefel accountant trial remain claim certify class direct purchaser schedule july secondary wholesaler putative class action suit file group july rxusa wholesale inc secondary wholesaler august united states district court file suit group pharmaceutical southern district new york complaint allege manufacturers wholesalers united states district group officer director certain employee court eastern district new york complaint allege mislead public statement avandia defendant engage conspiracy refuse supply allege mislead statement expose pharmaceutical product rxusa violation federal state value group stock drop plaintiff bring suit antitrust law group motion dismiss complaint behalf participant group grant united states court appeal second circuit retirement plan claim group individual affirm dismissal complaint case conclude defendant breach fiduciary duty plan participant erisa gsk annual report business review governance remuneration financial statement shareholder information note financial statement legal proceeding continue environmental matter group notify potential responsibility relate plaintiff amend complaint add allegation past operation past waste disposal practice certain concern wellbutrin paxil include additional site primarily usa matter subject group defendant individual member group litigation include proceeding initiate federal state benefit committee group file motion dismiss government waste disposal site remediation cost tort february action bring private party wage hour claim group advise responsible party december purport class action file approximately site appear national group behalf entire group priority list create comprehensive environmental response pharmaceutical sale representative action compensation liability act superfund proceeding file transfer united states district court seek require operator hazardous waste facilities central district california initially allege transporter waste site generator hazardous representative exempt employee california law waste dispose site clean site reimburse andor fair labor standard act flsa consequently government cleanup cost instance group entitle overtime pay thing involve allege generator hazardous waste superfund provide defendant jointly severally plaintiff subsequently amend complaint assert class liable cleanup cost proceeding frequently resolve action limit solely pharmaceutical sale representative basis nature quantity waste dispose work california assert claim california generator site group proportionate liability cleanup wage hour law cost substantially determine site suit seek variety compensatory punitive statutory refer damage group move summary judgment dismiss group potential liability vary greatly site site claim putative class representative grind cost investigation study remediation exempt employee court hold site time substantial group routinely accrue appeal pende united states court appeal amount related share liability matter ninth circuit case involve manufacturer virtually factual legal argument defer rule summary judgment motion stay activity case appellate court rule company pende case case file united states district court district arizona august seek establish nationwide collective action behalf entire group pharmaceutical sale representative ground representative exempt employee flsa plaintiff seek double damage overtime allegedly work group pharmaceutical sale representative year period november court grant group motion summary judgment dismiss lawsuit ground sale representative exempt employee outside sale exemption flsa plaintiff appeal decision united states court appeals ninth circuit february ninth circuit issue opinion favour group affirm judgment united states district court district arizona find group pharmaceutical sale representative exempt employee outside sale exemption flsa entitle overtime pay november purport class action file group united states district court northern district new york behalf group pharmaceutical sale representative work new york past year plaintiff allege sale representative exempt employee entitle overtime new york wage hour law closely follow fair labor standard act january plaintiff file similar purport class action florida state court allege group pharmaceutical sale representative entitle overtime flsa gsk annual report stnemetat laicnanif director statement responsibility director statement responsibility disclosure information auditor relation company financial statement director office date report director responsible prepare parent company confirm glaxosmithkline plc financial statement remuneration far aware relevant audit report accordance applicable law regulation information company auditor unaware company law require director prepare financial statement take step ought financial year law director elect take director aware prepare parent company financial statement accordance relevant audit information establish company united kingdom accounting standard applicable law auditor aware information united kingdom generally accept accounting practice company law director approve parent company confirmation give interpret accordance financial statement satisfied true provision section company act fair view state affair company period go concern basis prepare financial statement director make enquiry director reasonable require expectation company adequate resource continue select suitable accounting policy apply operational existence foreseeable future reason consistently continue adopt go concern basis prepare financial statement judgement accounting estimate reasonable prudent combine code state regard parent company financial statement board consider glaxosmithkline plc apply main applicable accounting standard follow principle section combine code mantaine subject material departure disclose explain frc describe corporate governance section page parent company financial statement comply provision describe director responsible keep adequate accounting record sufficient explain company require fsa list rule auditor consider transaction disclose reasonable accuracy time director statement compliance relation point financial position company enable ensure combined code specify review parent company financial statement remuneration report comply company act responsible safeguarding asset company take reasonable step prevention detection sir christopher gent fraud irregularity chairman march parent company financial statement year end december comprise balance sheet year end december support note set page report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end december include annual report publish hard copy print form available website director responsible maintenance integrity annual report company website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different gsk annual report business review governance remuneration financial statement shareholder information independent auditor report members glaxosmithkline plc audit parent company financial statement matter require report glaxosmithkline plc year end december exception comprise company balance sheet gaap report respect follow matter relate note financial reporting framework company act require report apply preparation applicable law united opinion kingdom accounting standard united kingdom generally accept accounting practice adequate accounting record keep parent company return adequate audit respective responsibility director receive branch visit auditor parent company financial statement explain fully director statement director remuneration report audit responsibility set director responsible agreement accounting record return preparation parent company financial statement satisfy true fair view certain disclosure director remuneration specify law responsibility audit express opinion parent company financial statement accordance applicable receive information explanation law international standard audit ireland require audit standard require comply auditing practice board ethical standard auditor matter report include opinion prepare report separately group financial statement companys member body accordance chapter glaxosmithkline plc year end december company act purpose company pass resolution accordance section give opinion accept assume responsibility company act senior statutory auditor purpose person report state show hand come save expressly agree prior consent write scope audit financial statement audit involve obtain evidence amount disclosure financial statement sufficient reasonable assurance financial statement free material misstatement cause fraud error include pricewaterhousecooper llp assessment accounting policy appropriate charter accountant statutory auditor parent company circumstance consistently london apply adequately disclose reasonableness significant march accounting estimate director overall presentation financial statement opinion financial statement opinion parent company financial statement true fair view state company affair december properly prepare accordance united kingdom generally accept accounting practice prepare accordance requirement company act opinion matter prescribed company act opinion director remuneration report audit properly prepare accordance company act information give director report financial year parent company financial statement prepare consistent parent company financial statement gsk annual report stnemetat laicnanif company balance sheet gaap december note fix asset investment debtor cash bank current asset creditor amount year net current liability net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund approve board march sir christopher gent chairman glaxosmithkline plc register number gsk annual report business review governance remuneration financial statement shareholder information note company balance sheet gaap presentation financial statement expenditure expenditure recognise respect good service receive description business supply accordance contractual term provision glaxosmithkline plc parent company gsk major global obligation exist future liability respect healthcare group engage creation discovery past event obligation development manufacture marketing pharmaceutical reliably estimate product include vaccine overthecounter otc medicine healthrelate consumer product investment subsidiary company investment subsidiary company hold cost preparation financial statement provision impairment financial statement prepare go concern basis draw accordance generally accept impairment investment accounting principle gaap accounting carrying value investment review impairment presentation december comparative figure indication investment impaired december appropriate comparative provision result impairment review charge figure reclassify ensure consistent presentation income statement year concern current year information share base payment permit company act profit issuance company subsidiary grant loss account company present annual report company option represent additional capital contribution accounting convention standard company subsidiarie additional investment balance sheet prepare historical cost subsidiary result correspond increase shareholder convention complie applicable accounting standard equity additional capital contribution base fair value grant issue allocate underlying grant accounting principle policy vest period preparation balance sheet conformity generally taxation accept accounting principle require management estimate assumption affect report amount current tax provide amount expect pay asset liability disclosure contingent asset apply tax rate enact substantially enact liability date balance sheet actual amount balance sheet date differ estimate company account taxation defer accelerate balance sheet prepare accordance reason timing difference originate company accounting policy approve board reverse balance sheet date defer tax asset describe note recognise extent consider recoverable future taxable profit accounting policy defer tax measure average tax rate foreign currency transaction expect apply period time difference expect reverse defer tax liability asset foreign currency transaction record exchange rate discount rule date transaction forward rate hedge forward exchange contract foreign currency asset financial guarantee liability translate rate exchange rule balance liability relate guarantee issue company behalf sheet date forward rate subsidiary initially recognise fair value amortise dividend pay receive life guarantee dividend pay receive include account operate profit period relate dividend actually pay receive fee relate audit company charge operating profit gsk annual report stnemetat laicnanif note company balance sheet gaap fix asset share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment debtor amount year corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking creditor amount year bank overdraft amount owe group undertaking creditor company guarantee debt issue subsidiary company receive annual fee subsidiary aggregate company outstanding guarantee billion debt instrument subsidiary company relation guarantee fee recover life bond disclose debtor note gsk annual report business review governance remuneration financial statement shareholder information note company balance sheet gaap share capital share premium account share ordinary share premium number share capital authorise december december share capital issue fully pay january issue share option scheme december issue share option scheme december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme company purchase share february gsk announce commence new longterm share buyback programme expect repurchase billion share depend market condition exact time purchase share hold treasury share cancel determined company dependent market condition factor share purchase period january february period february february million share purchase cost million reserve profit reserve loss account total january profit attributable shareholder dividend shareholder capital contribution relate share base payment december loss attributable shareholder dividend shareholder capital contribution relate share base payment december loss glaxosmithkline plc year million profit million dividend million million give retain loss million profit million profit loss account reserve december stand million million million unrealise million post balance sheet event february company initiate new longterm share buyback programme intention repurchase billion share depend market condition period february february million share purchase cost million gsk annual report noitamrofni redloherah financial record quarterly trend unaudite analysis group result pharmaceutical sale therapeutic area provide quarter sterle financial year income statement total month cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement result major restructure total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny dilute earning share penny calculation result major restructuring describe note financial statement presentation financial statement gsk annual report business review governance remuneration financial statement shareholder information financial record cer cer cer gsk annual report noitamrofni redloherah financial record quarterly trend pharmaceutical turnover total group cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report business review governance remuneration financial statement shareholder information financial record quarterly trend pharmaceutical turnover usa cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report noitamrofni redloherah financial record quarterly trend pharmaceutical turnover europe cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report business review governance remuneration financial statement shareholder information financial record quarterly trend pharmaceutical turnover emerge market cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report noitamrofni redloherah financial record quarterly trend pharmaceutical turnover rest world cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report business review governance remuneration financial statement shareholder information financial record quarterly trend consumer healthcare turnover cer cer cer cer overthecounter medicines oral healthcare nutritional healthcare cer cer cer cer usa europe rest world gsk annual report noitamrofni redloherah financial record year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board turnover business segment pharmaceutical consumer healthcare pharmaceutical turnover therapeutic area respiratory antiviral hiv central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatological pharmaceutical turnover geographic area usa europe emerge markets asia pacificjapan pharmaceutical turnover include copromotion income viiv healthcare turnover include geographic area sale consumer healthcare turnover otc medicine oral healthcare nutritional healthcare gsk annual report business review governance remuneration financial statement shareholder information financial record financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share financial result major restructuring turnover operate profit profit taxation profit taxation pence pence pence adjust earning share adjust diluted earning share million million million million million weight average number share issue basic diluted return capital employ return capital employ calculated total profit taxation percentage average net asset year balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity gsk annual report noitamrofni redloherah financial record number employee usa europe rest world asia pacific include china japan middle east africa latin america canada rest world manufacturing selling administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day year feb jan dec nov oct sept high low december federal reserve bank new york cease publish noon buying rate bank england buy rate subsequent calculation buy rate february gsk annual report business review governance remuneration financial statement shareholder information product development pipeline key inlicense alliance relationship party bla biological license application month submission maa marketing authorisation application europe month regulatory approval maa nda new drug application usa approval letter phase evaluation clinical pharmacology usually conduct volunteer alcr month approvable complete response letter receive indicate phase determination dose initial evaluation efficacy conduct ultimately approval give subject resolution small number patient outstanding query phase iii large comparative study compound versus placebo andor establish month positive opinion treatment patient establish clinical benefit safety fda tentative approval maa ndabla regulatory milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla biopharmaceutical beta amyloid monoclonal antibody alzheimer disorder monoclonal antibody metabolic disease nogoa monoclonal antibody amyotrophic lateral sclerosis multiple sclerosis domain antibody targette multicomponent malignant melanoma vaccine apn recombinant human angiotensin convert acute respiratory distress syndrome anzyme iboctadekin doxil immunomodulator topoisomerase ovarian cancer inhibitor otelixizumab anticd monoclonal antibody grave eye disease otelixizumab anticd monoclonal antibody rheumatoid arthritis otelixizumab anticd monoclonal antibody type diabete myelinassociate glycoprotein monoclonal stroke antibody oncostatin monoclonal antibody rheumatoid arthritis parathyroid hormone osteoporosis albiglutide glucagonlike peptide glp agonist heart failure benlysta antib lymphocyte stimulator monoclonal systemic lupus erythematosus antibody mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ofatumumab anticd human monoclonal antibody multiple sclerosis ofatumumab anticd human monoclonal antibody rheumatoid arthritis otelixizumab anticd monoclonal antibody myaesthenia gravis albiglutide glp agonist type diabete iii arzerra anticd human monoclonal antibody chronic lymphocytic leukaemia line therapy use iii relapse patient arzerra anticd human monoclonal antibody diffuse large cell lymphoma relapse patient iii arzerra anticd human monoclonal antibody follicular lymphoma refractory relapse patient iii otelixizumab anticd monoclonal antibody type diabete iii benlysta antib lymphocyte stimulator monoclonal systemic lupus erythematosus submit jun jun antibody denosumab antireceptor activator nuclear kappa bone metastatic disease submit rank ligand human monoclonal antibody arzerra anticd human monoclonal antibody chronic lymphocytic leukaemia refractory patient approve apr oct prolia antirank ligand human monoclonal antibody hormone ablativechemotherapy bone loss prostate approve cancer patient prolia antirank ligand human monoclonal antibody postmenopausal osteoporosis approve cardiovascular metabolic sodium dependent glucose transport sglt type diabetes inhibitor sirt activator sarcopaenia copd psoriasis high affinity nicotinic acid receptor hma metabolic disorders agonist oxytocin antagonist premature ejaculation prolyl hydroxylase inhibitor anaemia associated chronic renal disease prolyl hydroxylase inhibitor peripheral arterial disease gprotein couple receptor grp metabolic disorders agonist muopioid receptor inverse agonist compulsive eat disorder sirt activator type diabete copd psoriasis losmapimod kinase inhibitor cardiovascular disease copd pain retosiban oxytocin antagonist threaten preterm labour rilapladib lppla inhibitor atherosclerosis darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor inhibitor treatment acute coronary syndrome approve aug feb sep gsk annual report noitamrofni redloherah product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla infectious disease leucyl trna synthetase inhibitor oral bacterial infection hepatitis virus inhibitor hepatitis hepatitis virus inhibitor hepatitis polypeptide deformylase inhibitor bacterial infection tafenoquine aminoquinoline plasmodium vivax malaria relenza neuraminidase inhibitor influenza iii neuroscience sphingosinephosphate receptor multiple sclerosis agonist histamine antagonist dementia schizophrenia orexin antagonist sleep disorder antagonist dementia firategrast dual alpha integrin antagonist vla multiple sclerosis horizant voltagegate calcium channel modulator postherpetic neuralgia losmapimod kinase inhibitor pain cardiovascular disease copd orvepitant antagonist depression anxiety ipx dopamine precursor dopa decarboxylase parkinson disease iii inhibitor horizant voltagegate calcium channel modulator restless leg syndrome submit sep jan oct trobaltpotiga neuronal potassium channel opener epilepsy partial seizure submit jan nov retigabineezogabine oncology akt protein kinase inhibitor cancer kinase inhibitor cancer akt protein kinase inhibitor cancer focal adhesion kinase inhibitor cancer vestipitant antagonist post operative nausea vomit bkm mitogenactivate protein kinase inhibitor cancer mek alpha kinase inhibitor mek inhibitor pancreatic cancer mek inhibitor braf protein kinase inhibitor metastatic melanoma thrombopoietin receptor agonist thrombocytopaenia foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancer cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelate thrombocytopaenia mek inhibitor metastatic melanoma iii braf protein kinase inhibitor metastatic melanoma iii votrient multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii revoladepromacta thrombopoietin receptor agonist chronic liver disease induce thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis induce thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii votrient multikinase angiogenesis inhibitor sarcoma iii votrient tyverbtykerb multikinase angiogenesis inhibitor inflammatory breast cancer iii egfr dual kinase inhibitor avodart alpha reductase inhibitor reduction risk prostate cancer submit sep jan mar duodartjalyn alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fix dose combination approve mar jun revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approve mar nov tyverbtykerb egfr dual kinase inhibitor breast cancer line therapy approve jun jan votrient multikinase angiogenesis inhibitor renal cell cancer approve jun aoct ophthalmology pazopanib multikinase angiogenesis inhibitor oral agerelate macular degeneration cancer indication pazopanib multikinase angiogenesis inhibitor eye drop agerelate macular degeneration gsk annual report business review governance remuneration financial statement shareholder information product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla respiratory immunoinflammation kinase inhibitor inhale copd transient receptor potential vanilloid trpv pruritis antagonist topical motilin receptor agonist delay gastric empty chemokine receptor cxcr antagonist copd urotensin antagonist asthma sirt activator copd type diabetes sarcopaenia sirt activator psoriasis type diabetes sarcopaenia pde inhibitor inhale copd chemokine receptor cxcr antagonist cystic fibrosis glucocorticoid agonist asthma kinase inhibitor acute lung injury acute respiratory distress syndrome transient receptor potential vanilloid trpv nonallergic rhinitis antagonist intranasal novel glucocorticoid agonist inhale asthma novel glucocorticoid agonist topical atopic dermatitis muscarinic antagonist beta agonist copd motilin receptor agonist delay gastric empty antiinflammatory macrolide conjugate oral inflammatory bowel disease lipoxygenaseactivate protein flap asthma inhibitor losmapimod kinase inhibitor oral copd cardiovascular disease pain muscarinic acetylcholine antagonist copd iii vilanterol muscarinic acetylcholine antagonist copd iii longacte beta agonist vilanterol longacte beta agonist copd iii ccx ccr antagonist crohns disease iii relovair vilanterol longacte beta agonist asthma iii glucocorticoid agonist relovair vilanterol longacte beta agonist copd iii glucocorticoid agonist paediatric vaccine heptavalent combination conjugate neisseria meningitis haemophilus influenzae type vaccine diphtheria hepatitis tetanus pertussis poliomyelitis disease prophylaxis mmr live attenuate measle mump rubella prophylaxis usa oct pneumoniae paediatric recombinant conjugate streptococcus pneumoniae disease prophylaxis generation mosquirix recombinant malaria prophylaxis plasmodium falciparum iii nimenrix menacwytt conjugate neisseria meningitis groups disease prophylaxis submit menhibrix conjugate neisseria meningitis group haemophilus influenzae submit jun hibmencytt type disease prophylaxis vaccine flu pandemic cellculture base vaccine pandemic influenza prophylaxis hiv recombinant hiv disease prophylaxis hiv recombinant hiv disease immunotherapy tuberculosis recombinant tuberculosis prophylaxis flu vaccine inactivate split quadrivalent seasonal influenza prophylaxis iii zoster recombinant herpe zoster prevention iii flu pre pandemic inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis submit sjun canada pumarix inactivate split monovalent quebec pandemic influenza prophylaxis submit nov gsk annual report noitamrofni redloherah product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla antigen specific cancer immunotherapeutic asci prame recombinant treatment metastatic melanoma prame recombinant treatment resectable nonsmall cell lung cancer nyeso recombinant treatment metastatic melanoma recombinant treatment acute myelogenous leukaemia magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii rare disease antisense oligonucleotide duchenne muscular dystrophy iii exvivo stem cell gene therapy adenosine deaminase severe combine immune deficiency iii adascid migalastat hcl pharmacological chaperone fabry disease iii stiefel late stage asset tazarotene foam retinoid foam acne vulgaris iii duac low dose clindamycinbenzoyl peroxide gel acne vulgaris submit nov sorilux vitamin analog mild moderate plaque psoriasis approve oct calcipotriene foam itraconazole tablet oral antifungal onychomycosis approve apr veltin antibioticretinoid gel acne vulgaris approve jul hiv viiv healthcare hiv integrase inhibitor longacting formulation hiv infection nonnucleoside reverse transcriptase inhibitor hiv infections ccr antagonist hiv infections nonnucleoside reverse transcriptase inhibitor hiv infections hiv integrase inhibitor hiv infection iii abacavir hiv integrase inhibitor reverse transcriptase hiv infection iii sulphate lamivudine inhibitor fix dose combination optionbase alliance party include asset phase later development company disease area phase cancer research cancer chemocentryx inflammatory disease galapagos autoimmune disease oncome pharmaceutical oncology prosensa therapeutic neuroscience ranbaxy laboratory respiratory theravance pain telethon institute gene therapy stem cell gene therapy affiris alzheimer disease treatment vaccine nabi nicotine vaccine iii asset gsk annual report business review governance remuneration financial statement shareholder information shareholder information ordinary share company list london stock dividend ad exchange new york stock exchange nyse form table set dividend ad dollar american depositary share ad detail list debt year translate dollar applicable list refer note net debt exchange rate share price year january high year low year december increasedecrease pence table set middle market closing price companys share price decrease compare increase ftse index year share price february dividend share dividend ad dividend calendar quarter exdividend date record date payment date february february april share price adr price july august august october market capitalisation november november january market capitalisation base share issue exclude treasury share glaxosmithkline december billion date gsk sixth large company financial reporting calendar market capitalisation ftse index publication date smithkline beecham plc float rate result announcement unsecure loan stock quarter april quarter july loan stock list exchange quarter october redeem entirety par loan stock preliminaryquarter february hold june annual reportsummary februarymarch dividend gsk pay dividend quarterly continue increase cash return result announcement shareholder dividend policy dividend remain result announcement issue london stock exchange essential component total shareholder return gsk available news service shortly commit increase dividend longterm detail issue medium available website send dividend declare payment date securities exchange commission nyse give note financial statement dividend financial report dividend share gsk publish annual report shareholder need table set dividend share year detail report summary document available date publication website summary year penny send shareholder shareholder elect receive annual report writing registrar alternatively shareholder elect receive notification email publication financial report register wwwshareviewcouk copy previous financial report available gsk website print copy obtain registrar gsk response center usa gsk annual report noitamrofni redloherah shareholder information corporate responsibility report internet publish corporate responsibilty report information company include detail share online march outline gsk approach price available gsk website wwwgskcom information performance responsibility area include access available website constitute medicine research business ethic environmental annual report sustainability community investment annual general meeting nature trading market queen elizabeth conference centre follow table set period indicate high broad sanctuary westminster low middle market closing quotation pence share london swp london stock exchange high low report sale price dollar ad nyse agm company principal forum communication penny share private shareholder addition formal business high low presentation chief executive officer performance group future development quarter end march opportunity question board chairman february board committee question matter relate january committees december november investor hold share nominee service october arrange nominee service appoint corporate september representative proxy respect shareholding order quarter end december attend vote meeting quarter end september adr holder wish attend meeting obtain proxy quarter end june bank new york mellon enable quarter end march attend vote business transact adr holder quarter end december instruct bank new york mellon way quarter end september share represent adr vote complete quarter end june return voting card provide bank accordance quarter end march instruction give year end december year end december document display year end december articles association company document refer annual report available dollar ad inspection register office company high low exchange control limitation quarter end march affect security holder february january currently law decree regulation restrict december import export capital affect remittance november dividend payment holder company share october nonresident limitation relate september nonresident english law company quarter end december articles association right holder vote respect company share quarter end september quarter end june duplicate publication quarter end march quarter end december query relate receipt duplicate copy gsk publication quarter end september address registrar quarter end june investor relation quarter end march year end december investor relation contact follow year end december year end december great west road brentford middlesex february tel usa taxation franklin plaza box philadelphia general information concern tax effect tel toll free share ownership set taxation information tel outside usa shareholders gsk annual report business review governance remuneration financial statement shareholder information shareholder information cidregistrar glaxo wellcome smithkline beecham company registrar corporate pep share centre limited equiniti limited oxford house oxford road aylesbury buck aspect house spencer road lance west sussex tel wwwshareviewcouk tel inside adr programme administrator tel outside adr programme administer line open monday friday bny mellon shareowner services equiniti provide follow service box pittsburgh nominee deal account individual saving account isa wwwbnymelloncomshareowner laxosmithkline corporate sponsor nominee tel toll free tel outside usa hareview service email shrrelationsbnymelloncom share deal service administrator provide global buydirect direct ad dividend reinvestment plan purchasesale dividend reinvestment plan adr holder share deal service gsk response center shareholder trade share hold certificate tel toll free corporate sponsor nominee internet telephone shareview deal share deal service provide provision detail intend equiniti financial service limited internet deal log invitation inducement engage investment activity wwwshareviewcoukdeale telephone deal advice share dealing obtain stockbroker inside independent financial adviser investment account isa service wwwshareviewcoukdeale telephone service available monday friday market trading hour analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bank new york mellon hold hold bny nominees limited represent company adr programme ad represent ordinary share nominal value february bny nominees limit hold ordinary share represent issue share capital exclude treasury share date february number holders shares usa holdings share number register holder adr holdings adr certain share adr hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder gsk annual report noitamrofni redloherah taxation information shareholder summary certain tax federal income tax shareholder consequence certain holder share adr citizen summary apply shareholder citizen resident usa set complete analysis usa domestic corporation person possible tax consequence purchase ownership subject federal income tax net income basis respect security intend general guide holder share adr hold share adr capital asset advise consult adviser respect tax consequence resident tax purpose hold share purchase ownership share adr purpose trade profession vocation carry consequence state local tax law usa branch agency summary implication current ukus income tax convention address tax treatment holder subject special holders adr generally treat owner tax rule bank taxexempt entity insurance company underlie share purpose current usauk double dealer security currency person hold share adr taxation convention relate income gain income tax integrate investment include straddle comprise convention estate gift taxis estate gift tax convention share adr position person purpose internal revenue code directly indirectly vote stock gsk amend code taxation dividend shareholders gross dividend receive treat foreign source dividend income tax purpose eligible dividend summary apply resident shareholder hold receive deduction allow corporation dividend adr share capital asset payable dollar dividend share payable sterling taxation dividend dividend pay pound sterling include income dollar calculate reference exchange rate resident individual shareholder generally subject day dividend receive holder subject certain income tax dividend pay gross exception shortterm hedge position individual eligible ninth dividend tax credit tax credit holder subject taxation maximum rate set individual income tax liability respect gross respect qualified dividend receive dividend repayable shareholder tax liability associate tax credit tax year taxation capital gain subsequent tax year additional rate income tax dividend generally holder subject capital gain tax impose taxpayer income subject tax capital gain realise sale resident shareholder corporation taxpayer disposal share adr gain longterm note dividend generally entitle exemption capital gain subject reduce rate taxation individual corporation tax shareholder doubt holder share adr hold year position consult professional adviser information report backup withholding taxation capital gain dividend payment proceed sale share shareholder liable tax gain disposal adr pay usa certain usrelated financial share adr disposal individual subject intermediary subject information reporting availability exemption relief annual exempt subject backup withholding holder corporation taxable capital gain accrue disposal share exempt recipient provide taxpayer identification adr tax allowable deduction number certifie loss exemption occur shareholder taxable income tax year exceed basic rate nonus holder generally subject information report income tax limit case taxable capital gain accrue backup withholding require provide certification disposal share adr tax nonus status connection payment receive combination rate corporation taxpayer entitle amount withhold allow refund credit indexation allowance apply reduce capital gain holder federal income tax liability provide require extent gain arise inflation indexation information furnish irs allowance reduce chargeable gain create allowable loss estate gift taxis estate gift tax convention shareholder inheritance tax generally subject inheritance tax individual shareholder liable inheritance tax transfer share adr tax charge stamp duty value shareholder estate reduce result stamp duty sdrt subject certain exemption transfer way gift disposal payable issue transfer share adr custodian market value depository rate price issue consideration provide transfer sale value gift disposal subject inheritance transfer consideration tax estate gift tax estate gift tax convention generally provide tax pay usa credited sdrt payable transfer agreement tax payable transfer adr stamp duty payable transfer adr provide instrument transfer execute stamp duty remain time outside stamp duty transfer stamp duty stamp duty reserve tax sdrt subject adr payable rate consideration certain exemption payable transfer share rate transfer sale underlie share subject certain consideration transfer exception result liability stamp duty case sdrt rate gsk annual report business review governance remuneration financial statement shareholder information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenue gsk annual report noitamrofni redloherah index performance overview inventory accounting principle policy investment associate joint venture acquisition disposal investor relation adjustment reconcile profit tax operating cash flow key accounting judgement estimate annual general meeting key performance indicator annual remuneration legal proceeding asset hold sale major restructure programme associate joint venture manufacture supply board movement equity business review nature trading market cash cash equivalent net debt chairman ceo summary new accounting requirement combine code nonexecutive director term condition commitment nonexecutive director fee committee report note financial statement competition operating profit consolidate balance sheet intangible asset consolidate cash flow statement investment consolidated income statement noncurrent asset consolidate statement change equity noncurrent liability consolidated statement comprehensive income operating income consumer healthcare provision contingent liability outlook corporate executive team pension postemployment benefit corporate governance pharmaceutical turnover critical accounting policy post balance sheet event dialogue shareholder presentation financial statement director senior management price control director interest principal group company director interest contract product development pipeline director statement responsibility product dividend property plant equipment donation political organisation quarterly trend political expenditure reconciliation net cash flow movement net debt earning share registrar employee cost regulation employee share scheme relate party transaction employee remuneration policy exchange rate remuneration report executive director term condition research development finance cost responsible business finance income risk factor financial instrument relate disclosure segment information financial position resource segment review financial review share capital control financial review share capital share premium account financial statement glaxosmithkline plc prepare share option gaap share price year record shareholder information foreign exchange management strategy glossary term taxation goodwill taxation information shareholder governance policy total equity improve access medicine trade payable incentive plan trade receivable independent auditor report trademark intellectual property treasury operation interest rate risk management law regulation internal control framework world market gsk annual report history development company glaxosmithkline plc public limited company incorporate december english law share list london stock exchange new york stock exchange december company acquire glaxo wellcome plc smithkline beecham plc english public limited company way scheme arrangement merger company gsk subsidiary associate constitute major global healthcare group engage creation discovery development manufacture marketing pharmaceutical consumer healthrelated product annual report summary report annual report glaxosmithkline plc year end december prepare accordance united kingdom requirement approve board director march publish march summary year intend shareholder need detail annual report produce separate document issue shareholder summary constitute set summary financial statement define section company act annual report issue shareholder elect receive document available gsk website report glaxosmithkline group gsk mean glaxosmithkline plc subsidiary company mean glaxosmithkline plc glaxosmithkline share mean ordinary share glaxosmithkline plc american depositary share ad represent glaxosmithkline share brand name brand name appear italic report trademark own andor license glaxosmithkline associate company exception benlysta trademark human genome science bonivabonviva trademark roche botox trademark allergan levitra trademark bayer nicoderm trademark elan johnson johnson merrell novartis sanofiaventis glaxosmithkline potiga trademark valeant prolia trademark amgen vesicare trademark astella pharmaceutical country yamanouchi pharmaceutical certain country volibris trademark gilead certain country licence group exchange rate group operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterling currency average exchange rate prevail period translate result cash flow overseas subsidiary associate joint venture sterling period end rate translate net asset entity currency influence group result remain dollar euro yen sterling detail exchange rate group give note exchange rate average sterling exchange rate strong euro weak dollar yen compare year end sterling exchange rate strong euro weak dollar yenwe choose andrew witty introduction watch ceo review year outline commit case study run business responsibly demonstrate progress strategic priority story view online wwwgskcom corporatereporte case study find downloadable pdfs deliver generation medicine annual report review form corporate responsibility review maintain leadership position respiratory web information link world gsk invest nutritional healthcare link corporate responsibility report conduct sophisticated approach pricing strengthen biopharmaceutical business extend access develop world grow global vaccine business building leadership position dermatology evolve business model wwwgskcom head office register office create rare disease unit glaxosmithkline plc great west road brentford middlesex united kingdom tel register number print paper production document post consumer waste pulp bleach totally chlorine free process